

# ANATOLIA

## ANNUAL

## REPORT

# 2024

(Convenience translation of a report originally issued In Turkish)

## INDEPENDENT AUDITOR'S REPORT ON THE ANNUAL REPORT OF THE BOARD OF DIRECTORS

To the Shareholders and the Board of Directors of  
Anatolia Tanı Ve Biyoteknoloji Ürünleri Araştırma Geliştirme Sanayi Ve Ticaret A.Ş.

### 1) Opinion

We have audited the annual report of Anatolia Tanı Ve Biyoteknoloji Ürünleri Araştırma Geliştirme Sanayi Ve Ticaret A.Ş. ("the Company") and its subsidiaries ("the Group") for the period of 1 January- 31 December 2024.

In our opinion, the consolidated financial information provided in the annual report of the Board of Directors and the discussions made by the Board of Directors on the situation of the Group are presented fairly and consistent, in all material respects, with the audited full set consolidated financial statements and the information we obtained during the audit.

### 2) Basis for Opinion

We conducted our audit in accordance with standards on auditing as issued by the Capital Markets Board of Turkey and Independent Auditing Standards (TAS) which are part of the Turkish Auditing Standards as issued by the Public Oversight Accounting and Auditing Standards Authority of Turkey (POA). Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Annual Report section of our report. We are independent of the Group in accordance with the Code of Ethics for Independent Auditors (Code of Ethics) as issued by the POA, and we have fulfilled our other ethical responsibilities in accordance with the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

### 3) Our Auditor's Opinion on the Full Set Consolidated Financial Statements

We have expressed an unqualified opinion in our auditor's report dated February 28, 2024 on the full set consolidated financial statements of the Group for the period of 1 January - 31 December 2024.

### 4) The Responsibility of the Board of Directors on the Annual Report

In accordance with Articles 514 and 516 of the Turkish Commercial Code 6102 ("TCC") and the provisions of the Communiqué 11-14.1 on the Principles of Financial Reporting In Capital Markets" ("the Communiqué") of the Capital Market Board ("CMS"), the management of the Group is responsible for the following items:

- Preparation of the annual report within the first three months following the balance sheet date and submission of the annual report to the general assembly.
- Preparation and fair presentation of the annual report; reflecting the operations of the Group for the year, along with its financial position in a correct, complete, straightforward, true and honest manner. In this report, the financial position is assessed according to the consolidated financial statements. The development of the Group and the potential risks to be encountered are also noted in the report. The evaluation of the board of directors is also included in this report.

c) The annual report also includes the matters below  
Subsequent events occurred after the end of the fiscal year which have significance,

The research and development activities of the Group,

Financial benefits such as salaries and bonuses paid to the board members and to those charged governance, allowances, travel, accommodation and representation expenses, financial aids and aids in kind, insurances and similar deposits.

When preparing the annual report, the board of directors takes into account the secondary legislative arrangements published by the Ministry of Customs and Trade and related institutions.

### 5) Auditor's Responsibilities for the Audit of the Annual Report

Our aim is to express an opinion, based on the independent audit we have performed on the annual report in accordance with provisions of the Turkish Commercial Code and the Communiqué, on whether the consolidated financial information provided in this annual report and the discussions of the Board of Directors are presented fairly and consistent with the Group's audited consolidated financial statements and to prepare a report including our opinion.

The independent audit we have performed is conducted in accordance with TAS and the standards on auditing as issued by the Capital Markets Board of Turkey. These standards require compliance with ethical provisions and the independent audit to be planned and performed to obtain reasonable assurance on whether the consolidated financial information provided in the annual report and the discussions of the Board of Directors are free from material misstatement and consistent with the consolidated financial statements.

The name of the engagement partner who supervised and concluded this audit is Yunus Can Çarpatan

İstanbul, 28 February 2025

PKF Aday Bağımsız Denetim A.Ş.  
(A Member Firm of PKF International)



Yunus Can Çarpatan  
Partner

# Contents

<b>Anatolia at a Glance</b>	<b>3</b>
About Anatolia	4
Financial Indicators	6
Financial Ratios	7
Message from the Chairman of the Board of Directors	9
Milestones	10
Company Profile	12
Shareholding Structure	12
Subsidiaries	14
<b>2024 Operations</b>	<b>17</b>
2024 R&D Activities	18
2024 Customer Relations and Sales Activities	20
2024 Sales	22
Our Certificates	24
Our HR Policy	26
Growth Strategies	32
Fairs and Events	34
Objectives	36
<b>Management Structure and Organization</b>	<b>39</b>
Board of Directors	40
<b>Corporate Governance</b>	<b>43</b>
Shareholders and Investor Relations	44
Share Information	46
Committees and Working Principles	46
Sustainability	54
Policy	58
Corporate Governance Compliance Report	70
General Assembly	76
Miscellaneous Issues	76
<b>Independent Auditor's Report and Financial Statements</b>	<b>83</b>



**ANATOLIA AT  
A GLANCE**

---

# About Anatolia



Anatolia was established in Istanbul in 2010 by partners with decades of experience in molecular genetics, healthcare, mechanical engineering, and marketing. This interdisciplinary structure of the company is the key factor in creating solution-oriented and efficient products for people in a wide geography.

Our main expertise is designing, developing, and manufacturing Real-Time PCR Kits, nucleic acid extraction kits, rapid antigen test kits, recombinant enzymes, automated nucleic acid extraction devices, and PCR Setup robots. Anatolia Geneworks is one of the few companies in the world that can produce suitable solutions for Real-Time PCR applications with the integration of Real-Time PCR instruments produced in-house.

Anatolia Geneworks conducts its related activities in accordance with ISO 9001:2015, ISO 13485:2016 standards, 98/79/EC directive, EU 2017/746 IVDR, and 2006/42/EC regulations. Anatolia Geneworks is the first company in Türkiye to obtain IVDR certification for high-risk molecular diagnostic products.

Anatolia Tanı A.Ş. was authorized as an R&D Center by the Republic of Türkiye Ministry of Industry and Technology in April 2017. Anatolia became a publicly traded company on the Borsa Istanbul (BIST) as of October 21, 2021. Anatolia has subsidiaries in Germany, the Netherlands, Italy, Poland, Poland, Bulgaria, Pakistan, and the Philippines.

The company's primary goals are to achieve worldwide market success by developing and manufacturing high-quality molecular diagnostic products, as well as to increase Türkiye's independence in the field of molecular diagnostics and biotechnology. Anatolia Geneworks operates in the R&D and manufacturing laboratories and in the CNC workshops, which ultimately have an advanced infrastructure. The company guarantees high precision, sensitivity, reproducibility, performance, and quality of its products by stringent quality control procedures in compliance with the regulations and quality standards.


- It is an international company with 100% Turkish capital.
- Its expertise and focus are on the field of "Molecular Diagnostics", which is extremely important in the diagnosis and treatment of diseases.
- With its subsidiaries established abroad and a wide network of distributors, Anatolia has introduced its products to the market in more than 70 countries in Asia, Europe, Africa, and America.
- Anatolia has a 15,000 m<sup>2</sup> R&D and Production facility where the design, development, and production of Real-Time PCR kits, nucleic acid extraction kits, rapid antigen test kits, and automated nucleic

acid extraction devices are realized.


- The Company's R&D Center is accredited by the T.C. Ministry of Industry and Technology.
- The company has designed its state-of-the-art laboratories, which meet ISO Class 7 air quality criteria, to be able to carry out all R&D and production activities, as well as to organize workshops and practical training with training laboratories with the same equipment.
- In 2024, Anatolia employs a total of 223 people, 97 of whom are in R&D.
- The R&D project 'TR.AQUA: Innovative and Sustainable

Applications in Aquaculture Products within the Framework of Food Supply Security', which started in 2023, is supported by the Scientific and Technological Research Council of Türkiye (TÜBİTAK) under the 1004 program.

# Financial Indicators



# Financial Ratios



2024



# Message from the Chairman of the Board of Directors



Dear Partners and Esteemed Investors,

As we leave another year behind, we firmly believe that our achievements in 2024 will be our greatest asset in reaching our goals for 2025. Anatolia, deriving its strength and ability to make a difference from its R&D culture, continued its facility and product portfolio expansion activities in 2024, which were initially planned in 2023. The company successfully achieved its strategic goals of producing PCR enzymes and fully automated mass production of lateral flow-based rapid diagnostic tests. The investments made in these areas have already started to reflect in our product portfolio. In 2024, we made facility and equipment investments related to the lyophilization of PCR enzymes, and by 2025, we aim to become one of the few companies in the world capable of producing lyophilized PCR mixes.

As always, R&D has remained our primary focus. With the expansion of our R&D center, an increase in our R&D personnel, and numerous ongoing projects, we successfully completed the development of 67 new Real-Time PCR kits and 5 new lateral flow rapid diagnostic kits, all of which have been transferred to production. Additionally, we plan to launch new Real-Time PCR kits in the coming year that incorporate unique techniques beyond the standard ones currently used.

Our UNIO M32 DNA/RNA extraction robots, released in

2024, have been well received in their segment due to their compact size and affordability and have started being used in various countries. We are confident that UNIO M16, a version customized for food testing, will achieve similar success. The mold and filling line investments for the cartridge system of UNIO X series—designed for high sample throughput and volume capacity—have been completed, and we aim to begin production of these devices in 2025.

The production line for the automatic extraction kit cartridges used in UNIO A and B series has undergone revisions, resulting in improved production speed and automatic quality control functions, ensuring error-free results. UNIO X cartridge filling line, set to be commissioned in 2025, will further contribute to the diversification of our extraction device product range. To meet the increasing demand for robotic device production, additional CNC machines were ordered from abroad at the end of 2024, with plans to integrate them in the first half of 2025.

In 2024, our promotional and marketing activities continued both domestically and internationally. We successfully expanded our exports to five new countries where we had not previously conducted sales, while also significantly increasing the number of domestic institutions we collaborate with. Parallel to these developments, our exports increased by 45% in foreign currency terms, and our domestic sales grew by

28% in foreign currency terms. Given that both domestic and international prices are indexed to foreign exchange rates, the ongoing normalization of exchange rates is expected to positively impact our TL-denominated sales in the coming year.

What started in 2010 as a journey with five employees in a 100-square-meter laboratory evolved into a company with 20 million TL in sales by 2019, and by 2024, Anatolia has become a globally recognized brand, reaching a turnover of 530 million TL, including our international subsidiaries. As one of the rare Turkish companies developing and producing such sophisticated high-tech products while growing at this pace, we take pride in our leadership in the field. With this responsibility in mind, we will continue our operations in 2025 with all our knowledge and experience.

We extend our gratitude to all our employees and investors who have contributed to this success.

**Alper Akyüz**  
Chairman of the  
Board of Directors

# Milestones



\*Republic of Türkiye Ministry of Industry and Technology



## Company Profile

<b>Title of the Company</b>	Anatolia Tanı ve Biyoteknoloji Ürünleri Araştırma Geliştirme Sanayi ve Ticaret A.Ş.
<b>Date of Establishment</b>	11.06.2010
<b>Head Office of the Company</b>	Istanbul
<b>Address</b>	Hasanpaşa Mah. Beydağı Sok. No:1-9H Sultanbeyli/İstanbul/Türkiye
<b>Phone Number</b>	+90 216 330 04 55
<b>Registry</b>	Istanbul Trade Registry Directorate
<b>Registration No</b>	738589-0
<b>Tax Office</b>	Sultanbeyli Vergi Dairesi
<b>Tax No</b>	0680797583
<b>Central Registration System Number</b>	0068079758300025
<b>Paid Capital</b>	220.000.000 TL
<b>Registered Capital Ceiling</b>	500.000.000 TL

## Shareholder Structure

Shareholder	Share in Capital (TL)	Capital Percentage (%)
Alper Akyüz	93.562.286	42,53
Elif Akyüz	45.603.000	20,73
Other	80.834.714	36,74
<b>Total</b>	<b>220.000.000</b>	<b>100,00</b>



# Our Companies



## Alpha IVD S.p.A

Via XX Settembre, 30, 20025  
Legnano, Milano,  
ITALY

+39 348 588 7232  
sales@alphaivd.com  
alphaivd.com



## Euronano Diagnostics Private Limited

Plot No. 225/1/F, Block-2,  
P.E.C.H. Society, Karachi, 75400  
PAKISTAN

+92 21 343 90 808  
info@euronanodiagnostics.com  
euronanodiagnostics.com



## RhineGene B.V.

Keizersgracht 555, 1017DR  
Amsterdam  
NETHERLANDS

+31 20 2014961  
info@rhinegene.com  
rhinegene.com



## RhineGene Philippines Inc.

18th Floor, One World Place,  
32nd Street, Fort Bonifacio  
Taguig City, Metro Manila, 1630  
PHILIPPINES

+63 28 563 3280  
info@rhinegene.ph  
rhinegene.ph



## RhineGene Bulgaria EOOD

Sofia Tech Park 111B  
Tsarigradsko shosse Blvd.,  
District Mladost, Sofia,  
BULGARIA

+359 87 994 3039  
info@rhinegene.bg  
rhinegene.bg



## RhineGene Poland Sp. z.o.o

ul.Gdańska, Numer 47/49,  
90-729, Łódź  
POLAND


+48 42 237 11 37  
info@rhinegene.pl  
rhinegene.pl



## RhineGene Germany GmbH

Leopoldstrasse 244, 80807  
Munich  
GERMANY

+49 89 20 80 39 EXT:-255  
info@rhinegene.de  
rhinegene.de




**More than 350 unique products manufactured in Türkiye are used in more than 70 countries with subsidiaries in 7 countries.**



# 2024 OPERATIONS

---

# 2024 R&D Activities



**A total of 16 projects were carried out at the R&D Center between January 1 and December 31, 2024.**

## Overview

At the company's R&D Center, **a total of 16 projects** were conducted between **January 1 and December 31, 2024**. Among these, two projects were successfully completed within the year, while development activities continued **for the remaining 14**.

During this period, **73 products** were transferred to production and commercialized, distributed as follows:

- **56** Real-Time PCR kits (for the detection and genotyping of diseases caused by various viruses and bacteria in humans),
  - **11** Real-Time PCR kits (for food and veterinary applications),
  - **5** new rapid tests (cassette-based tests),
  - **1** automation-focused extraction and PCR Setup device.
- Additionally, the company expanded its R&D team,

increasing the number of R&D personnel by 15%, from 84 to 97, with the recruitment of new biomedical engineers, molecular biologists, and engineers. In 2024, Anatolia also made significant investments in enzyme synthesis and lateral flow test development, including:

- Establishing a 186-square-meter modern facility for lateral flow test production,
- Enhancing its R&D laboratory infrastructure for protein and enzyme synthesis.

## UNIO A24S Extraction & PCR Setup System

UNIO A24S instrument, designed for the rapid and reliable diagnosis of infectious diseases, particularly **sepsis**, was launched at the end of 2024. The system automates the entire process from DNA/RNA extraction to qPCR setup, supporting simultaneous DNA/RNA extraction from 24 samples and 4 different

PCR Setups using two 96-well modules. Initial field tests have provided positive feedback, confirming the clinical and laboratory potential of **UNIO A24S**.

## Project Support and Collaborations

Anatolia is a participant in the **Tr.Aqua Project (22AG009)**, titled **"Innovative and Sustainable Applications in Aquatic Products within the Framework of Food Supply Security,"** is successfully continuing under the TÜBİTAK 1004 program.

## New Project Applications

In 2024, our R&D center submitted new project applications: Anatolia joined a new TÜBİTAK 1004 project team, led by one of the country's most prestigious universities. The company collaborated with

Italian research centers to submit two separate project applications under **2524 – Italy-Turkey Science and Technology Cooperation Call for Joint Research** program.

These applications are currently under evaluation.

## R&D Activities in Food Analysis and Veterinary Applications

- The development of qPCR kits for detecting food pathogens in food microbiology laboratories continued, and 3 products were launched within this panel. R&D efforts to further expand the panel are ongoing.

- The African Swine Fever Virus (ASFV) detection kit, developed and produced by our R&D team, was successfully validated by EURL CISA INIA (European Union Reference Laboratory) and launched in the market. This validation confirms the

compliance of our product with international standards.

Our R&D activities in 2024 were marked by the launch of our new automation robot, our country's first molecular diagnostic IVDR certification studies, R&D studies that will enable us to launch new product groups with new techniques for Anatolia such as rapid card tests and protein synthesis, as well as validation studies on innovative multiplex qPCR techniques. Maturation of our R&D Center's know-how in innovative products and technologies, expansion of the existing product portfolio, and deepening of national/international collaborations are among the factors that will increase the international competitiveness of our company.

# 2024 Customer Relations and Sales Activities

**Anatolia's export volume in 2024 increased by 45% in foreign currency terms, while the increase in TL terms was 100%.**

## Overseas Customer Relations and Sales Activities

The demand for molecular diagnostics and the market size continue to grow rapidly every year. Additionally, both clinicians and patients are becoming increasingly aware of molecular diagnostic techniques. In this context, our company has strengthened its strong position in the sector in 2024 with its extensive and diversified product portfolio in the field of in vitro diagnostics, solidifying its status as one of the leading players recognized for quality in the global market.

Anatolia's export volume in 2024 increased by 45% in foreign currency terms and 100% in TL terms. This growth was made possible, particularly through the establishment of subsidiaries in previous years, the increasing market share in the sector, marketing efforts in new countries, and investments in equipment. Additionally, the company's broad product portfolio aligned with evolving trends in molecular diagnostics and its high product quality have been key factors influencing customer preferences.

Sales in South America continued their upward trajectory in 2024, increasing by 68%. In Europe, sales grew by 45% in foreign currency terms, with France, Italy, and the United Kingdom remaining the top export destinations. Furthermore, for the first time,

Anatolia entered new markets such as Guinea, Canada, Zambia, Kuwait, and Denmark in 2024.

As in previous years, respiratory infection detection panels remained among the most in-demand products. Viral and bacterial respiratory panels, including COVID-19 pathogens, gained prominence, particularly in France and South America. The World Health Organization (WHO) also showed interest in these panels in 2024, leading to their distribution in various African projects through different distributors.

Beyond COVID-19 and respiratory viruses, multiplex panel test sales for detecting various pathogens saw a significant increase in 2024. Anatolia's proprietary diagnostic devices were installed and sold to universities, state hospitals, and private laboratories, promoting the use of these tests and driving sales growth. Quantitative tests for Hepatitis infections saw a 105% year-over-year increase in sales in 2024.

Additionally, food safety panels were introduced to international markets, leading to growth in both the number of countries served and total sales volume. Extensive projects were launched in collaboration with Azerbaijan's reference laboratories, and the use of Anatolia's products in these labs has commenced.

New distribution agreements were signed in previously untapped or underdeveloped markets in South America, allowing Anatolia to gain a strong foothold in the region. The company secured a top position among leading firms in Chile and Paraguay, while sales were initiated for the first time in Bolivia, Guatemala, Costa Rica, and Mexico, accompanied by promotional activities.

Anatolia's subsidiaries in Italy, Poland, Bulgaria, Germany, and Pakistan expanded their sales and marketing operations, achieving a 72% TL-based sales increase in 2024. The company also participated in numerous local trade fairs and congresses, further enhancing Anatolia Geneworks' brand recognition. In 2024, the addition of new molecular diagnostic projects focusing on sepsis pathogens and antibiotic resistance will further strengthen our pioneering role in these markets.

## 2024 Domestic Sales Analysis

As of 2024, Anatolia's total revenue increased by 74.5% in TL terms compared to the previous year, while the increase in foreign currency terms was 27.5%. This success was largely driven by the new domestic tenders who won in 2024. The number of tendering institutions doubled, contributing significantly to revenue growth.

UNIO series extraction systems, which recently began production and have rapidly expanded in capacity, have played a major role in gaining a competitive edge in the domestic market. The development of our extraction systems has further differentiated Anatolia positively from competitors. Additionally, our broad range of molecular diagnostic parameters in tenders provided a strong advantage over competitors.



In the private sector diagnostic market, the decline in COVID-19 cases and the discontinuation of molecular testing by COVID-19-specific labs led to no significant increase in the number of institutions. While COVID-19 test kits' revenue impact has significantly decreased, seasonal respiratory tests and routine parameters have compensated for this decline. As a result, Anatolia's private sector diagnostics revenue increased by 52% in TL terms and 10% in foreign currency terms in 2024.

In the food safety sector, revenue grew by 95% in TL terms and 32% in foreign currency terms compared to the previous year. The public disclosure lists issued by T.C. Ministry of Agriculture and Forestry at the end of the year helped raise awareness in the food safety sector, reinforcing the importance of our long-standing presence in food safety testing in Food Control Laboratories.

Anatolia's high-performance and flexible isolation systems, used for many years in the food safety sector, continue to set us apart from competitors in the Turkish market.

# 2024 Sales

Anatolia maintained its strong performance in 2024 thanks to its product and service quality and penetration into prominent target markets in Western Europe.



# Our Certificates

**We are pleased to announce that, following the audits conducted on February 12-15, 2024, and March 29, 2024, we have become the first biotechnology company in Türkiye to receive an IVDR certificate and the only one in our field.**

In 2024, the company continued its operations in compliance with the 98/79/EC IVD Directive, EU 2017/746 (IVDR), ISO 9001:2015, and EN ISO 13485:2016 Quality Management Systems, ensuring that its products can be safely used both domestically and internationally.

The EN ISO 13485:2016 audit conducted by the Polish Testing and Certification Center (PCBC) on August 15-16, 2024, was successfully completed. Similarly, the Surveillance Audit performed under the 98/79/EC IVD Directive by PCBC on August 15-16, 2024, was also successfully completed. The first IVD CE audit under EU 2017/746 (IVDR) was carried out by QMD Services GmbH on February 12-15, 2024, and March 29, 2024.

Additionally, the company certifies its robotic devices in compliance with the 2006/42/EC Machinery Safety Directive. In 2024, another model from UNIO robotic family, an automated PCR extraction and Setup instrument, was certified with a CE mark.

The transition processes for the EU In Vitro Diagnostic Medical Devices Regulation 2017/746 and EU 2024/1860 are progressing successfully.

Following the audits from February 12-15, 2024, and March 29, 2024, we are proud to be the first biotechnology company in Türkiye to receive an IVDR certificate in our field.

Our Class C IVDR certificate covers multiple products, and certification processes for Class D products are advancing rapidly.

We are pleased to announce that we are the first IVDR-certified biotechnology company in Türkiye and the only one in its field.



# Our HR Policy



## Valued people add value to work...

Anatolia's Human Resources policy is shaped by the approach: "Valued people add value to work..."

In Anatolia, respect is the foundation of every interaction involving people. The company prioritizes building sustainable and lasting relationships based on mutual respect with its team, target audience, and all stakeholders. At the heart of Anatolia's high-quality products, which contribute to human health, lies a deep focus on people.

Anatolia's approach to human resources is rooted in respect for people and appreciation of labor. Recruitment, evaluation, and training activities are carefully conducted within this framework. To enhance product

and work environment quality, employees are encouraged to continuously develop their competencies by adding new training and experiences within Anatolia's culture to their existing education and skills. Anatolia's human resources policy aims to create a happy, healthy, and safe work environment for employees while ensuring team continuity. Believing that high-quality products are produced by happy individuals, Anatolia values diversity. As a reputable company that complies with laws and ethical principles, it does not discriminate based on race, religion, color, national origin, gender, sexual orientation, age, or marital status and emphasizes equal opportunities and fairness in its

human resources practices. Anatolia management is committed to ensuring continuous improvement by operating in compliance with national and international occupational health and safety regulations. This includes identifying hazards, assessing risks, implementing necessary controls and precautions, providing ongoing training on occupational health and safety (ISG) and risk management, and maintaining a safe and healthy environment for employees, subcontractors, and visitors.

### Our Human Resources Approach

A commitment to continuous improvement and development

forms the foundation of quality at Anatolia. Recognizing this, the company prioritizes instilling quality awareness, customer focus, process-oriented thinking, and risk-based decision-making within its team. Through training and performance evaluation initiatives, Anatolia supports the professional growth of its team while improving operational processes.

Anatolia's products benefit human health and society worldwide. Through its solutions for medical and food laboratories, the company ensures access to the best technologies for individuals and communities. Additionally, Anatolia actively works to prevent brain drain by creating

employment opportunities for graduates of Mechatronics Engineering, Molecular Biology and Genetics, and Bioengineering, enabling them to contribute to local production instead of seeking opportunities abroad.

New team members are expected to exhibit respect for people, competence, enthusiasm for work, and openness to learning and development. Alongside academic qualifications, soft skills such as communication and teamwork are also considered essential. Since team continuity is key to success, Anatolia prioritizes maintaining a cohesive and collaborative workforce.

Anatolia's R&D and production strategies focus on human resource development.

Employees receive training on ISO 9001, ISO 13485, the 98/79/EC IVD Directive, and the EU 2017/746 (IVDR) Regulation to actively contribute to the implementation of these quality systems.

In 2024, Anatolia provided training programs for employees, focusing on quality management systems, molecular genetics and engineering applications, legal requirements, and occupational health and safety regulations. A total of 2173 training effectiveness evaluations were completed, identifying additional training needs. Monitoring training efficiency remains one of Anatolia's quality objectives.

In 2024, Anatolia and its affiliated companies expanded their workforce from 205 to 223 employees.

Anatolia values employee satisfaction, health, and productivity. Employees are provided with daily lunch service, transportation support with extensive shuttle routes, comprehensive social security (SGK) coverage, and supplementary health insurance, effective from the start of employment, also covering dependents (spouse and children). Anatolia's employees are entitled to annual leave benefits in accordance with labor laws, along with additional leave for special circumstances. Various financial support packages for events such as childbirth and marriage are also provided to enhance employees' quality of life and sense of belonging.

Annual performance evaluations are conducted to

identify employees' strengths and areas for improvement, ensuring they are placed in roles where they are most productive and satisfied. Career development and personal growth are supported through targeted training and new responsibilities.

Performance criteria are established in accordance with quality management system requirements and assessed based on work output and efficiency, time management, contributions to process improvement, leadership skills, risk-based thinking, and problem-solving abilities.

Evaluations involve observations, practical and written technical exams, and feedback from customers and suppliers. Employees demonstrating leadership potential are given additional training and responsibilities to align with company goals. If an employee is identified as being better suited for a different role, interdepartmental transitions are facilitated to enhance job satisfaction and efficiency. Experienced team members mentor new employees who show exceptional performance, fostering the development of future leaders.

Leadership at Anatolia is not merely about hierarchical titles—it is about demonstrating effective leadership behavior.

**Anatolia organized training for its employees in 2024, mainly on the quality management system, technical issues related to molecular genetics and engineering applications, legal requirements, occupational health and safety rules. The effectiveness of the training was measured, and additional training requirements were identified. A total of 2173 training effectiveness evaluations were completed.**




## Equal Opportunity

Anatolia Geneworks management attaches importance to equal opportunity and fairness in human resources practices.


As of the end of 2024, the information about our employees is as follows:

Anatolia increased the number of employees from 205 to 223 in 2024.


Gender




Age Groups




R&D



Employment Type



Educational Status



# Growth Strategies

**The company continues to implement its growth strategies while maintaining its focus on molecular diagnostics.**

The company continues to implement its growth strategies while maintaining its focus on molecular diagnostics.

With its specialized team and strong R&D and production infrastructure, the company continues to execute the following growth strategies:

In 2024, the company participated in a total of 19 fairs, congresses, and events—9 domestically and 10 internationally. It established new relationships with distributors, began sales in five new countries where it had not previously sold products, and completed the necessary Ministry of Health registrations in 10 additional countries, expanding into new markets.


To enrich its product portfolio with new product families, the company has continued product development activities that offer innovative solutions tailored to user needs through various technologies such as innovative

multiplex test validations, direct blood sepsis diagnosis systems, enzyme synthesis, and lateral flow tests. These efforts aim to differentiate the company from competitors in the market.

Another key growth strategy of the company is to develop and manufacture modular robotic laboratory diagnostic devices with flexibility to meet the expectations of all types of laboratories, offering different capacities and automation levels. By doing so, the company aims to create a high-demand ecosystem for kits and consumables, fostering long-term mutual growth. Additionally, by establishing a wide sales network across numerous countries through distributors and subsidiaries, the company ensures top-level training and technical support for end-users. This approach strengthens brand recognition, enhances customer satisfaction and loyalty, and fosters a growing user base.



**Expansion of Product Portfolio**



**Robotics System Integration**



**Expansion to New Geographies**



## Fairs and Events

Throughout 2024, our company has participated in numerous prestigious national and international events, contributing to knowledge sharing and collaboration within the industry. By taking part in major events such as the Association of Italian Clinical Microbiologists Congress (AMCLI), the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), and MEDICA 2024, we had the opportunity to showcase our innovative solutions.

Additionally, we participated in special presentations on topics such as molecular diagnostic approaches in the management of sepsis and automation systems in syndromic testing. Scientific contributions were made through the KLIMUD Basic Molecular Microbiological Diagnosis Course and the Advanced Molecular Diagnosis Methods Course, supporting the advancement of innovative practices in the field.

At the regional level, meetings on HSL Surveillance Studies and Sexually Transmitted Infections aimed to enhance collaboration and scientific exchange. 2024 has been a successful period in which our company has continued its mission of industry leadership and knowledge sharing.

Date	Name of the Event
8.03.2024	51st Association of Italian Clinical Microbiologists Congress (AMCLI)
19.03.2024	2nd LABS EXPO Laboratory Equipment and Technology Fair
27.04.2024	34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
9.05.2024	"Molecular Diagnostic Approach in the Management of Sepsis" with R&D Participation
17.05.2024	KLIMUD Basic Molecular Microbiological Diagnosis Course, "PCR Based Syndromic Tests and Rapid Diagnostic Tests: Areas of Use"
2.06.2024	Automation Systems in Syndromic Testing-UNIO A24S Introduction
19.06.2024	XX. EtK Infectious Medicine Forum - From Theory to Practice
7.07.2024	8th National Congress of the Italian Society for Virology (SIV-ISV)
4.10.2024	HSL Surveillance Studies-Izmir Regional Meeting
7.10.2024	City Food Workshop
11.10.2024	"KLIMUD Diagnostic Molecular Microbiology Working Group-Ankara"
18.10.2024	Sexually Transmitted Infections Difficulties in Diagnosis and Monitoring in Clinical Practice-Istanbul Regional Meeting
28.01.2024	Diagnosis and Susceptibility Testing in Antimicrobial Management Course-Samsun
28.10.2024	9th SIPMeL Italian National Congress 2024
6.11.2024	FoodFakty Summit 2024
11.11.2024	MEDICA 2024
13.11.2024	National Clinical Microbiology Congress KLIMUD 2024
22.11.2024	Laboratory Diagnostics - Olsztyn 2024 "PTDL"
13.12.2024	Clinical Microbiology Advanced Molecular Diagnostic Methods Course



# Our Objectives



Increasing participation in congress and fairs organised abroad



Increasing customer visits to different countries and organizing workshops



Improving brand awareness by broadening international marketing activities



Making a difference in the market in terms of quality and reliability by making new investments in quality management and certification



Establishing new subsidiaries in Europe, Asia, and the Americas



Extending the R&D Center team and increasing the number of projects and products developed



Maximizing international market share through new dealers



Developing new products for diagnostic areas in which the company has never been active





# MANAGEMENT STRUCTURE AND ORGANIZATION

---

# Board of Directors

**The ratio of female members on the board of directors is 80% as of 2024.**



**Alper Akyüz**  
Chairman of the Board of Directors

Alper AKYÜZ was born in 1970 in Kırkkale.

After graduating from Bursa Anatolian High School, he continued his education in the Department of Electrical Engineering at Istanbul Technical University.

During his university years, he specialized in design, advertising and marketing in his working life.

He has been serving as the founding partner and chairman of the board of directors and also as the General Manager in Anatolia since 2010.

He is fluent in English and German.



**Elif Akyüz**  
Vice Chairman of the Board of Directors

Born in Istanbul in 1975, Elif AKYÜZ graduated from Kadıköy Anatolian High School and completed her bachelor's, master's and doctorate degrees at Boğaziçi University, Department of Molecular Biology and Genetics.

Elif AKYÜZ, who later worked as a research assistant in the same field at Boğaziçi University, used her expertise for the development of diagnostic products in the private sector.

Elif AKYÜZ, who has been the founding partner and vice president of the board of directors since 2010, is the R&D Center Director and fluent in English, German and Italian.



**Kumru Ece Saran Selçuk**  
Member of the Board of Directors

Born in 1992 in Bursa, Kumru Ece SARAN SELÇUK graduated from Boğaziçi University, Department of Economics in 2015.

SARAN SELÇUK, who was ranked as second and third in Turkish swimming championships, played volleyball as a licensed volleyball player between 2004-2014.

SARAN SELÇUK, who joined Hugo Boss in 2015 after her experience in Information Rights Management (IRM) at Sony Electronics Istanbul office, continues her role as Marketing and Brand Communications Leader at Hugo Boss Turkey.

SARAN SELÇUK is fluent in English and German.



**Işıl Kurnaz**  
Independent Member of the Board of Directors

Born in Istanbul in 1974, Işıl KURNAZ graduated from Hüseyin Avni Sözen Anatolian High School and completed her bachelor's degree in Boğaziçi University, Department of Molecular Biology and Genetics, and her doctorate degree in the field of biochemistry at the University of London.

Işıl KURNAZ, who worked as a lecturer at Boğaziçi University and as a postdoctoral researcher at Manchester University, returned to Turkey in 2003 and took part in the establishment of the Department of Genetics and Bioengineering at Yeditepe University, and became an Assistant Professor, Associate Professor and Professor at the same university.

L'oreal Young Scientist and The Turkish Academy of Sciences, Outstanding Young Scientist award winner Prof. Dr. KURNAZ has been working at Gebze Technical University since 2014, where she still works as the founding director of the Biotechnology Institute.



**Duygun Erol Barkana**  
Independent Member of the Board of Directors

Born in 1980, Duygun EROL BARKANA graduated from Eskişehir Osmangazi University, Department of Electrical and Electronics Engineering in 2001 with the first rank.

After completing her master's degree at Vanderbilt University in 2003, her doctorate degree in 2007 and working as a Research Assistant, BARKANA has been continuing her academic life at Yeditepe University since 2007.

BARKANA, who has been the Head of the Department of Electrical and Electronics Engineering at Yeditepe University since 2017, has numerous national and international academic publications. In 2018, BARKANA won the Outstanding Young Scientist Award in Science and Engineering Sciences from the Turkish Academy of Sciences.



# CORPORATE GOVERNANCE

---



# Shareholders and Investor Relations

While ensuring the coordination of the Company's disclosure policy and corporate governance, the Investor Relations Department also maintains relations with investors, analysts, rating experts, regulatory bodies and various professional organizations in their respective fields.

Manager Responsible for Investor Relations and Contact Information:

Name and Surname	Title	Phone	E-Mail	License Certificate Type	License Document No.
Mehmet Gökalp	Finance and Accounting Director	0216 330 04 55			
Ali Rıza Tüzüngüven	Investor Relations Manager	0216 336 10 66	yatirimci.iliskileri@anatoliagenetworks.com	SPF Level 3 License, Corporate Governance Rating License.	204194 -700904

According to the 11-17.1 numbered "Corporate Governance Communiqué" prepared within the scope of compliance with the Capital Markets Law No. 6362 (CMB), which entered into force after being published in the Official Gazette dated 03.01.2014 and numbered 28871, the responsibilities carried out by our Investor Relations Department under the Finance and Financial Affairs Directorate, which was established to ensure communication between the partnerships and investors of the companies whose shares are traded on the Stock Exchange, within the scope of its duties during the operating period starting on October 21, 2021, the date of our public offering, are presented for your information.

- 19 Material Event Disclosures were made through the Public Disclosure Platform (PDP) during the 2024 activity period.
- During the 2024 operating period, verbal and written inquiries received from investors were answered promptly and within the framework of the law and in a manner that does not fall within the scope of trade secrets.
- Requests received from the Capital Markets Board, Borsa Istanbul and the Central Registry Agency and the Company's communication with the Trade Registry were provided by the Investor Relations Department.
- "Based on the announcement made by the Index Directorate of Borsa Istanbul A.Ş., information regarding Participation Finance Principles was requested, a new notification template titled 'Participation Finance Principles Information Form' was created and disclosed on KAP, and our company has been included in the Borsa Istanbul Participation Index."
- The 2023 Ordinary General Assembly Meeting of Anatolia Tanı ve Biyoteknoloji Ürünleri Araştırma Geliştirme Sanayi ve Ticaret Anonim Şirketi was held on Wednesday, June 26, 2024 at 11.00 a.m. at Hasanağa Mahallesi, Beydağı Sokak, No:1- 9H Sultanbeyli/ISTANBUL under the supervision of Sibel CAN, the Ministry Representative assigned by the letter dated 25.06.2024 and numbered 059314 of the Provincial Directorate of Trade of the Governorship of Istanbul.

- The entries and publication of the "Interim and Annual Financial Statements" and "Activity Reports" on the Public Disclosure Platform (KAP) on a quarterly and annual basis have been carried out by the Investor Relations Department.
- The Corporate Governance Compliance Report (URF) and the Corporate Governance Information Form (KYBF), prepared in accordance with the procedures and principles determined in the Capital Markets Board's decision dated 10.01.2019 and numbered 2/49, have been announced on KAP.
- In accordance with the decision of the Capital Markets Board dated 23.06.2022 and numbered 34/977, and pursuant to the Communiqué on Corporate Governance (II-17.1), disclosures required under the sustainability principles compliance framework by partners whose shares are traded in Borsa Istanbul's Main Market, Star Market, and Sub-Market have been made for the year 2023 using the Public Disclosure Platform (KAP) Sustainability Report template. Within this scope, the compliance status with sustainability principles, which is applied on a voluntary basis, has been published using the Sustainability Report template within the notification period of annual financial reports.
- The information required by the legislation to be included on the Company's website under the heading "Investor Relations" has been prepared and uploaded to the page.
- It was ensured that the Board of Directors' decisions taken during the year were duly kept.

# Share Information

<b>Traded on Stock Exchange:</b>	Istanbul Stock Exchange (BIST)
<b>Date Traded:</b>	21.10.2021
<b>Traded Market:</b>	BIST MAIN
<b>Company Sector:</b>	MANUFACTURING / CHEMICALS, PETROLEUM RUBBER AND PLASTIC PRODUCTS
<b>Trade Code :</b>	ANGEN
<b>Reuters Code :</b>	ANGEN.IS
<b>Bloomberg Code :</b>	ANGEN.TI

# Committees and Working Principles

At the Board of Directors meeting dated June 26, 2024 held after the Ordinary General Assembly within the framework of the provisions of the Capital Markets Board's Corporate Governance Communiqué No. 11-17.1 ("Communiqué");

i) Duygun Erol BARKANA to be appointed as the Chairman of the Corporate Governance Committee, Işıl KURNAZ and Ali Rıza TÜZÜNGÜVEN to be appointed as members, and the Corporate Governance Committee to fulfill the duties of the Nomination Committee and Remuneration Committee as described in the Communiqué,

ii) Duygun Erol BARKANA be appointed as the Chairman and Işıl KURNAZ be appointed as the member of the Early Identification of Risk Committee, which was established as a separate committee by the Board of Directors decision dated 05/07/2021 and numbered 21 within the scope of Article 378 of the Turkish Commercial Code No. 6102,

iii) To appoint Duygun Erol BARKANA as the Chairman and Işıl KURNAZ as the member of the Audit Committee established within the scope of the Capital Markets legislation.

## ANATOLIA TANI VE BİYOTEKNOLOJİ ÜRÜNLERİ ARAŞTIRMA GELİŞTİRME SANAYİ VE TİCARET A.Ş. WORKING PRINCIPLES OF THE AUDIT COMMITTEE

### 1. ESTABLISHMENT

At the Board of Directors meeting of Anatolia Tanı ve Biyoteknoloji Ürünleri Araştırma Geliştirme Sanayi ve Ticaret

Anonim Şirketi ("Company") dated 05/07/2021 and numbered 17, within the scope of the provisions of the Corporate Governance Principles in the Corporate Governance Communiqué (11-17.1) ("Communiqué") and Borsa İstanbul A.Ş. Audit Committee Duties and Working Principles Directive, the Audit Committee ("Committee") was established in order to ensure the healthy supervision of the financial and operational activities of our Company.

### 2. PURPOSE

The Committee was established to oversee the functioning of the Company's accounting and reporting systems within the framework of applicable laws and regulations, public disclosure of financial information, independent audit and the functioning and effectiveness of the internal control system.

These principles have been established within the framework of the regulations, provisions and principles in the Turkish Commercial Code, capital markets legislation and the Corporate Governance Principles in the Communiqué.

### 3. DUTIES AND RESPONSIBILITIES OF THE COMMITTEE

- 3.1. Public disclosure of the accounting system and financial information of the Company, independent audit and monitoring the operation and effectiveness of the internal control and internal audit system of the Company,
- 3.2. Selection of independent audit institution, initiation of independent audit process by preparing independent audit contracts and realization of works of independent audit institution at each stage under the supervision of the Committee. In addition, taking the necessary measures to conduct all kinds of internal and independent audits in an adequate and transparent manner,
- 3.3. Determining the services to be received from these institutions with the independent audit institution from which the service will be obtained and submitting it to the approval of the Board of Directors,
- 3.4. Determining the methods and criteria to be applied in the examination and conclusion of the complaints received by the Company regarding the accounting and internal control system and independent audit of the Company, and in the evaluation of the Company's employees' notifications on accounting and independent audit within the framework of the confidentiality principle,
- 3.5. Obtaining the opinions of the Company's responsible managers and independent auditors regarding the annual and interim financial statements and footnotes to be disclosed to the public, the rules brought by the legal regulations and international accounting principles and standards, the accounting principles followed by the Company, their truthfulness and accuracy, and notifying the Board of Directors in writing with their own evaluations,
- 3.6. In the meetings to be held following the publication of the relevant quarterly financial statements, a report shall be submitted to the Board of Directors after the examination of the related party transactions carried out in accordance with the continuous related party transaction whose annual approval has been obtained in the said period and the annual review of the related party transactions,
- 3.7. Observing the compliance with the internal regulations of the Company to prevent conflicts of interest that may arise between the members of the Board of Directors, senior management or other related parties and the misuse of information that may affect the value of the Company's shares within the scope of trade secret and
- 3.8. Fulfillment of the Capital Markets Board regulations and other duties assigned/to be assigned to the Committee by the Turkish Commercial Code.

### 4. STRUCTURE OF THE COMMITTEE

- 4.1. The Committee consists of at least 2 (two) members. All members of the committee must be independent members of the board of directors.
- 4.2. If the committee consists of two members, the majority of the members of the board of directors are required to consist of members of the board of directors who are not in charge of execution if they have more than two members. The chief executive officer/general manager cannot take part in the committee.
- 4.3. Experts who are not members of the Board of Directors cannot be members of the Committee.
- 4.4. All resources and support required for the Committee to fulfill its duties shall be provided by the Board of Directors. The Committee may invite the manager it deems necessary to its meetings and receive their opinions. The Committee makes use of independent expert opinions on matters it deems necessary in relation to its activities. The cost of the consultancy services required by the Committee shall be covered by the Company.

4.5. The Committee meets at least four times a year, at least once every three months, and the results of the meeting are recorded in the minutes and the decisions taken are submitted to the Board of Directors.

4.6. A disclosure is made in the annual activity report about the activities of the committee and the results of the meeting.

4.7. The Committee shall immediately notify the Board of Directors in writing of its findings and evaluations and suggestions regarding its duties and responsibilities.

4.8. When the new board of directors is elected at the ordinary general assembly meeting, the relevant board of directors shall appoint the members of the Committee in parallel with its term of office. The duties of the former committee members shall continue until the new members are elected.

4.9. The Committee is gathered with the participation of more than half of the members and the decision is taken with the majority of those attending the meeting. In case of equality of votes, the decision shall be taken in accordance with the vote of the Committee chairperson.

4.10. Meetings of the Committee may be held at the headquarters of the Company or elsewhere where the access of the members of the Committee is easy.

4.11. The decisions of the Committee are advisory to the Board of Directors, and the Board of Directors is the final decision-maker on relevant matters.

## 5. EFFECTIVENESS

This regulation on the duties and working principles of the Committee and amendments thereto shall enter into force upon the resolution of the Board of Directors.

## ANATOLIA TANI VE BİYOTEKNOLOJİ ÜRÜNLERİ ARAŞTIRMA GELİŞTİRME SANAYİ VE TİCARET A.Ş. WORKING PRINCIPLES OF THE CORPORATE GOVERNANCE COMMITTEE

### 1. ESTABLISHMENT

At the Board of Directors meeting of Anatolia Tanı ve Biyoteknoloji Ürünleri Araştırma Geliştirme Sanayi ve Ticaret Anonim Şirketi ("Company") dated 05/07/2021 and numbered 17, the Corporate Governance Committee ("Committee") was established to advise the Board of Directors in order to improve the Company's corporate governance practices within the scope of the Corporate Governance Principles provisions in the Corporate Governance Communiqué (11-17.1) ("Communiqué") and Borsa İstanbul A.Ş. Corporate Governance Committee Duties and Working Principles Directive.

### 2. PURPOSE

The Committee was established in order to determine whether the Corporate Governance Principles are implemented in our Company, if not, to determine the reasons thereof and the conflicts of interest arising from the failure to fully comply with these principles, to make recommendations to the board of directors to improve corporate governance practices and to oversee the work of the investor relations department. The Corporate Governance Committee also fulfills the duties of the Nomination Committee and the Remuneration Committee within the scope of the Communiqué.

These principles have been established within the framework of the regulations, provisions and principles in the Turkish Commercial Code, capital markets legislation and the Corporate Governance Principles in the Communiqué.

### 3. DUTIES AND RESPONSIBILITIES OF THE COMMITTEE

#### 3.1. Duties and Responsibilities Regarding Corporate Governance

3.1.1. Determining whether corporate governance principles are applied and conflicts of interest that may occur due to not fully complying with these principles, making recommendations to the Board of Directors to improve their practices,

3.1.2. Making annual evaluation within the scope of compliance with corporate management principles, preparing a report on compliance with corporate management principles and sending the results to the Board of Directors,

3.1.3. Monitoring whether the distribution of duties and powers among the organs, units, managers and employees

of the Company has been clearly and precisely determined, to make suggestions about the regulations to be made and the policies to be determined regarding the prevention of conflicts of interest that may arise in practice, to observe the compliance with these regulations and policies,

3.1.4. Making recommendations for the determination of the Company's information policy, observing the implementation of the determined policies, reviewing the scope, quality, consistency and accuracy of the disclosures and information to be given on the Company's website and activity report,

3.1.5. Following up the procedures for protecting the rights of those concerned with an impartial and balanced approach when conflicts of interest arise between the company and shareholders and other stakeholders, examining requests and complaints from shareholders and stakeholders in matters falling within the scope of their duties, submitting solution proposals to the Board of Directors,

3.1.6. Monitoring the facilitation of the protection and use of shareholding rights, in particular the right to information and review,

3.1.7. Monitoring the Company's business and transactions with related parties within the framework of corporate governance principles,

3.1.8. Carrying out studies for the establishment of corporate governance culture in the company and its adoption by managers and personnel at all levels,

3.1.9. Contributing to the determination and development of the Company's ethical rules and observing the execution of the Company's activities within the framework of these rules,

3.1.10. Monitoring the Company's sensitivity to corporate social responsibilities and compliance with environmental and public health regulations,

3.1.11. Supervision of Investor Relations unit,

3.1.12. Conducting studies on other matters that can be evaluated within the scope of corporate governance requested by the Board of Directors, and

3.1.13. Fulfillment of the Capital Markets Board regulations and other duties assigned/to be assigned to the Committee by the Turkish Commercial Code.

#### 3.2. Duties and Responsibilities within the scope of Nomination and Remuneration

3.2.1. Fulfillment of the duties of the Nomination Committee and Remuneration Committee,

3.2.2. Establishing a transparent system for determining, evaluating and training the appropriate candidates for the Board of Directors and managerial positions with administrative responsibility and determining the policies and strategies in this regard,

3.2.3. Making regular evaluations about the structure and efficiency of the Board of Directors and to submit its recommendations to the Board of Directors regarding the changes that can be made on these issues,

3.2.4. Determining the principles, criteria and practices to be used in the remuneration of the members of the Board of Directors and the managers with administrative responsibility by taking into account the long-term objectives of the company and supervising them,

3.2.5. Submitting proposals to the board of directors regarding the remuneration of board members and executives with administrative responsibilities, taking into account the degree of achievement of the criteria used in remuneration.

### 4. STRUCTURE OF THE COMMITTEE

4.1. The Committee consists of at least 2 (two) members, provided that the chairman is an independent board member.

4.2. If the committee consists of two members, the majority of the members of the board of directors are required to consist of members of the board of directors who are not in charge of execution if they have more than two members. The chief executive officer/general manager cannot take part in the committee.

4.3. Persons who can contribute to the functioning of the Company and who have sufficient knowledge and experience about the Company may be elected to the Committee. When necessary, experts who are not members of the Board of Directors are also assigned to the Committee.

4.4. All resources and support required for the Committee to fulfill its duties shall be provided by the Board of Directors. The Committee may invite the manager it deems necessary to its meetings and receive their opinions. The Committee makes use of independent expert opinions on matters it deems necessary in relation to its activities. The cost of the consultancy services required by the Committee shall be covered by the Company.

4.5. When the new board of directors is elected at the ordinary general assembly meeting, the relevant board of directors shall appoint the members of the Committee in parallel with its term of office. The duties of the former committee members shall continue until the new members are elected.

4.6. The Committee is gathered with the participation of more than half of the members and the decision is taken with the majority of those attending the meeting. In case of equality of votes, the decision shall be taken in accordance with the vote of the Committee chairperson. Decisions taken by the Committee are put in writing and recorded, and the Committee's recommendations are submitted to the Board of Directors.

4.7. The decisions of the Committee are advisory to the Board of Directors, and the Board of Directors is the final decision-maker on relevant matters.

4.8. In January of each year, the Committee prepares an annual evaluation report on the activities carried out in the previous year to form the basis of the Company's annual report and submits it to the Board of Directors.

4.9. The Committee shall meet as often as required by the task assigned to it. Meetings of the Committee may be held at the headquarters of the Company or elsewhere where the access of the members of the Committee is easy.

## 5. EFFECTIVENESS

This regulation on the duties and working principles of the Committee and amendments thereto shall enter into force upon the resolution of the Board of Directors.

### ANATOLIA TANI VE BİYOTEKNOLOJİ ÜRÜNLERİ ARAŞTIRMA GELİŞTİRME SANAYİ VE TİCARET A.Ş. WORKING PRINCIPLES OF THE EARLY IDENTIFICATION OF RISK COMMITTEE

#### 1. ESTABLISHMENT

At the Board of Directors meeting of Anatolia Tanı ve Biyoteknoloji Ürünleri Araştırma Geliştirme Sanayi ve Ticaret Anonim Şirketi ("Company") dated 05/07/2021 and numbered 17, the Early Detection of Risk Committee ("Committee") was established for the purpose of early detection of risk and establishment of an effective risk management system of our Company within the scope of the provisions of the Corporate Governance Principles contained in the Corporate Governance Communiqué (11-17.1) ("Communiqué") and Borsa İstanbul A.Ş. Early Detection of Risk Committee Duties and Working Principles Directive.

#### 2. PURPOSE

The Committee was established to advise and make recommendations to the Board of Directors of the Company on the early detection, evaluation, calculation of the impact and probability of strategic, operational, financial, legal and any other risks that may jeopardize the existence, development and continuity of the Company, management and reporting of these risks in accordance with the Company's corporate risk-taking profile, implementation of necessary measures regarding the risks identified, consideration in decision-making mechanisms and establishment and integration of effective internal control systems in this direction.

These principles have been established within the framework of the regulations, provisions and principles in the Turkish Commercial Code, capital markets legislation and the Corporate Governance Principles in the Communiqué.

#### 3. DUTIES AND RESPONSIBILITIES OF THE COMMITTEE

3.1. Identifying current and potential operational, strategic and other risks and preparing suggestions for taking relevant measures in connection with these risks,

3.2. Establishing risk management systems and establishing organizational infrastructures within the Company and increasing functionality, preparing proposals for the development of relevant systems,

3.3. Identifying, evaluating, monitoring the existing and possible risk factors that may affect the achievement of the objectives of the Company within the framework of the corporate risk management system and determining the principles related to the management of the risks in accordance with the risk of the Company taking profile and ensuring that they are used in the decision-making mechanisms,

3.4. Determining the risks to be kept and managed, shared or completely eliminated in the Company according to probability and impact calculations,

3.5. Providing an opinion to the Board of Directors in order to establish internal control systems in a way that shall include the processes of risk management and information systems that can minimize the effects of risks that may affect the stakeholders of the Company, especially shareholders,

3.6. Ensuring the integration of risk management and internal control systems into the corporate structure of the Company,

3.7. Reviewing the risk management systems at least once a year and ensuring that the applications in the relevant departments assuming the management responsibility of the risks are performed in line with the committee decisions,

3.8. Early identification of technical bankruptcy and ensuring that the Board of Directors is warned about this issue and developing suggestions regarding the measures to be taken,

3.9. Early detection of risks that may jeopardize the existence, development and continuation of the Company, taking the necessary measures regarding the identified risks and conducting studies to manage the risk,

3.10. Fulfillment of the Capital Markets Board regulations and other duties assigned/to be assigned to the Committee by the Turkish Commercial Code.

## 4. STRUCTURE OF THE COMMITTEE

4.1. The Committee consists of at least 2 (two) members, provided that the chairman is an independent board member.

4.2. If the committee consists of two members, the majority of the members of the board of directors are required to consist of members of the board of directors who are not in charge of execution if they have more than two members. The chief executive officer/general manager cannot take part in the committee.

4.3. Persons who can contribute to the functioning of the Company and who have sufficient knowledge and experience about the Company may be elected to the Committee. When necessary, experts who are not members of the Board of Directors are also assigned to the Committee.

4.4. All resources and support required for the Committee to fulfill its duties shall be provided by the Board of Directors. The Committee may invite the manager it deems necessary to its meetings and receive their opinions. The Committee makes use of independent expert opinions on matters it deems necessary in relation to its activities. The cost of the consultancy services required by the Committee shall be covered by the Company.

4.5. When the new board of directors is elected at the ordinary general assembly meeting, the relevant board of directors shall appoint the members of the Committee in parallel with its term of office. The duties of the former committee members shall continue until the new members are elected.

4.6. The Committee is gathered with the participation of more than half of the members and the decision is taken with the majority of those attending the meeting. In case of equality of votes, the decision shall be taken in accordance with the vote of the Committee chairperson. Decisions taken by the Committee are put in writing and recorded.

4.7. The Committee submits the findings and suggestions it has reached regarding its duties and responsibilities to the Board of Directors with a report to be prepared. The report is also sent to the auditor.

4.8. The decisions of the Committee are advisory to the Board of Directors, and the Board of Directors is the final decision-maker on relevant matters.

4.9. In January of each year, the Committee prepares and submits to the Board of Directors an annual evaluation report on the activities conducted in the previous year to form the basis for the issues to be included in the Company's annual report on risk.

4.10. The Committee shall meet as often as required by the task assigned to it. Meetings of the Committee may be held at the headquarters of the Company or elsewhere where the access of the members of the Committee is easy.

## 5. EFFECTIVENESS

This regulation on the duties and working principles of the Committee and amendments thereto shall enter into force upon the resolution of the Board of Directors.

## SUSTAINABILITY

At our Company's board of directors meeting dated January 16, 2023;

The provisions of the "Corporate Governance Communiqué" numbered 11-17.1 of the Capital Markets Law No. 6362 (CMB) were amended on October 02, 2020 in order to ensure "sustainability" of publicly traded companies and to ensure that they take concrete steps. Pursuant to the amendment, in the Sustainability Principles Compliance Framework, boards of directors will be able to determine their priorities in these areas, formulate policies and establish committees responsible for the implementation of these policies.

By evaluating these developments; establishing a Sustainability Committee to report to the Board of Directors in order to determine the sustainability strategy of Anatolia Tanı ve Biyoteknoloji Ürünleri Araştırma Geliştirme Sanayi ve Ticaret Anonim Şirketi in the fields of environmental, social and corporate governance, to carry out, monitor and audit the policies, targets and implementation plans in the field of sustainability and to fulfill the duties of improvement and development, to accept the duties and working principles of the Sustainability Committee, to appoint Duygun Erol BARKANA as the Chairman of the Sustainability Committee and Serra Ekin ŞEKERCİ as the member.

## **ANATOLIA TANI VE BİYOTEKNOLOJİ ÜRÜNLERİ ARAŞTIRMA GELİŞTİRME SANAYİ VE TİCARET A.Ş. DUTY AND WORKING PRINCIPLES OF THE SUSTAINABILITY COMMITTEE**

### **1. ESTABLISHMENT**

At the Board of Directors meeting of Anatolia Tanı ve Biyoteknoloji Ürünleri Araştırma Geliştirme Sanayi ve Ticaret Anonim Şirketi ("Company") dated 16/01/2023 and numbered 03, the Sustainability Committee ("Committee") was established with the amendment made to the Corporate Governance Communiqué (11-17.1) ("Communiqué") on October 02, 2020 in order to determine the sustainability strategy in the fields of environmental, social and corporate governance, to carry out the execution, monitoring and auditing of policies, targets and implementation plans in the field of sustainability, and to perform improvement and development duties.

### **2. SCOPE**

The working principles and duties determined by this committee include a harmonized management of sustainability principles and rules for managers and employees, consultants, dealers, business partners and suppliers serving Anatolia Tanı ve Biyoteknoloji Ürünleri Araştırma Geliştirme Sanayi ve Ticaret Anonim Şirketi in every step of all processes.

### **3. DUTIES AND RESPONSIBILITIES OF THE COMMITTEE**

- 3.1. Establishing the Company's Sustainability strategy, goals and policies,
- 3.2. Following national and international developments in sustainability,
- 3.3. Ensuring that reviews and improvements are carried out regarding the identification, measurement, monitoring, recording, recording, auditing, reporting of environmental, social and economic risks and impact dimensions of all activities in which the Company is involved, and disclosures to the public,
- 3.4. Ensuring that all employees are informed in line with the Company's sustainability strategy and goals, to work towards the internalization of employees, and to organize necessary trainings on relevant issues,
- 3.5. Communicating with Company stakeholders on Sustainability and coordinating stakeholder engagement,
- 3.6. Supporting the transition to a low-carbon economy within the scope of combating climate change and to ensure that projects are carried out to reduce carbon emissions in business processes,
- 3.7. Performing activities to ensure compliance with the principles included in the Sustainability Principles Compliance Framework announced by the CMB, to prepare the reports required by the Capital Markets Legislation in relation to sustainability and to submit them to the Board of Directors for approval to be disclosed to the public.

### **4. STRUCTURE OF THE COMMITTEE**

- 4.1. The Committee consists of at least 2 (two) members, provided that the chairman is an independent board member.
- 4.2. If the committee consists of two members, the majority of the members of the board of directors are required to consist of members of the board of directors who are not in charge of execution if they have more than two members. The chief executive officer/general manager cannot take part in the committee.
- 4.3. Persons who can contribute to the functioning of the Company and who have sufficient knowledge and experience about the Company may be elected to the Committee. When necessary, experts who are not members of the Board of Directors are also assigned to the Committee.
- 4.4. All resources and support required for the Committee to fulfill its duties shall be provided by the Board of Directors. The Committee may invite the manager it deems necessary to its meetings and receive their opinions. The Committee makes use of independent expert opinions on matters it deems necessary in relation to its

activities. The cost of the consultancy services required by the Committee shall be covered by the Company. 4.5. When the new board of directors is elected at the ordinary general assembly meeting, the relevant board of directors shall appoint the members of the Committee in parallel with its term of office. The duties of the former committee members shall continue until the new members are elected.

4.6. The Committee is gathered with the participation of more than half of the members and the decision is taken with the majority of those attending the meeting. In case of equality of votes, the decision shall be taken in accordance with the vote of the Committee chairperson. Decisions taken by the Committee are put in writing and recorded, and the Committee's recommendations are submitted to the Board of Directors.

4.7. The decisions of the Committee are advisory to the Board of Directors, and the Board of Directors is the final decision-maker on relevant matters.

4.8. In January of each year, the Committee prepares an annual evaluation report on the activities carried out in the previous year to form the basis of the Company's annual report and submits it to the Board of Directors.

4.9. The Committee shall meet as often as required by the task assigned to it. Meetings of the Committee may be held at the headquarters of the Company or elsewhere where the access of the members of the Committee is easy.

### **5.EFFECTIVENESS**

This regulation on the duties and working principles of the Committee and amendments thereto shall enter into force upon the resolution of the Board of Directors.

### **Sustainability Principles Compliance Statement**

With the Communiqué No. 11-17.1 of the Capital Markets Board on Amendments to the Corporate Governance Communiqué (11-17.1.a) published in the Official Gazette dated 02.10.2020, the Sustainability Principles Compliance Framework was put into practice and disclosed to the public through a press release issued by the Capital Markets Board. "Sustainability Principles Compliance Framework" includes the basic principles that publicly traded companies are expected to disclose while conducting their Environmental, Social and Corporate Governance (ESG) activities. While the implementation of these principles is voluntary, it is mandatory to report whether they have been implemented or not under the "Comply or Explain" principle.

Anatolia Tanı ve Biyoteknoloji Ürünleri Araştırma Geliştirme Sanayi ve Ticaret A.Ş. established the Sustainability Committee on 16.01.2023. During the year, efforts will be made in parallel with the Sustainability Principles Compliance Framework in terms of the company's compliance and reporting, and efforts will be made to ensure compliance with generally accepted best practices in this field as much as possible.

Full compliance has not yet been achieved due to the difficulties experienced in the implementation of some of the principles, uncertainties in the general, national and international arena, the fact that some of the principles do not fully overlap with the current structure and field of activity of the Company, and the principles of compliance will be determined as a result of the studies to be carried out. In order to ensure full compliance with the principles that overlap with the Company, work has started with the committee established and it is planned to achieve maximum compliance in the coming periods.

Within this framework, Sustainability Principles Compliance Report of Anatolia Tanı ve Biyoteknoloji Ürünleri Araştırma Geliştirme Sanayi ve Ticaret A.Ş.'s covering the 2022 Activity period includes the implementation of Environmental, Social and Corporate Governance activities in accordance with the Capital Markets Board principles with the principle of "Comply or Explain", and the main principles that have been complied with, not yet fully complied with or partially complied with are explained. The Sustainability Principles Compliance Report prepared within the framework of the Sustainability Principles has been examined by us and as a result of the evaluation made, the said Report has been found appropriate in line with our declaration above and submitted to your information.

# Sustainability Compliance Report

		COMPLIANCE STATUS				STATEMENT	LINKS TO PUBLICLY ANNOUNCED REPORTS
		YES	NO	PARTIALLY	N/A		
<b>A</b>	<b>GENERAL PRINCIPLES</b>						
<b>A1</b>	<b>Strategy, Policies and Goals</b>						
A1.1	The prioritised environmental, social and corporate governance (ESG) issues, risks and opportunities have been determined by the Company's Board of Directors.	X				The Board of Directors has identified the priority environmental, social, and governance (ESG) issues, risks, and opportunities. Environmental risks and opportunities are periodically reviewed by senior management.	
A1.1	The ESG policies (Environmental Policy, Energy Policy, Human Rights and Employee Policy etc.) have been created and disclosed to the public by the Company's Board of Directors.	X				The Board of Directors has published sustainability and Human Resources policies, sharing our views on human rights, employee policies, and environmental and sustainability issues with all our stakeholders through our website.	
A1.2	The short and long-term targets set within the scope of ESG policies have been disclosed to the public.	X				The Board of Directors has published human resources, environmental, and sustainability policies, setting our objectives in these areas.	<a href="https://www.anatoliagenetworks.com/kurumsal/surdurulebilirlik/">https://www.anatoliagenetworks.com/kurumsal/surdurulebilirlik/</a> <a href="https://www.anatoliagenetworks.com/wp-content/uploads/2024/05/Anatolia-Surdurulebilirlik-Politikasi.pdf">https://www.anatoliagenetworks.com/wp-content/uploads/2024/05/Anatolia-Surdurulebilirlik-Politikasi.pdf</a>
<b>A2</b>	<b>Implementation/Monitoring</b>						
A2.1	The responsible committees and/or business units for the implementation of ESG policies and the senior officials related to ESG issues in the Company and their duties have been identified and disclosed to the public.	X				The responsible committee was established on January 16, 2023, and has been reported to the Public Disclosure Platform (KAP).*	
A2.1	The activities carried out within the scope of policies by the responsible committee and/or unit have been reported to the Board of Directors at least once a year.	X				Activities carried out in 2024 with the committee were submitted to the board of directors in December and evaluated by the board of directors on January 10, 2025.	
A2.2	In line with the ESG targets, the implementation and action plans have been formed and disclosed to the public.			X		Although we have received an Environmental Impact Assessment (EIA) exempt opinion within the scope of our activities, it is aimed to bring our activities to the relevant law and maximum sensitivity level as much as possible due to our sustainability and environmental sensitivity, traceable targets such as key performance indicators have not been set for 2024.	
A2.3	The Key ESG Performance Indicators (KPI) and the level of reaching these indicators have been disclosed to the public on yearly basis.			X		Although we have received an Environmental Impact Assessment (EIA) exempt opinion within the scope of our activities, it is aimed to bring our activities to the relevant law and maximum sensitivity level as much as possible due to our sustainability and environmental sensitivity, traceable targets such as key performance indicators have not been set for 2024.	
A2.4	The activities for improving the sustainability performance of the business processes or products and services have been disclosed to the public.	X				Our activities aimed at improving the sustainability performance of our business processes, products, and services have been shared with our stakeholders through our website.	<a href="https://www.anatoliagenetworks.com/kurumsal/surdurulebilirlik/">https://www.anatoliagenetworks.com/kurumsal/surdurulebilirlik/</a>
<b>A.3</b>	<b>Reporting</b>						
A3.1	The information about the sustainability performance, targets and actions have been given in annual reports of the Company an understandable, accurate and sufficient manner.	X				The data related to our company's sustainability performance, objectives, and actions have been detailed in the 2024 Annual Activity Report.	

A3.2	The information about activities which are related to the United Nations (UN) 2030 Sustainable Development Goals have been disclosed to the public.	X					Our United Nations (UN) 2030 Sustainable Development Goals were determined and disclosed to the public in our 2024 Sustainability Report.	<a href="https://www.anatoliagenetworks.com/wp-content/uploads/2025/02/Surdurulebilirlik-Raporu-2024.pdf">https://www.anatoliagenetworks.com/wp-content/uploads/2025/02/Surdurulebilirlik-Raporu-2024.pdf</a>
A3.3	The lawsuits filed and/or concluded against the Company about ESG issues which are material in terms of ESG policies and/or will significantly affect the Company's activities, have been disclosed to the public.						X	There are no lawsuits filed against our company.
<b>A4.</b>	<b>Verification</b>							
A4.1	The Company's Key ESG Performance metrics have been verified by an independent third party and publicly disclosed.					X		There is currently no ongoing work related to this issue in the company.
<b>B</b>	<b>ENVIRONMENTAL PRINCIPLES</b>							
B1	The policies and practices, action plans, environmental management systems (known by the ISO 14001 standard) and programs have been disclosed.						X	An environmental management policy has been prepared and published on the website in 2024. The development of implementation-action plans, documentation for the environmental management system, and preparation of reports are ongoing.
B2	The environmental reports prepared to provide information on environmental management have been disclosed to the public which is including the scope, reporting period, reporting date and limitations about the reporting conditions.						X	Following audits and controls for the activities of both our facilities, the Ministry of Environment, Urbanization and Climate Change has shared the opinion that there is no harmful environmental impact. For our Free Zone Branch, we have a Zero Waste Certificate, and for both our facilities, recyclable wastes are processed, and all wastes are disposed of using appropriate disposal methods.
B4	The environmental targets within the scope of performance incentive systems which included in the rewarding criteria have been disclosed to the public on the basis of stakeholders (such as members of the Board of Directors, managers and employees).						X	There is currently no ongoing work/procedure related to this issue in the company.
B5	How the prioritised environmental issues have been integrated into business objectives and strategies has been disclosed.						X	Efforts are ongoing to identify our priority environmental issues, integrate and manage them within our business objectives and strategies.
B7	The way of how environmental issues has been managed and integrated into business objectives and strategies throughout the Company's value chain, including the operational process, suppliers and customers has been disclosed.						X	There is ongoing work within the scope of sustainability policies.
B8	Whether the Company have been involved to environmental related organizations and non-governmental organizations' policy making processes and collaborations with these organizations has been disclosed.						X	Necessary collaborations are being planned for the upcoming periods.
B9	In the light of environmental indicators (Greenhouse gas emissions (Scope-1 (Direct), Scope-2 (Energy indirect), Scope-3 (Other indirect), air quality, energy management, water and wastewater management, waste management, biodiversity impacts)), information on environmental impacts is periodically disclosed to the public in a comparable manner.						X	The company has not disclosed information about its environmental impacts to the public in a comparable manner on a periodic basis, based on environmental indicators.
B10	Details of the standard, protocol, methodology, and baseline year used to collect and calculate data has been disclosed.						X	The details of the standard, protocol, methodology, and base year used to collect and calculate the data have not been disclosed to the public. Despite not being publicly disclosed, we are implementing our policy within the institution to reduce energy consumption as much as possible and ensure complete processes for waste disposal and recycling.
B11	The increase or decrease in Company's environmental indicators as of the reporting year has been comparatively disclosed with previous years.						X	Consumption and recycling amounts are disclosed in the sustainability report.
B12	The short and long-term targets for reducing the environmental impacts have been determined and the progress compared to previous years' targets has been disclosed.						X	Not disclosed.
B13	A strategy to combat the climate crisis has been created and the planned actions have been publicly disclosed.						X	These actions are planned to be shared with the public in the future.

B14	The programs/procedures to prevent or minimize the potential negative impact of products and/or services on the environment have been established and disclosed.		X			These actions are planned to be shared with the public in the future.	
B14	The actions to reduce greenhouse gas emissions of third parties (suppliers, subcontractors, dealers, etc.) have been carried out and disclosed.		X			Not disclosed.	
B15	The environmental benefits/gains and cost savings of initiatives/projects that aims reducing environmental impacts have been disclosed.		X			Not disclosed.	
B16	The data related to energy consumption (natural gas, diesel, gasoline, LPG, coal, electricity, heating, cooling, etc.) has been disclosed as Scope-1 and Scope-2.		X			Not disclosed.	
B17	The information related to production of electricity, heat, steam and cooling as of the reporting year has been disclosed.				X	Not disclosed.	
B18	The studies related to increase the use of renewable energy and transition to zero/low carbon electricity have been conducted and disclosed.				X	Not disclosed.	
B19	The renewable energy production and usage data has been publicly disclosed.				X	Not disclosed.	
B20	The Company conducted projects about energy efficiency and the amount of reduction on energy consumption and emission achieved through these projects have been disclosed.				X	Not disclosed.	
B21	The water consumption, the amount, procedures and sources of recycled and discharged water from underground or above ground (if any), have been disclosed.				X	Not disclosed.	
B22	The information related to whether Company's operations or activities are included in any carbon pricing system (Emissions Trading System, Cap & Trade or Carbon Tax).				X	Not disclosed.	
B23	The information related to accumulated or purchased carbon credits within the reporting period has been disclosed.				X	Not disclosed.	
B24	If carbon pricing is applied within the Company, the details have been disclosed.				X	Not disclosed.	
B25	The platforms where the Company discloses its environmental information have been disclosed.				X	Not disclosed.	
<b>C</b>	<b>SOSYAL İLKELER</b>						
<b>C1</b>	<b>İnsan Hakları ve Çalışan Hakları</b>						
C1.1	İnsan Hakları Evrensel Beyanname, Türkiye'nin onayladığı ILO Sözleşmeleri ve diğer ilgili mevzuatı kapsayacak şekilde Kurumsal İnsan Hakları ve Çalışan Hakları Politikası oluşturulmuş, politikanın uygulanmasıyla ilgili sorumlular belirlenmiş ve politika ile sorumlular kamuya açıklanmıştır.			X		The Human Rights and Employee Rights Policy is included in the Management and Occupational Health and Safety Procedures. Additionally, personnel are employed in full compliance with current labor laws and regulations. The Human Resources policy has been published on the website.	<a href="https://www.anatoliagenetworks.com/kurumsal/insan-kaynaklari-politikamiz/">https://www.anatoliagenetworks.com/kurumsal/insan-kaynaklari-politikamiz/</a>
C1.2	Tedarik ve değer zinciri etkileri de gözeticilerle adil iş gücü, çalışma standartlarının iyileştirilmesi, kadın istihdamı ve kapsayıcılık konularına (cinsiyet, ırk, din, dil, medeni durum, etnik kimlik, cinsel yönelim, cinsiyet kimliği, ailevi sorumluluklar, sendikalar faaliyetleri, siyasi görüş, engellilik, sosyal ve kültürel farklılıklar vb. konularda ayırım yapılmaması gibi) çalışan haklarına ilişkin politikasında yer verilmiştir.	X				It is included in our Human Resources Policy and HR Procedures.	<a href="https://www.anatoliagenetworks.com/kurumsal/insan-kaynaklari-politikamiz/">https://www.anatoliagenetworks.com/kurumsal/insan-kaynaklari-politikamiz/</a>
C1.3	The measures taken for the minority rights/equality of opportunity or the ones who are sensitive about certain economic, environmental, social factors (low income groups, women, etc.) along the supply chain have been disclosed.	X				There are efforts in place to consider the rights and equal opportunities of groups sensitive to specific economic, environmental, and social factors (such as low-income groups, women, etc.) or minority rights. These efforts are included in our HR policy and activity report.	<a href="https://www.anatoliagenetworks.com/kurumsal/insan-kaynaklari-politikamiz/">https://www.anatoliagenetworks.com/kurumsal/insan-kaynaklari-politikamiz/</a>

C1.4	The developments regarding preventive and corrective practices against discrimination, inequality, human rights violations, forced and child labor have been disclosed.	X					It is included in our Human Resources Policy and activity report.	<a href="https://www.anatoliagenetworks.com/kurumsal/insan-kaynaklari-politikamiz/">https://www.anatoliagenetworks.com/kurumsal/insan-kaynaklari-politikamiz/</a>
C1.5	Investments in employees (education, development policies), compensation, fringe benefits, right to unionize, work/life balance solutions and talent management are included in the employee rights policy.	X					Our internal policies have been provided to employees, and our Human Resources policy has been published on our website.	
C1.5	Mechanisms for resolving employee complaints and disputes have been established and dispute resolution processes have been determined.	X					It is included in our Human Resources Policy.	
C1.5	Activities carried out during the reporting period to ensure employee satisfaction were disclosed to the public.		X				Not disclosed.	
C1.6	The occupational health and safety policies have been established and disclosed.				X		Occupational health and safety policies have been created and shared with employees but have not been disclosed to the public. It is planned to be disclosed in future periods.	
C1.6	The measures taken for protecting health, preventing occupational accidents and related statistics have been disclosed.				X		Measures to prevent workplace accidents and protect health have been established and shared with employees but have not been disclosed to the public.	
C1.7	The personal data protection and data security policies have been established and disclosed.				X		Policies for the protection of personal data and data security have been established and shared with employees and relevant stakeholders, but they have not been disclosed to the public.	
C1.8	The ethics policy have been established and disclosed.	X					Ethics policy has been established and disclosed to the public.	
C1.9	Activities within the scope of social investment, social responsibility, financial inclusion, and access to finance were explained.		X				Not disclosed.	
C1.10	The informative meetings and training programs related to ESG policies and practices have been organized for employees.	X					Informational meetings and training programs on ESG (Environmental, Social, and Governance) policies and practices are conducted for employees.	
<b>C2</b>	<b>Stakeholders, International Standards and Initiatives</b>							
C2.1	The customer satisfaction policy regarding the management and resolution of customer complaints has been prepared and disclosed.				X		Customer satisfaction policies for managing and resolving customer complaints have been established and shared with employees and relevant stakeholders but have not been disclosed to the public.	
C2.2	The information about the communication with stakeholders (which stakeholder, subject and frequency) have been disclosed.	X					As part of investor relations efforts, meetings held with investors have been included in the activity report.	
C2.3	The international reporting standards that adopted in reporting have been explained.		X				The international reporting standards adopted in the reports have not been disclosed.	
C2.4	The principles adopted regarding sustainability, the signatory or member international organizations, committees and principles have been disclosed.					X		
C2.5	The improvements have been made and studies have been carried out in order to be included in the Borsa Istanbul sustainability indices and/or international index providers.		X				After transforming the committee's activities into concrete steps, it is planned to take the necessary actions to be included in the sustainability index.	
	<b>CORPORATE GOVERNANCE PRINCIPLES</b>							
D1	The opinions of stakeholders have been sought in the determination of measures and strategies related to sustainability field.		X				No feedback has been received from stakeholders.	
D2	The social responsibility projects, awareness activities and trainings have been carried out to raise awareness about sustainability and its importance.	X					Training activities within the scope of environmental consultancy, which started in 2024 for both of our facilities, are continued periodically.	

# Policies

## ANATOLIA TANI VE BİYOTEKNOLOJİ ÜRÜNLERİ ARAŞTIRMA GELİŞTİRME SANAYİ VE TİCARET A.Ş. DISCLOSURE POLICY

Anatolia Tanı ve Biyoteknoloji Ürünleri Araştırma Geliştirme Sanayi ve Ticaret Anonim Şirketi ("Company") disclosure policy ("Policy") has been prepared in accordance with the Turkish Commercial Code No. 6102 ("TCC") and Capital Markets Law No. 6362 ("CMB Law") and the Capital Markets Board's ("CMB") Communiqué on Material Events (11-15.1) ("Communiqué on Material Events"), Communiqué on Corporate Governance (11-17.1) ("Communiqué") and the Corporate Governance Principles ("Corporate Governance Principles").

### 1. Purpose and Scope

The Company management maintains a transparent and close communication with its shareholders. The main objective is to increase the value of the Company for shareholders and potential investors.

The purpose of this Disclosure Policy is to ensure that information and developments regarding the Company's strategy and targets, which may affect the Company's investment decisions and which do not constitute trade secrets, are presented in a fair, complete, accurate, timely and easily understandable manner to the information of stakeholders, particularly investors, within the framework of the relevant legislation. The Company complies with the Capital Markets Law, capital markets legislation, Turkish Commercial Code and Borsa İstanbul A.Ş. ("BIST") regulations regarding public disclosure and pays utmost attention to the realization of the principles set forth in the CMB's Corporate Governance Principles.

This Policy covers all employees and consultants of the Company and regulates the written and verbal communication of the Company with capital market participants.

This Policy has been prepared in accordance with Article 17 of the CMB's Communiqué on Material Events and is disclosed to all stakeholders via the Company's website (www.anatoliagenetworks.com).

### 2. Authority and Responsibility

This Policy has been established and approved by the Board of Directors within the framework of the CMB Corporate Governance Principles. The Board of Directors reserves the authority to amend this policy. Amendments to this policy are published on the Company's website following the approval of the Board of Directors. The monitoring, supervision and development of the Company's public disclosure and information policy is under the authority and responsibility of the Board of Directors. The head of the Company's investor relations department is assigned to oversee and monitor all matters related to public disclosure.

### 3. Public Disclosure Methods and Tools

Disclosures are made through disclosure tools such as material event disclosures, financial statements and reports, annual reports, website, presentations, investor meetings and teleconferences, information letters, press releases, Trade Registry Gazette. Without prejudice to the provisions of the Capital Markets Legislation and the Turkish Commercial Code, the main public disclosure methods and tools used by the Company are set out below;

- Material event disclosures communicated through the Public Disclosure Platform ("PDP"),
- Financial statements and footnotes, independent audit report, declarations and annual report periodically disclosed to PDP,
- Announcements and notices made through the Turkish Trade Registry Gazette and daily newspapers,
- Press releases made through written and visual media,
- Informational meetings and meetings held with capital market participants face-to-face or via tele-conference,

- Corporate website, (www.anatoliagenetworks.com) disclosures,
- Disclosures made through communication methods and tools such as telephone, communication via mobile phone (wap and similar technologies), electronic mail, telefax, etc.

### 4. Public Disclosure of Financial Statements

The Company's financial statements and notes are prepared on a consolidated basis and in accordance with Turkish Accounting Standards/Turkish Financial Reporting Standards (TAS/TFRS). Annual and semi-annual financial statements are independently audited and disclosed to the public.

Financial statements and footnotes are approved by the Board of Directors with the approval of the Audit Committee within the framework of the provisions of the Capital Markets Legislation before being disclosed to the public. After the statement of accuracy is signed, the financial statements and footnotes, the independent auditor's report and the annexed documents are disclosed to the public through the Public Disclosure Platform (PDP) and published on the Company's website in accordance with the CMB and BIST regulations, following the approval of the Board of Directors. Prior period financial statements and footnotes as well as information that may be required by shareholders are available on the Company's website.

### 5. Public Disclosure of Annual and Interim Activity Reports

Annual and interim activity reports are prepared in accordance with the Capital Markets Legislation and CMB Corporate Governance Principles and other regulations in force within this scope. Annual reports are approved by the Board of Directors and disclosed to the public through PDP together with the financial statements and published on the Company website (www.anatoliagenetworks.com). The annual activity report is also printed in hard copy to be given to those concerned.

### 6. Public Disclosure of Inside Information and Authorized Persons

Material event disclosures regarding the Company's insider information are prepared by the Company's investor relations department and disclosed to the public by signing electronically and submitting to the PDP.

Material event disclosures are prepared in a timely, accurate, understandable, adequate and free from misleading statements in order to help the persons and organizations that will benefit from the disclosure to make decisions. If any Company employee determines that any important and private information that has not been previously disclosed to the public has been disclosed to the public unintentionally, he/she shall immediately notify the investor relations department. In this case, an appropriate material event disclosure is prepared by the investor relations department in accordance with the provisions of the Capital Markets Legislation and submitted to the PDP.

The Company announces the material event disclosures on its website (www.anatoliagenetworks.com) in Turkish no later than the business day following the public disclosure and keeps the said disclosures on its website for five years.

### 7. Persons Authorized to Make Public Disclosures

In addition to the above-mentioned notifications, written and verbal information requests submitted by Capital Market Participants, or any organization/person are evaluated by the Investor Relations Department. In the evaluation made; according to the content of the request, it is taken into consideration whether it is a trade secret or not and whether it is of a type that may affect investment decisions and the value of capital market instruments within the framework of the Communiqué on Material Events. Written and verbal information requests are generally answered by the investor relations department.

Press releases to the written and visual media may only be made by the members of the board of directors, the general manager, the assistant general manager responsible for the software business group, the assistant general managers responsible for the business and product development business group, the assistant general manager responsible for the marketing, sales and corporate communications business group and the director responsible for the financial and administrative affairs business group. Unless specifically authorized to do so, Company employees do not answer questions from capital market participants. Incoming information requests are directed to the investor relations department.

#### 8. List of Persons with Administrative Responsibility and Access to Inside Information

Persons with administrative responsibility are those who, directly or indirectly, have regular access to the Company's internal information and are authorized to make administrative decisions affecting the Company's future development and business objectives. Therefore, persons who are not authorized to make administrative decisions are not considered as persons with administrative responsibility and continuous access to inside information.

In addition to the members of the Board of Directors, the persons who have regular access to information and who are also authorized to make administrative decisions are deputy general managers. All transactions carried out by persons with administrative responsibility and persons closely related to them in relation to the shares representing the capital and other capital market instruments based on these shares are disclosed to the public by those who make the transaction within the framework of the principles written in the Communiqué on Material Events.

In accordance with Article 7 of the Communiqué on Material Events, the list of those who have access to insider information is kept in writing to be submitted to the CMB and/or BIST upon request. Everyone on the list is informed about the protection of inside information and the need to comply with the rules of confidentiality in the course of their duties. This list is available at the Company and has been notified to Merkezi Kayıt Kuruluşu A.Ş. When there is a change in these persons, the necessary update is made within two business days at the latest.

#### 9. Communication with Capital Market Participants

To the extent permitted by Turkish capital markets legislation, the Company may provide guidance on expectations regarding interim and annual operating results. Instead, the Company may communicate to capital market participants critical issues affecting its results of operations, strategic approaches and important elements that provide a better understanding of the industry and the environment in which it operates. Unless otherwise stated in the Disclosure Policy, only persons authorized to make public disclosures may communicate with capital market participants on behalf of the Company.

#### 10. Unsubstantiated News Circulating in the Market

News and rumours in the market in written, visual or audio media organs and/or on the internet are monitored by keeping up to date with the market. In principle, the Company does not comment on market rumor and speculation. The Investor Relations Department monitors news and rumours about the Company in the press and on websites. This section assesses whether this news and information will have an impact on capital market instruments. If necessary, the Company also decides whether to make a material event disclosure within the framework of Article 9 of the Communiqué on Material Events.

In cases where there is a decision to postpone an announcement, the Company may refrain from making any announcement until the reasons for the postponement are lifted.

On the other hand, when a verification request is received from the CMB and/or BIST within the provisions of the capital markets legislation or if the management decides that a response is necessary and more appropriate, a statement is made about the rumor and gossip in the market.

#### 11. Postponement of Public Disclosure of Inside Information

Persons on the Company's list who have access to inside information are informed about their obligations to keep the inside information that they may have during the performance of their duties or the execution of business and

transactions on behalf of the Company, which has not yet been disclosed to the public, confidential, not to use it for the benefit of themselves or third parties, or not to disclose it to third parties without authorization.

The Company may postpone the public disclosure of insider information within the framework of Article 6 of the Communiqué on Material Events in order to prevent damage to its legitimate interests and to avoid misleading investors; in this case, the Company shall inform the relevant persons about the postponement and take measures to ensure confidentiality. Deferral is made upon the written approval of the board of directors or senior executives who are generally authorized by the board of directors.

As soon as the reasons for postponement of public disclosure of insider information are removed, public disclosure is made in accordance with the legislation. The statement shall state the decision to postpone and the underlying reasons for the postponement.

#### 12. Measures to Ensure Confidentiality of Inside Information until Public Disclosure

As a general principle, employees working on behalf of and on account of the Company may not share with third parties any information that has not yet been disclosed to the public and that may be considered a material event. In the event that it is determined that inside information has been disclosed to third parties without being requested by these persons, a material event disclosure shall be made immediately if it is concluded that the confidentiality of the information cannot be ensured within the scope of capital markets regulations. If the disclosure of the information is postponed, a list of the persons who have access to the information subject to the postponement is drawn up at the time of the postponement decision and the "List of Persons with Access to Inside Information" is updated in this context. Reasonable measures shall be taken by carrying out the necessary work to inform both these persons and parties who have information other than these persons. Persons on the list of those who have access to such insider information are informed by the investor relations department that they are on the list for the purpose of protecting insider information and ensuring compliance with confidentiality rules until the public disclosure of material events, financial and operational results. The Company signs confidentiality agreements with the institutions that need inside information or use this information on behalf of and on account of the Company in the performance of its duties, from which it receives services such as consultancy and translation services, and obliges these institutions to keep such information confidential. The Company takes all kinds of measures to ensure the confidentiality of insider information in accordance with the relevant legislation.

#### 13. Meetings and Discussions with Investors and Analysts

The Company may organize informative meetings for analysts, investors, creditors and shareholders when deemed necessary. Meetings do not have a predetermined calendar year and the frequency of the meetings is determined according to need. The Company uses various instruments such as roadshows, teleconferences, e-mails, teleconferences, e-mails, faxes, analyst presentations, statements/announcements for direct information in order to increase the recognition and preferability of the Company in the field of international investment, to highlight the advantages of the Company compared to other companies in an equivalent position and to make the Company preferable for investing institutions compared to other companies.

The Company considers analyst reports to be the property of the company that prepared the analyst report and does not publish them on the Company's website (www.anatoliagenetworks.com). The Company does not review, verify, endorse, take responsibility for or disseminate analyst reports or revenue models. However, in certain specific and limited circumstances and upon request, the Company may review analyst reports to avoid misinforming the public, provided that it uses only publicly available historical information and is limited to a specific topic.

#### 14. Public Disclosure of Future Assessments

From time to time, the Company may disclose its future expectations to the public in accordance with its disclosure policy. Forward-looking statements may be disclosed subject to a resolution of the board of directors or the written approval of the person authorized by the board of directors. A maximum of four announcements can be made per year. It may be disclosed on PDP in material disclosure format or presentation format. If there is a significant change in future assessments, this number limit may be exceeded and the necessary disclosure

is made. Future assessments may be made by utilizing press and media organs, press conferences, press releases, national and international conferences, meetings or other means of communication in addition to material event disclosures within the framework of the principles set forth in the Capital Markets Legislation.

It is submitted for the information of those concerned that forward-looking assessments shared with the public are based on certain assumptions and may differ from actual results. In the event of significant changes in future assessments or if it is understood that the assessments will not be realized, the public is periodically informed by the same means without delay.

#### 15. Silent Period

The Company refrains from discussing the Company's results of operations and financial position to be reported in the financial statements with capital market participants during certain periods of the calendar year in order to prevent asymmetric information dissemination and unauthorized disclosures related to the financial statements. This period is called the "silent period". For the Company, the quiet period begins on the day following the end of each quarterly, half-yearly and annual accounting period and ends one business day after the day on which the financial statements and footnotes are publicly announced.

In addition, during the silent period (only for annual and semi-annual accounting periods), persons who possess inside information or continuous information or their spouses, children or persons living in the same household are prohibited from trading in the Company's capital market instruments.

#### 16. Market Distorting Actions

Within the framework of the relevant provisions of the CMB's Communiqué on Market Abuse (VI-104.1), the board of directors takes and implements the necessary measures to ensure that the persons included in the insider information list do not use confidential and/or trade secret and non-public information about the Company, which are within the scope of market abuse, in a way to benefit themselves or others, and that they do not provide false or misleading information about the Company or spread news.

#### 17. Company Website (www.anatoliagenetworks.com)

The Company's website at www.anatoliagenetworks.com is actively used for public disclosure as recommended by the CMB Corporate Governance Principles. The disclosures on the Company's website do not replace the notifications and material event disclosures required to be made pursuant to the provisions of capital markets legislation. All public disclosures made by the Company are accessible via the website, and the website is structured and segmented accordingly. All kinds of measures are taken regarding the security of the website. The website is organized in the content and manner stipulated by the CMB Corporate Governance Principles. In particular, the announcement regarding the general assembly meetings to be held, the information document regarding the agenda items, other information, documents and reports related to the agenda items, and information on the methods of participation in the general assembly meetings are prominently displayed on the website. Continuous efforts are made to improve the website.

#### ANATOLIA TANI VE BİYOTEKNOLOJİ ÜRÜNLERİ ARAŞTIRMA GELİŞTİRME SANAYİ VE TİCARET A.Ş. DONATION AND AID POLICY

Anatolia Tanı ve Biyoteknoloji Ürünleri Araştırma Geliştirme Sanayi ve Ticaret Anonim Şirketi ("Company") donation and aid policy ("Policy") has been established in accordance with the Corporate Governance Communiqué (11-17.1) of the Capital Markets Board ("CMB").

Subject to the limitations set forth in this Policy, our Company may make aids and donations to individuals, non-governmental organizations, associations or foundations, universities, public institutions and organizations operating in the fields of education, culture, arts, environment and sports with an understanding of corporate social responsibility, including but not limited to the aforementioned, in accordance with the principles set forth in the Capital Markets Law No. 6362, CMB's Dividend Communiqué (11-19.1) and other capital markets legislation. The Company may donate and provide assistance to natural persons and public or private legal entities in a manner that shall not disrupt the purpose and subject of the Company, provided that it shall make necessary special case

disclosures and shall submit the donations made within the year to the information of the shareholders in the General Assembly, provided that it shall act in compliance with the concealed profit transfer regulations of the Capital Market legislation and other relevant legislation.

All donations and grants made upon the decision of the Company's management are made in accordance with the Company's vision, mission and policies and in consideration of the Company's ethical principles and values. Donations and grants can be made in two ways as cash and in kind.

In line with the principles set forth in this Policy and the legislation to which it is subject, the Company submits all donations and grants made in each accounting period to the information of the shareholders with a separate agenda item at the general assembly meeting of the relevant year.

In case the last balance sheet assets total of the donations and aids made by the Company within the framework of the Capital Market legislation is at least 1% or more or the sum of donations and grants below 1% reaches at least 1% of the last balance sheet assets declared to the public, necessary special case statements are made.

#### ANATOLIA TANI VE BİYOTEKNOLOJİ ÜRÜNLERİ ARAŞTIRMA GELİŞTİRME SANAYİ VE TİCARET A.Ş. PROFIT DISTRIBUTION POLICY

Anatolia Tanı ve Biyoteknoloji Ürünleri Araştırma Geliştirme Sanayi ve Ticaret Anonim Şirketi ("Company") dividend distribution policy ("Policy") has been prepared in accordance with the provisions of the Turkish Commercial Code No. 6102 ("TCC"), Capital Markets Law No. 6362 ("CMB Law"), Capital Markets Legislation, Capital Markets Board ("CMB") Dividend Communiqué (11-19.1), and our articles of association.

The profit for the period shown in the annual balance sheet is determined by determining the amount remaining after deducting from the income determined at the end of the fiscal year the amounts that must be paid and set aside by the Company in accordance with general accounting principles, such as general expenses and depreciation costs of the Company, and the provisions set aside for taxes and financial liabilities to be paid by the Company, from the income determined at the end of the fiscal year, and the net profit for the period distributable after deducting the losses of previous years, if any, is determined.

The Company aims to distribute at least 40% of the distributable net profit for the period calculated in accordance with the Articles of Association, TCC, CMB, Dividend Communiqué (11-19.1) and tax regulations, provided that it is approved by the General Assembly and dividend distribution is not restricted in accordance with the relevant legislation. Although companies whose shares are traded on Borsa İstanbul A.Ş. are not obliged to make any dividend distribution decisions, the Company aims to establish an ongoing tradition of dividend distribution. For the avoidance of doubt, this target is not a commitment and cannot be interpreted as a commitment. Dividend may be distributed in cash and/or free of charge and/or by using these two methods together in certain proportions. The implementation of this policy and the proportion of the dividend to be distributed depend on a number of factors, including but not limited to the Company's investment and financing strategies and needs, changes and developments in the relevant legislation, market expectations, the Company's medium and long-term strategies, the capital and investment requirements of the Company and/or its affiliates and subsidiaries, profitability, financial position, indebtedness and cash status, and national and global economic conditions. In line with these conditions, the rate of distributable profit may be reduced each year with the recommendation of the board of directors and the approval of the general assembly, or it may be decided not to distribute any profit within the framework of the principles stated above.

The dividends shall be distributed to the shareholders on the date determined by the general assembly following the approval of the general assembly within the legal periods, regardless of their issuance and acquisition dates, to all of the existing shares as of the date of distribution. Profit share distribution can be made at a time or in installments.

In the event that the Company defaults due to the failure to fulfill its obligations arising from the contracts to which it is a party, especially credit contracts, it may not be able to distribute profits due to the restrictions in the relevant contracts.

From the income determined at the end of the Company's operating period, the amount that is required to be paid or reserved by the Company, such as general expenses and various depreciation, and the remaining profit after deducting the compulsory taxes to be paid by the Company's legal entity, and the amount after deducting the loss of previous years, if any, are distributed in the following order and principles:

**a. General Legal Reserves:** Until it reaches 20% of the capital, 5% is set aside as general legal reserves.

**b. First Dividend:** The first profit share is allocated from the remaining amount over the amount to be found with the addition of the donation amount, if any, within the framework of the Company's profit distribution policy in accordance with the Turkish Commercial Code and capital market legislation.

c. After the above-mentioned deductions are made, the General Assembly has the right to decide on the distribution of dividends to the members of the Board of Directors, employees of the Company and persons other than shareholders.

**d. Second Dividend:** The General Assembly is authorized to distribute the amount remaining after deducting the amounts specified in subparagraphs (a), (b) and (c) from the net profit for the period, in whole or in part, as second dividend, to add it to the reserves set aside by law and the articles of association, to set it aside as extraordinary reserves or to leave it in the balance sheet as retained earnings. Unless the amounts specified in subparagraphs (a) and (b) above are set aside, the General Assembly cannot decide to set aside other reserves, to transfer profit to the following year or to distribute dividends under any name.

**e. General Legal Reserves:** After deducting the dividend at the rate of 5% of the capital from the portion decided to be distributed to the shareholders and other persons participating in the profit, 10% of the amount found after deducting the dividend at the rate of 5% of the capital shall be added to the general legal reserve fund.

Unless the dividend determined for the shareholders in the articles of association and the reserve funds required to be allocated in accordance with the TCC and the profit share determined for the shareholders in the articles of association are allocated; no decision may be made to allocate another reserve fund, to transfer profit to the following year and to distribute a share from the profit to the members of the Board of Directors, partnership employees and persons other than the shareholder and no share from the profit can be distributed to these persons unless the profit share determined for the shareholders is paid in cash.

The decision to distribute profits made by the General Assembly in accordance with the provisions of the Articles of Association shall not be revoked unless permitted by the relevant legal regulations.

The dividend is distributed to all of the existing shares as of the date of distribution, regardless of their issuance and acquisition dates. The form and time of distribution of the profit agreed to be distributed shall be agreed by the general assembly upon the proposal of the board of directors in this regard.

The General Assembly may decide to distribute profit share advance to shareholders within the framework of the relevant provisions of the TCC and capital market legislation.

## ANATOLIA TANI VE BİYOTEKNOLOJİ ÜRÜNLERİ ARAŞTIRMA GELİŞTİRME SANAYİ VE TİCARET A.Ş. . REMUNERATION POLICY

Anatolia Tanı ve Biyoteknoloji Ürünleri Araştırma Geliştirme Sanayi ve Ticaret Anonim Şirketi ("Company") remuneration policy ("Policy") has been prepared in accordance with the Corporate Governance Communiqué (11-17.1) of the Capital Markets Board ("CMB").

This Policy is a guideline and aims to determine the principles of remuneration in a fair, consistent, balanced with the responsibilities taken and competitive with the market and has been approved by the Board of Directors.

### 1. Scope

Şirket bu Politika'da belirtilen esaslar, 6362 sayılı Sermaye Piyasası Kanunu ve SPK'nın Kurumsal Yönetim Tebliği (II-17.1) ve diğer Sermaye Piyasası Mevzuatı çerçevesinde idari sorumluluğu bulunanlar kapsamındaki yönetim kurulu üyelerimiz ve üst düzey yöneticilerimizin ücretlendirme sistem ve uygulamalarını kapsamaktadır.

### 2. Policy

Dividends, share options or payment plans based on the Company's performance cannot be used in the remuneration of independent board members.

The Company may not lend money or extend credit to any member of the Board of Directors or executives with administrative responsibility.

The remuneration of the members of the Board of Directors shall be determined by a resolution of the General Assembly.

Expenses incurred by the members of the Board of Directors due to their contributions to the Company (transportation, accommodation, telephone, insurance, etc. expenses) may be covered by the Company.

As part of our policy; wage and fringe benefits management is organized and implemented in line with fair, objective, high performance, competitive, rewarding and motivating criteria and main objectives.

The main objectives of our policy are to make remuneration by emphasizing the concepts of job size, performance, contribution to the business, knowledge/skills and competencies, to motivate employees and increase their loyalty by ensuring intra-company and inter-company wage balance and competitiveness in the market, and to recruit the workforce with appropriate competencies that will enable our Company to achieve its goals.

Senior executive remuneration is based on a fixed (base) salary system:

Fixed salaries are cash payments made regularly and continuously on a monthly basis and in fixed amounts, regardless of performance. Such remuneration is determined taking into account the financial situation of the Company and is paid to all employees based on the duration of employment, title and nature of the work performed. While determining the remuneration of the members of the Board of Directors and other senior executives, the Company determines an annual remuneration for these persons on an annual basis in accordance with the market conditions, the Company's strategies, policies and performance, taking into account the duties and responsibilities they have undertaken in the Company. The Company may also exceptionally make payments in cash or in kind to some or all of the employees or only to the members of the Board of Directors and senior executives for incentive purposes without a contractual commitment. Incentive payments are not regular performance-based achievement bonuses, but rather an appreciation payment given to reward the extra success of the Company's employees in their work and to encourage success.

In order to support salary management with additional benefits, the Company provides "fringe benefits" (fringe benefits). The fringe benefits provided by the Company are in line with market conditions, competitive and fair. In line with this, benefits such as [company car] may be provided to senior executives, as well as other benefits such as supplementary health insurance.

#### Remuneration and similar benefits provided to senior executives:

As of December 31, 2024, the total gross number of salaries and similar benefits provided to the Chairman, Vice Chairman, members of the Board of Directors, and other key management in the current period is 28.222.026 TL (December 31, 2023: 9.567.727 TL).

## ANATOLIA TANI VE BİYOTEKNOLOJİ ÜRÜNLERİ ARAŞTIRMA GELİŞTİRME SANAYİ VE TİCARET A. Ş. ENVIRONMENTAL POLICY

We, Anatolia Geneworks (Anatolia Tanı ve Biyoteknoloji Ürünleri Ar-Ge San. ve Tic. A.Ş.), are a company operating in the field of biotechnology, and we are committed to the sustainable use of natural resources and reducing our environmental impact. The fundamental principles of our environmental policy are as follows:

### 1. Legal Compliance

We strive to fully comply with relevant environmental legislation in all our activities. By considering the specific requirements of the biotechnology industry, we embrace standards that exceed legal requirements and promote best practices in environmental protection.

### 2. Resource Efficiency

We continuously review our processes and explore opportunities for improvement to ensure the efficient utilization of natural resources. In biotechnological processes, our focus is on reducing energy, water, and other resource consumption, thereby minimizing waste generation.

### 3. Waste Management

We are actively working on reducing, reusing, and recycling waste. We continuously develop waste management processes to minimize the waste generated in biotechnological processes and to manage hazardous waste appropriately.

### 4. Environmental Awareness and Education

We regularly organize training and awareness programs to educate and inform our employees about environmental issues. We encourage innovative practices in the field of biotechnology and the participation of our employees in efforts to reduce environmental impact. Whether mandatory or not, we ensure compliance with environmental laws by obtaining environmental consulting in all our branches.

### 5. Supply Chain Management

We expect our suppliers to promote nature-friendly practices and adhere to sustainability standards. We continuously assess our biotechnology supply chain and cooperate to reduce environmental impact.

### 6. Innovation and Technology

We encourage the adoption of nature-friendly technologies and focus on reducing our environmental impact by seeking innovative solutions. In the field of biotechnology, we invest in research and development to promote sustainable practices and contribute to the development of green technologies.

### 7. Stakeholder Collaboration

We collaborate with our stakeholders to jointly reduce our environmental impact. By cooperating with our suppliers, local governments, academic institutions, and the community, we strive to find joint solutions.

This policy reflects our commitments to our employees, customers, suppliers, and the community. We will continuously monitor and seek to improve our environmental performance. We will regularly review and update our environmental policy and maintain open and transparent communication with all our stakeholders. The implementation and effectiveness of this policy will play a critical role in achieving the environmental sustainability goals of Anatolia Geneworks.

## ANATOLIA TANI VE BİYOTEKNOLOJİ ÜRÜNLERİ ARAŞTIRMA GELİŞTİRME SANAYİ VE TİCARET A.Ş. PRINCIPLES REGARDING RELATED PARTY TRANSACTIONS

Anatolia Tanı ve Biyoteknoloji Ürünleri Araştırma Geliştirme Sanayi ve Ticaret Anonim Şirketi ("Company") related party transactions principles ("Principles") have been prepared in accordance with the Capital Markets Board's ("CMB") Corporate Governance Communiqué (11-17.1) ("Communiqué").

Pursuant to Article 9 of the Communiqué, except for the common and continuous transactions of our Company with its related parties;

- In transactions similar to asset and service procurement and liability transfer transactions; the ratio of the transaction amount to the total amount of the asset according to the last financial statements disclosed to the public or to the revenue amount according to the last annual financial statements disclosed to the public or to the company value to be calculated on the basis of the arithmetic average of the adjusted weighted average prices for the six months before the date of the decision of the board of directors,

- For transactions similar to the sale of assets and services; the transaction amount (net book value if the net book value of the asset is higher) is equal to the total assets according to the last publicly disclosed financial statements or the amount of revenue generated according to the last publicly disclosed annual financial statements (if the asset is transferred, leased or a right in rem is established on it, If it is foreseen that the ratio of the profit obtained from the said asset according to the latest annual financial statements to the profit before tax from continuing operations of the partnership) or to the company value to be calculated on the basis of the arithmetic average of the daily adjusted weighted average prices for the six months prior to the date of the board of directors' decision will be realized as more than 5%; a valuation must be made by an organization determined by the CMB prior to the transaction. In addition, before starting the said transactions, it is necessary to take a decision of the board of directors that determines the principles of the transaction to be made.

If it is foreseen that the rates related to the above-mentioned transactions will reach more than 10%, in addition to the obligation to have valuation, the approval of the majority of independent members is required in the decisions of the board of directors regarding the transaction. Members of the board of directors who are related parties may not vote at meetings of the board of directors at which the subject is to be discussed. In the event that the majority of the independent members do not approve the transaction, this situation is disclosed on the Public Disclosure Platform ("PDP") in a manner to include sufficient information regarding the transaction and the transaction is submitted to the approval of the general assembly. In the said general assembly meetings, decisions shall be taken in a vote in which the parties to the transaction and the persons associated with them shall not vote.

In case it is decided to carry out related party transactions; summary of valuation report including direct or indirect relations between the parties of the transaction, nature of the transactions, assumptions used in valuation and valuation results, if the transactions have not been carried out in accordance with the results reached in the valuation report, the justification of this situation is announced to the public by way of making a special case statement.

In accordance with the Communiqué, the following principles are complied with for the Company's common and continuous transactions with related parties.

The scope of the widespread and continuous transactions between the company and its related parties and the conditions related to these transactions are decided by the board of directors. In case of a significant change in the scope and conditions of the said transactions, the decision of the board of directors is taken again. The amount of common and continuous transactions between the Company and its related parties in an accounting period,

- the ratio of the sales to the cost of the last annual financial statements disclosed to the public in the purchase transactions,

- If it is foreseen that the ratio of the sales transactions to the revenue amount according to the last annual financial statements disclosed to the public will reach a ratio of more than 10%, in addition to the decision of the board of directors, a report shall be prepared by the board of directors of the corporation regarding the conditions of the transactions and their comparison with the market conditions, and the entire report or the result of this report shall be disclosed on PDP.

In the calculation of the ratios, collective evaluation of the transactions of the same nature is the basis, and each of the transactions made with the same partnership and with different qualities should be evaluated as a separate transaction. If the majority of the members of the independent board of directors do not approve the said transactions, it is obligatory to explain the reason for opposition in PDP.

At a minimum, the following issues must be included in these reports:

- Information about the companies that are parties to the transaction, including their trade name, activities related to the company, whether they are publicly traded or not, summarized financial data such as total assets, operating profit, net sales on an annual basis, and similar information.
- General information about the nature of the relations with the companies party to the transaction and its impact on the activities of the partnership.
- The date and subject of the contract on which the transaction is based, the important elements in the contract, provided that they are not trade secrets, and information on this if it has been previously included in documents such as prospectus.
- Criteria for assessing the appropriateness of the transaction to market conditions.
- An assessment of whether the transaction is in line with market conditions.

#### ANATOLIA TANI VE BIYOTEKNOLOJİ ÜRÜNLERİ ARAŞTIRMA GELİŞTİRME SANAYİ VE TİCARET A. Ş. ETHICAL RULES POLICY

Anatolia Genetworks (Anatolia Tanı ve Biyoteknoloji Ürünleri Ar-Ge San. ve Tic. A.Ş.) conducts all its professional activities within the framework of the fundamental principles specified below. It acts based on these principles in its relationships with national and international official institutions and authorities, as well as with customers, suppliers, shareholders, and stakeholders.

##### **Honesty and Reliability**

Anatolia Genetworks adopts the principle of integrity in all its activities, establishing trustworthy relationships with all stakeholders and relevant parties. By avoiding misleading statements and actions, it ensures a transparent working environment.

##### **Transparency and Communication**

Anatolia Genetworks operates with a transparent management approach and establishes open communication with all stakeholders. It shares clear, accurate, and timely information while considering confidentiality criteria.

##### **Fair and Equal Treatment**

Anatolia Genetworks treats all employees, customers, suppliers, and other stakeholders fairly and equally. It does not tolerate any discrimination or biased behavior.

##### **Privacy and Protection of Data**

Anatolia Genetworks keeps the personal data of its customers, employees, and other stakeholders confidential and protects it in accordance with the law. It does not use or disclose this information without permission.

##### **Employee Rights and Human Resources**

Anatolia Genetworks respects the rights of all its employees and shapes its human resource policies accordingly. It values the opinions and contributions of its employees.

##### **Responsibility towards the Environment and Society**

Anatolia Genetworks conducts its activities with an environmentally sensitive approach and fulfills its responsibilities towards the community. It adopts sustainability principles and aims to minimize environmental impact.

##### **Compliance with Laws and Legislation**

Anatolia Genetworks conducts its activities in accordance with applicable laws and regulations and takes necessary measures for compliance. It expects all its stakeholders to show the same diligence.

##### **Fight Against Corruption and Bribery**

The company adopts a zero-tolerance policy towards bribery and corruption and commits to complying with the legislation on bribery and corruption, universal legal norms, and ethical and professional principles in all countries where it operates and is represented. It takes necessary measures to ensure this compliance.



# Corporate Governance Compliance Report and Information Form

Our Company has shown due diligence in the implementation of the principles set out in the Corporate Governance Principles published by the Capital Markets Board (CMB) for the fiscal period January 1 - December 31, 2024, and Corporate Governance Compliance Reporting is made through the PDP Platform using the Corporate Governance Compliance Report (URF) and Corporate Governance Information Form (KYBF) templates in accordance with the Corporate Governance Communiqué numbered 11-17.1 with the decision of the Capital Markets Board dated 10.01.2019 and numbered 2/49.

	Compliance Status					Description
	Yes	Partially	No	Exempt	Irrelevant	
<b>Corporate Governance Compliance Report</b>						
<b>1.1. FACILITATING THE EXERCISE OF SHAREHOLDER RIGHTS</b>						
1.1.2 - Up-to-date information and disclosures that may affect the exercise of shareholders' rights are made available to investors on the corporate website.	X					
<b>1.2. RIGHT TO INFORMATION AND INSPECTION</b>						
1.2.1 - The Company's management has refrained from taking actions that make it difficult to conduct a special audit.		X				Although there is no provision in the Articles of Association for shareholders to request the appointment of a special auditor at the general assembly, the right of shareholders to obtain and review information is legally guaranteed by Article 438 of the TCC.
<b>1.3. GENERAL ASSEMBLY</b>						
1.3.2 - The Company has ensured that the General Assembly agenda is clearly stated and that each proposal is given under a separate heading	X					
1.3.7 - Persons with privileged access to partnership information have informed the board of directors to be added to the agenda in order to ensure that the general shareholders' meeting is informed about the transactions conducted on their behalf within the scope of the partnership's field of activity.	X					
1.3.8 - The members of the board of directors, other related persons, authorized persons who are responsible for the preparation of the financial statements and auditors were present at the general shareholders' meeting.	X					
1.3.10 - In the agenda of the general assembly, the amounts of all donations and aids and the beneficiaries of these donations and aids are included in a separate item.	X					
1.3.11 - The General Assembly meeting was held open to the public, including stakeholders and media, without the right to speak.	X					

<b>1.4. RIGHT TO VOTE</b>						
1.4.1 - There are no restrictions and practices that make it difficult for shareholders to exercise their voting rights.	X					The Company avoids practices that make it difficult to exercise voting rights. Right holders who have the right to attend the General Assembly meetings of the Company may participate in these meetings electronically in accordance with Article 1527 of the Turkish Commercial Code and exercise their voting rights.
1.4.2 - The Company has no shares with privileged voting rights.		X				Regarding the voting privileges mentioned in the related principle, there are regulations in the Articles of Association.
1.4.3 - The Company has not exercised its voting rights in the General Assembly of any corporation with which it has a cross-shareholding relationship that brings with it a relationship of dominance.	X					
<b>1.5. MINORITY RIGHTS</b>						
1.5.1 - The Company has paid utmost attention to the exercise of minority rights.	X					
1.5.2 - Minority rights are also granted to holders of less than one-twentieth of the share capital and the scope of minority rights is expanded by the articles of association.		X				Rights are provided within the framework of general regulations in the legislation.
<b>1.6. RIGHT TO DIVIDEND</b>						
1.6.1 - The dividend distribution policy approved by the general shareholders' meeting is disclosed to the public on the corporate web site.	X					
1.6.2 - The dividend distribution policy contains minimum information clear enough to enable shareholders to predict the procedures and principles of profit distribution for the future periods.	X					
1.6.3 - The reasons for not distributing dividends and the method of utilization of the undistributed profit are stated in the relevant agenda item.	X					
1.6.4 - The board of directors reviewed whether the dividend distribution policy strikes a balance between the interests of shareholders and those of the Company.	X					
<b>1.7. TRANSFER OF SHARES</b>						
1.7.1 - There are no restrictions on the transfer of shares	X					
<b>2.1. CORPORATE WEBSITE</b>						
2.1.1 - The company's corporate website contains all the elements included in the corporate governance principle numbered 2.1.1.	X					
2.1.2 - Shareholding structure (names, privileges, number and ratio of shares held by real person shareholders holding more than 5% of the issued capital) is updated on the corporate website at least every 6 months.	X					Information on the shareholding structure is updated on the website and in the Company's annual report every quarter in case of any changes.
2.1.4 - The information on the Company's corporate website is also prepared in foreign languages selected according to need, with the same content as Turkish.	X					

<b>2.2. OPERATION REPORT</b>						
2.2.1 - The board of directors ensures that the annual report fully and accurately reflects the company's activities.	X					
2.2.2 - The annual activity report includes all elements of principle 2.2.2.	X					
<b>3.1. COMPANY POLICY ON STAKEHOLDERS</b>						
3.1.1- Stakeholders' rights are protected within the framework of relevant regulations, contracts and goodwill rules.	X					
3.1.3 - Policies and procedures regarding the rights of stakeholders are published on the corporate website.	X					
3.1.4 - Necessary mechanisms have been established for stakeholders to report transactions that are contrary to legislation and unethical.	X					
3.1.5 - The Company oversees conflicts of interest between stakeholders in a balanced manner.	X					
<b>3.2. SUPPORTING STAKEHOLDERS' PARTICIPATION IN COMPANY MANAGEMENT</b>						
3.2.1 - Employee participation in management is regulated by the articles of association or internal regulations.	X					
3.2.2 - Methods such as surveys/consultations have been applied to obtain the opinions of stakeholders on important decisions that have consequences for stakeholders.			X			Not implemented.
<b>3.3. COMPANY'S HUMAN RESOURCES POLICY</b>						
3.3.1 - The Company has adopted an equal opportunity employment policy and succession planning for all key management positions.	X					
3.3.2- Criteria for staff recruitment are set in writing.	X					
3.3.3 - The Company has a Human Resources Development Policy and organizes trainings for employees within this scope.	X					
3.3.4- Meetings were organized to inform employees on issues such as the Company's financial position, remuneration, career planning, training and health.	X					
3.3.5- Decisions that may affect employees are communicated to them and employee representatives. The relevant trade unions were also consulted on these issues.		X				Necessary information is provided by the Human Resources Department, there is no union.
3.3.6- Job descriptions and performance criteria were prepared in detail for all employees, announced to employees and used in remuneration decisions.	X					
3.3.7- Measures such as procedures, trainings, awareness raising, targets, monitoring, complaint mechanisms have been taken to prevent discrimination among employees and to protect employees against physical, mental and emotional mistreatment within the company.	X					

3.3.8 - The Company supports freedom of association and the effective recognition of the right to collective bargaining.			X			There is no regulation on this issue.
3.3.9 - A safe working environment is provided for employees.	X					
<b>3.4. RELATIONS WITH CUSTOMERS AND SUPPLIERS</b>						
3.4.1 - The company measured customer satisfaction and operated with an understanding of unconditional customer satisfaction.	X					
3.4.2- When there is a delay in the processing of the customer's requests for the goods and services purchased, this situation is notified to the customers.	X					
3.4.3 - The Company is committed to quality standards for goods and services.	X					
3.4.4 - The Company has controls to protect the confidentiality of sensitive information of customers and suppliers within the scope of trade secrets.	X					
<b>3.5. ETHICS AND SOCIAL RESPONSIBILITY</b>						
3.5.1 - The board of directors has determined the Code of Ethical Conduct and published it on the corporate website.	X					Work is ongoing to determine the code of ethical behavior.
3.5.2- The partnership is sensitive about social responsibility. It has taken measures to prevent corruption and bribery.	X					
<b>4.1. FUNCTION OF THE BOARD OF DIRECTORS</b>						
4.1.1 - The board of directors ensures that strategies and risks do not threaten the long-term interests of the company and that effective risk management is in place.	X					
4.1.2- Meeting agendas and minutes reveal that the board of directors discusses and approves the company's strategic goals, determines the resources needed and audits the performance of the management.	X					
<b>4.2. OPERATING PRINCIPLES OF THE BOARD OF DIRECTORS</b>						
4.2.1 - The board of directors has documented its activities and submitted them to the shareholders for information.	X					
4.2.2 - Duties and authorities of the members of the board of directors are explained in the annual report.	X					
4.2.3 - The board of directors has established a system of internal control appropriate to the scale of the company and the complexity of its operations.		X				Efforts are underway to establish the necessary mechanisms.
4.2.4 - Information on the functioning and effectiveness of the internal control system is provided in the annual report.		X				The reports prepared by the Committees of the Board of Directors and the Financial Affairs Department on the Company's Risk Management and Internal Control were found to be adequate. The existing structure for Risk Management and Internal Control is maintained.
4.2.5 - The duties of the chairman of the board of directors and the chief executive officer (general manager) are separated and defined.			X			Since the knowledge, experience and expertise of the Chairman of the Board of Directors in the sector make a significant contribution to the management in decision-making processes, no distinction has been made.

4.2.7 - The board of directors ensures that the investor relations department and the corporate governance committee function effectively and has worked in close cooperation with the investor relations department and the corporate governance committee in resolving disputes between the company and shareholders and in communicating with shareholders.	X					
4.2.8 - The Company has taken out a directors and officers liability insurance with an amount exceeding 25% of the share capital for the damages that may be caused by the faults of the members of the board of directors during the execution of their duties.			X			There is no regulation on this issue.
<b>4.3. STRUCTURE OF THE BOARD OF DIRECTORS</b>						
4.3.9- The Company has set a minimum target of 25% for the ratio of female members on the board of directors and established a policy to achieve this goal. The composition of the board of directors is reviewed annually and the nomination process is conducted in accordance with this policy.	X					
4.3.10- At least one of the members of the audit committee has 5 years of experience in audit/accounting and finance.			X			The members of the Committee consist of specialized lecturers with experience in genetics and electronics, which are the main fields of activity of the Company.
<b>4.4. FORM OF BOARD OF DIRECTORS MEETINGS</b>						
4.4.1 - All board members physically attended the majority of board meetings.	X					
4.4.2 - The board of directors has defined a minimum time period for the information and documents related to the agenda items to be sent to all members before the meeting.	X					
4.4.3 - The opinions of the members who could not attend the meeting but submitted their opinions in writing to the Board of Directors were submitted for the information of the other members.	X					
4.4.4 - Each member has one vote in the Board of Directors.	X					
4.4.5 - The conduct of the board meetings is documented in writing through internal regulations.	X					
4.4.6 - The minutes of the board of directors meeting show that all items on the agenda have been discussed and the minutes are prepared to include dissenting opinions.	X					
4.4.7 - Members of the board of directors are restricted from assuming other duties outside the company. The external duties of the members of the board of directors were submitted to the shareholders' information at the general shareholders' meeting.	X					
<b>4.5. COMMITTEES ESTABLISHED UNDER THE BOARD OF DIRECTORS</b>						
4.5.5 - Each board member serves on only one committee.			X			There are no board members other than independent board members serving on more than one committee.
4.5.6 - Committees invited the persons they deemed necessary to receive their views to the meetings and received their views.			X			In accordance with the Committee working principles, the committees may benefit from the opinions of experts in their fields when necessary. No such need has been raised by committee members in the past year.

4.5.7 - Information on the independence of the person/ organization that the Committee receives consultancy services from is included in the annual report.					X	No special work has been conducted at the Board of Directors level within the scope of performance evaluation.
4.5.8 - A report on the results of the committee meetings was prepared and presented to the members of the board of directors.	X					
<b>4.6. FINANCIAL BENEFITS PROVIDED TO BOARD MEMBERS AND EXECUTIVES WITH ADMINISTRATIVE RESPONSIBILITIES</b>						
4.6.1 - The board of directors conducted a board performance evaluation to assess whether it fulfilled its responsibilities effectively.				X		No special work has been conducted at the Board of Directors level within the scope of performance evaluation.
4.6.4 - The Company has not extended any loans or credits to any of the members of the Board of Directors or executives with administrative responsibilities, or extended the term of the loan, improved the terms, extended loans under a personal loan title through third parties, or provided guarantees such as surety in favor of them.	X					
4.6.5- Remuneration of board members and executives with administrative responsibilities is disclosed on individual basis in the annual report.				X		Financial benefits provided to board members and senior executives are disclosed collectively in the annual report.

# General Assembly

The 2023 Ordinary General Assembly Meeting of Anatolia Tanı ve Biyoteknoloji Ürünleri Araştırma Geliştirme Sanayi ve Ticaret Anonim Şirketi was held on Wednesday, 26.06.2024 at 11.00 a.m. at Hasanpaşa Mahallesi, Beydağı Sokak, No:1- 9H Sultanbeyli/İSTANBUL under the supervision of Sibel CAN, the Ministry Representative assigned by the letter dated 25.06.2024 and numbered 059314 of the Provincial Directorate of Trade of the Governorship of Istanbul.

The invitation for the meeting was made in due time by announcing the date, time, place and agenda of the meeting on May 17, 2024, on the Public Disclosure Platform (PDP) and our company's www.anatoliagenetworks.com website, as well as on the Electronic General Assembly System (E-GEM) of Merkezi Kayıt Kuruluşu A.Ş. and in the Turkish Trade Registry Gazette dated May 24, 2024 and numbered 11089, as stipulated in the Law and Articles of Association.

From the examination of the List of Attendants, it is understood that out of 220,000,000 shares with a nominal value of 1 TL, corresponding to the total issued capital of the Company amounting to 220,000,000 TL, 143.728.453 shares in person and 353.150 shares by proxy, totaling 144.081.603 shares were represented at the meeting, and Sabri GÜNAY, the representative of the Independent Audit Company PKF ADAY BAĞIMSIZ DENETİM A.Ş. was present, and thus the minimum meeting quorum stipulated in the Turkish Commercial Code and the Articles of Association was present.

Regarding the 2023 Ordinary General Assembly Meeting, it has been determined that the preparations for the electronic general assembly were fulfilled in accordance with the legal regulations in accordance with the fifth and sixth paragraphs of Article 1527 of the Turkish Commercial Code, and the meeting was held simultaneously in electronic and physical environment.

## Miscellaneous Issues

### Additional Explanations Made within the Scope of the Regulation Dated October 28, 2012, and Numbered 28395 on Determining the Minimum Content of the Annual Report of Companies

#### Explanations regarding Privileged Shares and Voting Rights of Shares

In accordance with the articles of association 6, Group A shareholders has privilege rights in the election of members of the Board of Directors. Accordingly, Group A shares have the privilege of nomination to the board of directors and voting at the general assembly, while Group B shares do not have the privilege.

#### Information on Own Shares Acquired by the Company

The Company has not acquired any shares of its own.

#### Administrative and Judicial Sanctions

As of December 31, 2024, there are no administrative or judicial sanctions against the members of the Company's management body.

#### Legislative Changes That May Significantly Affect Company Activities

There are no legislative changes that may significantly affect the Company's operations.

#### Disclosures Regarding the Special Audit and Public Audit Conducted During the Accounting Period

In the 2024 activity year, there was no special audit request within the scope of Article 438 of the TCC.

#### Information on Lawsuits Filed Against the Company that May Affect the Financial Position and Activities of the Company and Their Possible Results

In 2024, there is no significant lawsuit filed against the Company that may affect the Company's Financial Position and Operations.

#### Disclosures on Administrative and Judicial Sanctions Imposed on the Company and the Members of the Governing Body Due to Practices Contrary to the Provisions of the Legislation

In 2024, there were no administrative and judicial sanctions imposed on the Company and the members of the management body due to practices contrary to the legislation.

#### Information and Evaluations on Whether the Targets Set in the Previous Periods were Achieved, Whether the Resolutions of the General Assembly were Fulfilled, and the Reasons for Failure to Achieve the Targets or Failure to Fulfill the Resolutions

An annual budget is prepared in accordance with the targets set by the Company's Board of Directors and the compliance of the operating results with the budget is monitored. The resolutions of the Ordinary General Assembly for 2023 activities held in June 2024 have been implemented by our Company.

#### If an Extraordinary General Assembly Meeting was held during the year, information on the Extraordinary General Assembly Meeting, including the date of the meeting, the decisions taken at the meeting, and the actions taken in relation to the meeting

The Company did not organize an Extraordinary General Assembly during the period.

#### The Number of Meetings of the Board of Directors during the Year and the Participation Status of the Members of the Board of Directors

The Board of Directors has met 18 times in 2024. The meetings were held in a physical environment. The majority of its members participated in the meetings on a largely regular basis and the members of the Board of Directors participation rate in the meetings were 88%.

#### Significant changes in the environment in which the Company operates and the Company's policies in response to these changes

There has been no significant change in the geographical environment in which the Group operates during the period.

#### Determination of whether the Company's Capital is Uncovered or the Company is Insolvent and Assessments of the Management Body

Within the framework of the calculation made by taking into account the ratios specified in Article 376 of the TCC, the Company's capital does not remain uncovered.

## Amendments to the Articles of Association

There are no amendments to the articles of association in 2024.

## Information on the Conflicts of Interest between the Company and the Institutions Providing Services such as Investment Advisory and Rating Services and the Measures Taken by the Company to Prevent These Conflicts of Interest

During the period, the Company did not receive any services such as investment consultancy and rating.

## Legislative Changes

Pursuant to the CMB's decision dated December 28, 2023 and numbered 81/1820, Turkish Accounting / Financial Reporting Issuers subject to financial reporting regulations that apply standards and capital market institutions, It has been decided to apply inflation accounting by applying the provisions of TMS 29 to start from the annual financial reports for the accounting periods ended as of December 31, 2023.

## Significant Events During and After the Annual Report Period

### # Our material event disclosure dated 03.01.2024

By our company's board of directors; It was unanimously decided by the participants of the meeting to participate in the decision to increase the company capital of our 100% subsidiary RhineGene B.V (Trade Registry Number 85448982), whose address and headquarters is in Amsterdam/Netherlands, from 2,000,000 EUR to 8,000,000 EUR.

### # Our material event disclosure dated 10.05.2024

Our company's independently audited financial statements for the accounting period 01.01.2023 - 31.12.2023 were disclosed to the public today.

In accordance with the CMB's decision dated 28 December 2023 and numbered 81/1820, it has been decided that issuers and capital market institutions subject to financial reporting regulations implementing Turkish Accounting/Financial Reporting Standards will apply inflation accounting by applying the provisions of TMS 29, starting from their annual financial reports for the accounting periods ending as of 31 December 2023.

In this context, since our financial statements are subject to inflation accounting for the first time, selected indicative financial information is presented to all our stakeholders on our Company's website (<https://www.anatoliagenetworks.com/yatirimci-iliskileri/finansal-operasyonel-veriler/>) under the name "information note on the financial results of the 2023 accounting period" for the evaluation of our investors, without being adjusted according to inflation accounting and without being independently audited.

### #Our material event disclosure dated 14.05.2024

The total fixed investment amount of our company's incentive certificate dated 14.03.2021 and numbered 521333, approved within the scope of High-Tech Industrial Products under the heading of Priority Investment Topics in Article 17 of the Council of Ministers' Decision on State Aid in Investments numbered 2012/3305, has been updated and increased from 50,170,370 TL to 98,062,904 TL, last update date 13.05.2024 (yesterday) and the extension date is until 22.08.2025.

### # Our material event disclosure dated 17.05.2024

1. By our company's board of directors; Upon the recommendation of the Audit Committee, in accordance with the Turkish Commercial Code No. 6102 and the Capital Markets Law No. 6362, "Communiqué on Principles Regarding Financial Statements" and other legislative provisions, the selection of PKF Aday Independent Audit Inc. and the approval of the first ordinary General Assembly to be held for the independent auditing and reporting of the financial statements of the Company for the accounting period of 01 January 2024 - 31 December 2024. It was decided unanimously by those who attended the meeting.

2. By our company's board of directors; Capital Markets Board (CMB) Series: II 14.1. Prepared in accordance with the International Financial Reporting Standards within the framework of the provisions of Communiqué No. PKF Aday Independent Audit Inc. In our financial statements for the accounting period of 01.01.2023 - 31.12.2023, audited by A.Ş., a net period loss of (136,670,391) TL was incurred due to the inflation adjustment due to the provisions of "Turkish Accounting Standard 29 Financial Reporting in Economies with High Inflation" (TMS 29), which was applied for the first time this year.

It was unanimously decided by the participants to submit the decision that no profit distribution will be made for the accounting period of 01.01.2023 - 31.12.2023 to the approval of the shareholders at the 2023 Ordinary General Assembly Meeting.

3. Our Board of Directors,

The shareholders of the company will be invited to the Ordinary General Assembly Meeting for 2023 at 11:00 on Wednesday, 26.06.2024, at Hasanpaşa Mahallesi, Beydağı Sokak, No:1-9H Sultanbeyli/İstanbul, to discuss the following agenda items,

The date, place and agenda of the Ordinary General Assembly Meeting will be announced in the Trade Registry Gazette, Public Disclosure Platform, Central Registry Agency and the company website,

It was unanimously decided by the participants to request the presence of the Ministry Representative at the meeting by applying to the Istanbul Provincial Regional Directorate of the Ministry of Commerce of the Republic of Turkey.

### # Our material event disclosure dated 28.05.2024

Anatolia Tanı ve Biyoteknoloji A.Ş. has received the European Union Quality Management System IVDR certificate as the first molecular diagnostic kit manufacturer in Turkey to successfully complete the audit within the scope of (EU) 2017/746 In Vitro Diagnostic Medical Device Regulation (IVDR) carried out by the Notified Body authorized by the European Union.

With this certificate, Anatolia has made an important step towards its goal of becoming one of the world's leading manufacturers of molecular diagnostic products, as the first Turkish company to have the Class C product group IVDR Certificate in the field of molecular diagnostic products.

### # Our material event disclosure dated 26.06.2024

1. The results of the 2023 Ordinary General Assembly Meeting have been announced.

2. A statement was made about the approval of the Decision on Not Distributing Profits at the 2023 Ordinary General Assembly Meeting.

3. By our Board of Directors; In the new Board of Directors formed at the Ordinary General Assembly Meeting of our Company held on June 26, 2024, ..... Prof. Dr. Işıl KURNAZ with ID number and ..... Prof. Dr. Duygun Erol BARKANA with ID number has been elected as independent board members for 2 (two) years, and it has been decided unanimously by those who participated in the registration and announcement of this decision.

4. By our Board of Directors; Within the framework of the provisions contained in the Capital Markets Board's Corporate Governance Communiqué numbered II-17.1 ("Communiqué");

i) Prof. Dr. Duygun Erol BARKANA will be appointed as the Chairman of the Corporate Governance Committee, Prof. Dr. Işıl KURNAZ will be appointed as the Deputy and Ali Rıza TÜZÜNGÜVEN will be appointed as the member, and the Corporate Governance Committee will also fulfill the duties of the Nomination Committee and Remuneration Committee explained in the Communiqué,

ii) Prof.Duygun Erol BARKANA was appointed as the Chairman of the Early Detection of Risk Committee and Prof.Dr.Işıl KURNAZ was appointed as the member,

iii) Prof.Duygun Erol BARKANA was appointed as the Chairman of the Audit Committee established within the scope of the Capital Markets legislation, and Prof.Dr.Işıl KURNAZ was appointed as the member,

iv) Prof.Duygun Erol BARKANA was appointed as the Chairman of the Sustainability Committee, and Prof.Dr.Işıl KURNAZ and Serra Ekin ŞEKERCİ were appointed as members,

It was decided by unanimous vote of the participants.

#### # Our material event disclosure dated 09.07.2024

1. The 2023 Annual General Assembly Meeting was registered by the Istanbul Trade Registry Office on July 8, 2024, and published in the Trade Registry Gazette dated 09 July 2024, with registration number 11118.

2. In the general assembly meeting held on 26.06.2024, the financial reports for the period of 01.01.2024 – 31.12.2024 will be audited, and PKF Independent Audit A.Ş. has been selected as the independent auditor. This decision was registered by the Istanbul Trade Registry Office on 08.07.2024 and published in the Trade Registry Gazette on 09.07.2024 with registration number 11118.

#### # Our material event disclosure dated 16.08.2024

Based on the letter of Borsa Istanbul A.Ş. dated 16/08/2024 and numbered E-18454353-100.06-28433, Regarding the unusual price and quantity movements regarding our Company's shares in recent days, there is no matter that has not been disclosed to the public by our Company in accordance with the provisions of the Capital Markets Board's Special Circumstances Communiqué numbered II-15.1.

#### # Our material event disclosure dated 02.09.2024

To inform investors:

Due to a deadly and highly contagious Mpox (monkeypox) outbreak in the Democratic Republic of the Congo (DRC), the World Health Organization (WHO) has declared a global public health emergency. Laboratory tests that detect the Monkeypox Virus are crucial in controlling the spread of the disease and initiating rapid treatment for patients.

Our Bosphore Monkeypox Virus Detection Kit v2 is designed to detect the Monkeypox virus in human biological samples.

In August, among our 70,425 real-time PCR test sales abroad, 1,650 tests of the Monkeypox Real-Time PCR Kit were sold to six countries. Similarly, among our 41,200 domestic test sales, 150 tests of the Monkeypox Real-Time PCR Kit were sold. Based on these figures, in August:

- Sales of Bosphore Monkeypox Virus Detection Kit v2 accounted for 2.3% of our total international sales,
- 0.4% of our domestic sales,
- 1.6% of our total real-time PCR test sales.

Currently, due to the spread of the disease and the frequency of test applications, the demand for our Monkeypox v2 kit remains limited. However, if demand increases, our two production facilities have a total annual production capacity of approximately 150 million tests, allowing us to meet all required production needs.

This announcement is made in accordance with Article 24 of the Capital Markets Board's (CMB) Special Cases Communiqué, ensuring that investors receive information that is timely, accurate, complete, direct, understandable, and sufficient for decision-making.

We present this information to the public.

#### # Our material event disclosure dated 03.09.2024

A contract worth 26,448,478.79 TL was signed between our company and a public institution on 03.09.2024 for the purchase of various PCR kits.

#### # Our material event disclosure dated 17.10.2024

A contract worth 11,625,400.00 TL was signed between our company and a public institution on 17.10.2024 for the purchase of various PCR kits for 12 months.

Regarding the tender issue, our Company's Board of Directors decided to postpone the disclosure of inside

information within the scope of Article 6 of the CMB's II-15.1 Special Situations Communiqué, with the decision dated 23/09/2024. As the justification for the said postponement decision,

-Since the transaction carries uncertainty within the framework of the provisions of the Special Circumstances Communiqué numbered II-15.1 of the Capital Markets Legislation, making a public disclosure may both mislead investors and negatively affect our Company's activities in terms of competition. For these reasons, the disclosure of the information in question is postponed until the date on which the contract regarding the relevant work and transactions is signed and/or the work/transaction is notified to our company with certainty,

-During the postponement period, this information will not be shared with Company personnel and third parties other than the managers and consultants who will follow the issue closely, and that the necessary agreements have been and/or will be concluded with other third parties with whom the information and, when necessary, our Company's data will be shared, regarding the confidentiality of the information and documents shared with them, and also that provisions stating that they accept the obligations in the law and relevant legislation in the said agreements and that they are aware of the sanctions regarding the misuse or improper distribution of this information,

-If the contract regarding the Transaction has been signed and/or the business/transaction has been notified to our company with certainty or if this information becomes public, it has been decided to make the necessary disclosures to the public in accordance with the legislation, together with the decision to postpone within the framework of the legislation.

It has been taken within the framework of CMB Communiqués and this statement is made as soon as the reasons for postponement are eliminated.

#### # Our material event disclosure dated 03.12.2024

The total fixed investment amount of our company's High-Tech Industrial Products comprehensive investment incentive certificate, which is valid until 22.08.2025, has been updated and increased to 99,562,904 TL.

#### # Our material event disclosure dated 25.12.2024

A contract worth 17,030,632.23 TL was signed between our company and a public institution on 25.12.2024 regarding the procurement of laboratory services in exchange for 36-month results.

Regarding the tender issue, our Company's Board of Directors decided to postpone the disclosure of inside information within the scope of Article 6 of the CMB's II-15.1 Special Situations Communiqué, with the decision dated 04/11/2024. As the justification for the said postponement decision,

-Since the transaction carries uncertainty within the framework of the provisions of the Special Circumstances Communiqué numbered II-15.1 of the Capital Markets Legislation, making a public disclosure may both mislead investors and negatively affect our Company's activities in terms of competition. For these reasons, the disclosure of the information in question is postponed until the date on which the contract regarding the relevant work and transactions is signed and/or the work/transaction is notified to our company with certainty,

-During the postponement period, this information will not be shared with Company personnel and third parties other than the managers and consultants who will follow the issue closely, and that the necessary agreements have been and/or will be concluded with other third parties with whom the information and, when necessary, our Company's data will be shared, regarding the confidentiality of the information and documents shared with them, and also that provisions stating that they accept the obligations in the law and relevant legislation in the said agreements and that they are aware of the sanctions regarding the misuse or improper distribution of this information,

-If the contract regarding the Transaction has been signed and/or the business/transaction has been notified to our company with certainty or if this information becomes public, it has been decided to make the necessary disclosures to the public in accordance with the legislation, together with the decision to postpone within the framework of the legislation.

It has been taken within the framework of CMB Communiqués and this statement is made as soon as the reasons for postponement are eliminated.



**INDEPENDENT  
AUDITOR'S REPORT  
AND FINANCIAL  
STATEMENTS**

---

**INDEPENDENT AUDITOR'S REPORT**

**To the Shareholders and the Board of Directors of  
Anatolia Tanı Ve Biyoteknoloji Ürünleri  
Araştırma Geliştirme Sanayi Ve Ticaret A.Ş.  
İstanbul**

**Independent Audit of Consolidated Financial Statements****Opinion**

We have audited the financial statements of Anatolia Tanı Ve Biyoteknoloji Ürünleri Araştırma Geliştirme Sanayi Ve Ticaret Anonim Şirketi ("the Company" or "Anatolia") and its Subsidiary (together "the Group"), which comprise the consolidated statement of financial position as at December 31, 2024 and the consolidated statement of profit or loss and other comprehensive income, statement of changes in equity and statement of cash flows for the year then ended, and notes to the financial statements, including a summary of significant accounting policies

In our opinion, the accompanying consolidated financial statements present fairly, in all material respects, the financial position of the Group as at December 31, 2024 and its financial performance and its cash flows for the year then ended in accordance with Turkish Financial Reporting Standards (TFRSs).

**Basis for Opinion**

Our independent audit was conducted in accordance with the Independent Auditing Standards published by the Capital Markets Board (CMB) and the Independent Auditing Standards (ISAs), which are part of the Turkish Auditing Standards published by the Public Oversight, Accounting and Auditing Standards Authority (KGK). Our responsibilities under these standards are described in detail in the "Independent Auditor's Responsibilities for the Independent Audit of the Financial Statements" section of our report. We declare that we are independent of the Group in accordance with the Code of Ethics for Independent Auditors ("Code of Ethics") issued by KGK and the ethical requirements in the regulations issued by KGK that are relevant to our audit of the financial statements. We have fulfilled our other ethical responsibilities in accordance with the Code of Ethics and regulations. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

**ANATOLIA TANI VE BİYOTEKNOLOJİ  
ÜRÜNLERİ AR-GE SANAYİ VE TİCARET A.Ş.  
AND GROUP COMPANIES CONSOLIDATED  
FINANCIAL STATEMENTS FOR THE  
PERIOD ENDED 31 DECEMBER 2024**

## Key Audit Issues

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the consolidated financial statements of the current period. Key audit matters were addressed in the context of our audit of the consolidated financial statements as a whole and in forming our opinion thereon, and we do not provide a separate opinion on those matters.

The matters described below have been identified as key audit matters and disclosed in our report:

Key Audit Matter	Key Audit Subject How it is Handled in Audit
<b>Recognition of Revenue</b>	
<p>The Group's revenue within the scope of its core business consists of revenue from the sales of diagnostic kits and devices that the Group manufactures and sells.</p> <p>Revenue has been identified as a key audit matter because it is an important measurement criterion in terms of evaluating the results of the strategy implemented during the year and monitoring performance, and because of its inherent risks of fraud and error.</p> <p>The Company recognizes revenue when it fulfills its performance obligation by transferring control of the products to its customers.</p> <p>As of December 31, 2024, the Group's sales revenue is TL 529.831.707 and the related accounting policies are disclosed in Note 2.</p>	<p>During our audit, we performed the following audit procedures related to revenue recognition.</p> <p>Evaluated the design, implementation and testing of internal controls over the revenue process. We tested the Group's internal controls over the sales process by using the sampling method to cover the IT processes.</p> <p>The substantive procedures focused on the assessment of instances where revenue was invoiced but not earned.</p> <p>In order to test the completeness, accuracy and correctness of the transactions selected by the sampling method, customer-based sales contracts, calculation tables for commission income and income records were compared with sales invoices.</p> <p>In addition, we assessed the adequacy of the disclosures in Note 23, Revenue, in accordance with TFRS 15.</p>

## Management's and Senior Management's Responsibilities for the Consolidated Financial Statements

Management is responsible for the preparation and fair presentation of these consolidated financial statements in accordance with TFRSs and for such internal control as management determines is necessary to enable the preparation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the consolidated financial statements, management is responsible for assessing the Group's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Group or to cease operations, or has no realistic alternative but to do so.

Those charged with governance are responsible for overseeing the Group's financial reporting process.

## Independent Auditor's Responsibilities for the Audit of the Consolidated Financial Statements

In an audit, we, the independent auditors, are responsible for the following: Our objective is to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error. Misstatements are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial statements.

As part of an audit in accordance with ISAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also consider:

- Identify and assess the risks of material misstatement of the consolidated financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. (The risk of not detecting a material misstatement due to fraud is higher than the risk of not detecting a material misstatement due to error, as fraud may involve collusion, forgery, intentional omission, misrepresentation or violation of internal control).
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Group's internal control.
- We assess the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Group's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our report to the related disclosures in the consolidated financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on audit evidence obtained up to the date of the independent auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the consolidated financial statements, including the disclosures, and whether the consolidated financial statements give a true and fair view of the underlying transactions and events.
- Obtain sufficient appropriate audit evidence regarding the financial information of the entities or business segments within the Group to express an opinion on the consolidated financial statements. We are responsible for the direction, supervision and performance of the Group audit. We are also solely responsible for our audit opinion.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We have communicated to those charged with governance that we comply with relevant ethical requirements regarding independence. We have also communicated to those charged with governance all relationships and other matters that may reasonably be thought to bear on our independence and, where applicable, related safeguards

From the matters communicated to those charged with governance, we determine those matters that were of most significance in our audit of the financial statements of the current period, that is, key audit matters. We may decide not to disclose a matter in our auditor's report if the matter is not permitted by law or in very exceptional circumstances where the adverse consequences of disclosure could reasonably be expected to outweigh the public interest in disclosure.

#### Other Liabilities Arising from Legislation

1. In accordance with paragraph four of Article 402 of the Turkish Commercial Code ("TCC") No. 6102, nothing has come to our attention that may cause us to believe that the Company's bookkeeping activities and financial statements for the period 01.01.-31.12.2024 are not in compliance with the code and provisions of the Company's articles of association in relation to financial reporting.
2. Pursuant to subparagraph 4 of Article 402 of the TCC, the Board of Directors provided us with the necessary explanations and requested documents within the scope of audit.
3. 6102 The Auditor's Report on the Early Detection of Risk System and Committee prepared in accordance with the fourth paragraph of Article 398 of the Turkish Commercial Code No. 6102 ("TCC") has been submitted to the Company's Board of Directors on February 28, 2025. The Auditor's Report on the Early Detection of Risk System and Committee prepared in accordance with the fourth paragraph of Article 398 of the Turkish Commercial Code No. 6102 ("TCC") was submitted to the Company's Board of Directors on February 28, 2024.

The engagement partner on the audit resulting in this independent audit is Yunus Can Çarpatan

İstanbul, 28.02.2024

PKF Aday Bağımsız Denetim Anonim Şirketi  
(Member Firm of PKF International)



Yunus Can Çarpatan  
Partner

#### CONTENTS

#### CONSOLIDATED STATEMENT OF FINANCIAL POSITION CONSOLIDATED STATEMENTS OF PROFIT OR LOSS AND COMPREHENSIVE INCOME CONSOLIDATED STATEMENT OF CHANGES IN EQUITY CONSOLIDATED STATEMENTS OF CASH FLOWS CONSOLIDATED NOTES TO THE FINANCIAL STATEMENTS

#### Contents

1.	GROUP'S ORGANIZATION AND NATURE OF OPERATIONS	8
2.	BASIS OF PRESENTATION OF CONSOLIDATED FINANCIAL STATEMENTS	9
3.	SHARES IN OTHER BUSINESS	21
4.	CASH AND CASH EQUIVALENTS	24
5.	FINANCIAL INVESTMENTS	25
6.	TRADE RECEIVABLES AND PAYABLES	25
7.	RELATED PARTIES TRANSACTION	26
9.	INVENTORIES	26
10.	PREPAID EXPENSES AND DEFERRED INCOME	27
12.	PROPERTY, PLANT AND EQUIPMENTS	28
13.	INTANGIBLE ASSETS	30
13.	INTANGIBLE ASSETS (continued)	31
14.	RIGHTS OF USE ASSETS	31
14.	RIGHTS OF USE ASSETS (continued)	32
15.	LEASE LIABILITIES	32
16.	FINANCIAL BORROWINGS	33
17.	EMPLOYEE BENEFITS	34
18.	COMMITMENTS, CONTINGENT ASSETS AND LIABILITIES	35
19.	PAYABLES WITHIN BENEFIT TO EMPLOYEES	36
20.	INCOME TAX	36
21.	SHARE CAPITAL AND NON-CONTROLLING INTERESTS	38
22.	EARNINGS PER SHARE	39
23.	REVENUE AND COST OF SALES	39
24.	MARKETING, SELLING AND DISTRIBUTION EXPENSES	40
25.	GENERAL ADMINISTRATIVE EXPENSES	40
26.	RESEARCH AND DEVELOPMENT EXPENSES	40
27.	OTHER OPERATING INCOME AND EXPENSES	40
28.	INCOME AND EXPENSES FROM INVESTMENT ACTIVITIES	41
29.	FINANCIAL INCOME AND EXPENSES	41
29.	FINANCIAL INCOME AND EXPENSES (continued)	42
30.	FINANCIAL INSTRUMENTS	42
31.	NATURE AND LEVEL OF RISKS ARISING FROM DERIVATIVE FINANCIAL INSTRUMENTS	43
32.	FINANCIAL INSTRUMENTS (FAIR VALUE EXPLANATION)	46
33.	OTHER MATTERS THAT SIGNIFICANTLY AFFECT THE FINANCIAL STATEMENTS OR SHOULD BE DISCLOSED IN ORDER TO MAKE THE FINANCIAL STATEMENTS CLEAR, INTERPRETABLE AND UNDERSTANDABLE.	47
35.	SUBSEQUENT EVENTS	47

**Anatolia Tanı ve Biyoteknoloji Ürünleri Ar-Ge Sanayi Ticaret A.Ş. and Group Companies**  
Consolidated Statements of Financial Position for The Years Ended 31 December 2024 and 31 December 2023  
(Amounts expressed in thousands of Turkish Lira (“TRL”) in terms of the purchasing power of the TRL at December 31, 2024 unless otherwise indicated)

ASSETS	Notes	Audited 31 December 2024	Audited 31 December 2023
<b>Current Assets</b>			
Cash and cash equivalents	4	205.023.951	435.637.009
Financial investments	5	16.286.162	84.274.964
Trade receivables	6	109.252.547	112.506.091
- <i>Due from third parties</i>		<i>109.252.547</i>	<i>112.506.091</i>
Other receivables	8	10.840.893	25.478.341
- <i>Other receivables from third parties</i>		<i>10.840.893</i>	<i>25.478.341</i>
Inventories	9	360.984.956	326.434.043
Prepaid expenses	10	14.802.709	13.468.198
Current tax assets		732.835	19.187.760
Other current assets	11	40.246.383	36.581.947
<b>TOTAL CURRENT ASSETS</b>		<b>758.170.436</b>	<b>1.053.568.353</b>
<b>Non-current Assets</b>			
Financial investments		3.432.367	1.231.372
Other receivables	8	973.552	1.325.142
- <i>Other receivables from third parties</i>		<i>973.552</i>	<i>1.325.142</i>
Right use of assets	14	19.789.031	24.467.381
Tangible assets	12	616.539.753	642.351.096
Intangible assets	13	380.411.725	229.912.143
- <i>Other intangible assets</i>		<i>380.411.725</i>	<i>229.912.143</i>
Prepaid expenses	10	7.413.888	784.431
<b>TOTAL NON-CURRENT ASSETS</b>		<b>1.028.560.315</b>	<b>900.071.565</b>
<b>TOTAL ASSETS</b>		<b>1.786.730.752</b>	<b>1.953.639.918</b>

The accompanying notes form an integral part of these consolidated financial statements.

**Anatolia Tanı ve Biyoteknoloji Ürünleri Ar-Ge Sanayi Ticaret A.Ş. and Group Companies**  
Consolidated Statements of Financial Position for The Years Ended 31 December 2024 and 31 December 2023  
(Amounts expressed in thousands of Turkish Lira (“TRL”) in terms of the purchasing power of the TRL at December 31, 2024 unless otherwise indicated)

LIABILITIES	Notes	Audited 31 December 2024	Audited 31 December 2023
<b>Current Liabilities</b>			
Lease liabilities	15	2.527.649	2.714.617
Short-term borrowings	16	1.335.737	10.519.630
Short-term portion of long-term borrowings	16	--	405.363
Trade payables	6	46.436.576	15.659.009
- <i>Due to third parties</i>		<i>46.436.576</i>	<i>15.659.009</i>
Employee benefit obligations	19	6.147.457	9.091.003
Other Payables	8	4.006.000	6.721.074
- <i>Due to third parties</i>		<i>4.006.000</i>	<i>6.721.074</i>
Deferred income	10	9.851.904	6.528.277
Period Profit Tax Liability		197.219	--
Provisions		7.107.361	7.139.428
- <i>Provisions for employee benefits</i>	17	<i>7.107.361</i>	<i>7.139.428</i>
Other short-term liabilities	11	9.932.461	8.335.146
<b>TOTAL CURRENT LIABILITIES</b>		<b>87.542.364</b>	<b>67.113.547</b>
<b>Non-current liabilities</b>			
Lease liabilities	15	15.423.004	21.625.321
Deferred income		1.920.381	3.211.345
Long-term provisions		7.552.762	4.090.229
- <i>Long-term provisions for employee benefits</i>	17	<i>7.552.762</i>	<i>4.090.229</i>
Deferred tax liabilities	20	122.926.724	105.922.444
<b>TOTAL NON-CURRENT LIABILITIES</b>		<b>147.822.871</b>	<b>134.849.340</b>
<b>EQUITY</b>			
<b>Equity attributable to owners of the Company</b>		<b>1.551.365.517</b>	<b>1.751.677.031</b>
Share capital	21	220.000.000	220.000.000
Adjustment to share capital		577.534.014	577.534.014
Share premium		766.723.882	766.723.882
Other accumulated comprehensive income and expense not to be reclassified to profit or loss		2.009.346	1.680.573
- <i>Gain/loss arising from defined benefit plans</i>		<i>2.009.346</i>	<i>1.680.573</i>
Other accumulated comprehensive income and expense to be reclassified to profit or loss		96.390.402	78.154.543
- <i>Currency translation reserve</i>		<i>96.390.402</i>	<i>78.154.543</i>
Restricted reserves		227.322.639	227.322.639
Retained earnings		(119.738.620)	77.584.411
Profit for the period		(218.876.146)	(197.323.031)
<b>Non-controlling interests</b>			
<b>TOTAL SHAREHOLDER'S EQUITY</b>		<b>1.551.365.517</b>	<b>1.751.677.031</b>
<b>TOTAL LIABILITIES</b>		<b>1.786.730.752</b>	<b>1.953.639.918</b>

The accompanying notes form an integral part of these consolidated financial statement.

**Anatolia Tam ve Biyoteknoloji Ürünleri Ar-Ge Sanayi Ticaret A.Ş. and Group Companies**

Consolidated Statements of Financial Position and Other Comprehensive Income as of

1 January – 31 December 2024 and 2023

(Amounts expressed in thousands of Turkish Lira (“TRL”) in terms of the purchasing power of the TRL at December 31, 2024 unless otherwise indicated)

	Notes	Audited 1 January-31 December 2024	Audited 1 January-31 December 2023
Revenue	23	529.831.707	343.918.384
Cost of sales (-)	23	(195.263.123)	(69.404.734)
<b>GROSS PROFIT</b>		<b>334.568.584</b>	<b>274.513.650</b>
General administrative expenses (-)	25	(139.752.016)	(134.470.846)
Marketing expenses (-)	24	(171.834.782)	(142.266.617)
Research and development expenses (-)	26	(3.139.933)	(12.993.064)
Other income from operating activities	27	59.047.528	213.849.255
Other expenses from operating activities (-)	27	(15.917.933)	(95.948.657)
<b>OPERATING PROFIT</b>		<b>62.971.448</b>	<b>102.683.721</b>
Other income from investing activities	28	13.561.244	24.088.895
Other income from investing activities (-)	28	(3.561.034)	(13.859.058)
<b>OPERATING INCOME BEFORE FINANCIAL INCOME/(EXPENSE)</b>		<b>72.971.658</b>	<b>112.913.558</b>
Finance expenses (-)	29	(3.938.834)	(31.424.815)
Finance income	29	28.846.078	176.006.475
Monetary position gain/(loss)		(266.616.008)	(468.446.488)
<b>PROFIT BEFORE TAX FROM CONTINUING OPERATIONS</b>		<b>(168.737.106)</b>	<b>(210.951.270)</b>
<b>Tax income/(expense), continuing operations</b>		<b>(50.139.040)</b>	<b>13.628.239</b>
Tax expenses		(125.932)	(1.963.528)
Deferred tax expense / incomes	20	(50.013.108)	15.591.767
<b>NET PROFIT FOR THE PERIOD</b>		<b>(218.876.146)</b>	<b>(197.323.031)</b>
<b>Attributable to:</b>			
Non-controlling interests		--	--
Equity holders of the parent		(218.876.146)	(197.323.031)
Earnings per Share	22	(0,9949)	(0,8969)
<b>OTHER COMPREHENSIVE INCOME</b>			
<b>Not to be reclassified to profit or loss</b>		<b>328.773</b>	<b>4.687.974</b>
Gain/ loss arising from defined benefit plans		426.978	6.684.704
<b>Not to be reclassified to profit or loss, tax effect</b>		<b>(98.205)</b>	<b>(1.996.730)</b>
-Deferred tax income/(expense)		(98.205)	(1.996.730)
<b>TOTAL COMPREHENSIVE INCOME FOR THE PERIOD</b>		<b>18.235.859</b>	<b>31.679.258</b>
Foreign Currency Translation Differences		18.235.859	31.679.258
<b>OTHER COMPREHENSIVE INCOME</b>		<b>18.564.632</b>	<b>36.367.232</b>
<b>TOTAL COMPREHENSIVE INCOME</b>		<b>(200.311.514)</b>	<b>(160.955.799)</b>
<b>Attributable to</b>		<b>(200.311.514)</b>	<b>(160.955.799)</b>
Non-controlling interests		--	--
Equity holders of the parent		(200.311.514)	(160.955.799)

The accompanying notes form an integral part of these consolidated financial statements.

**Anatolia Tam ve Biyoteknoloji Ürünleri Ar-Ge Sanayi Ticaret A.Ş. and Group Companies**

Consolidated Statement of Changes in Share Holder's Equity as of 1 January – 31 December 2024 and 31 December 2023

(Amounts expressed in thousands of Turkish Lira (“TRL”) in terms of the purchasing power of the TRL at December 31, 2024 unless otherwise indicated)

	Share capital (Note 21)	Share capital adjustments (Note 21)	Share premium/(discount) (Note 21)	Other comprehensive income not to be reclassified under profit and loss (Note 21)	Other comprehensive income to be reclassified under profit and loss (Note 21)	Restricted reserves (Note 21)	Retained earnings (Note 21)	Net income/(loss) (Note 21)	Equity holders of the parent (Note 21)	Total equity (Note 21)
<b>Balance at January 1, 2023</b>	116.896.990	401.805.306	1.045.555.600	(5.004.131)	46.475.285	173.618.396	397.421.454	--	2.176.768.901	2.176.768.901
Transfers	--	--	--	--	--	53.704.243	(53.704.243)	--	--	--
Capital increase	103.103.010	175.728.708	(278.831.718)	--	--	--	--	--	--	--
Total comprehensive income	--	--	--	6.684.703	31.679.258	--	--	(197.323.031)	(158.959.070)	(158.959.070)
Dividends	--	--	--	--	--	--	(266.132.800)	--	(266.132.800)	(266.132.800)
<b>As of December 31, 2023</b>	<b>220.000.000</b>	<b>577.534.014</b>	<b>766.723.882</b>	<b>1.680.573</b>	<b>78.154.543</b>	<b>227.322.639</b>	<b>77.584.411</b>	<b>(197.323.031)</b>	<b>1.751.677.031</b>	<b>1.751.677.031</b>
<b>Balance at January 1, 2024</b>	<b>220.000.000</b>	<b>577.534.014</b>	<b>766.723.882</b>	<b>1.680.573</b>	<b>78.154.543</b>	<b>227.322.639</b>	<b>77.584.411</b>	<b>(197.323.031)</b>	<b>1.751.677.031</b>	<b>1.751.677.031</b>
Transfers	--	--	--	--	--	--	(197.323.031)	197.323.031	--	--
Capital increase	--	--	--	--	--	--	--	--	--	--
Total comprehensive income	--	--	--	328.773	18.235.859	--	--	--	(200.311.514)	(200.311.514)
Dividends	--	--	--	--	--	--	--	--	(218.876.146)	(218.876.146)
<b>As of December 31, 2024</b>	<b>220.000.000</b>	<b>577.534.014</b>	<b>766.723.882</b>	<b>2.009.346</b>	<b>96.390.402</b>	<b>227.322.639</b>	<b>(119.738.620)</b>	<b>(218.876.146)</b>	<b>1.551.365.518</b>	<b>1.551.365.518</b>

The accompanying notes form an integral part of these consolidated financial statements.

**Anatolia Tanı ve Biyoteknoloji Ürünleri Ar-Ge Sanayi Ticaret A.Ş. and Group Companies**  
Consolidated Statements of Cash Flows For The Periods Ended at 1 January – 31 December 2024 and 31 December 2023  
(Amounts expressed in thousands of Turkish Lira (“TRL”) in terms of the purchasing power of the TRL at December 31, 2024 unless otherwise indicated)

	Notes	Audited 1 January- 31 December 2024	Audited 1 January- 31 December 2023
<b>A. Cash flow from Operating activities</b>			
<b>Income for the period</b>		<b>(218.876.146)</b>	<b>(197.323.031)</b>
<i>Adjustments to reconcile net profit (loss) for the period to cash flows from operating activities</i>			
Adjustments Related to Depreciation and Amortization Expenses	12,13,14	109.509.422	86.445.269
Corrections Regarding Provisions		356.238	142.272
Provision for employment termination benefit	17	6.272.964	146.673
Provision for unused vacation	17	(832.808)	2.369.810
Adjustments for Interest (Income) and Expenses		(893.460)	(39.900.721)
Provision for impairment of inventories	9	(2.246.623)	(768.779)
Adjustments related to unrealized foreign currency translation differences		24.281.059	(437.836)
Adjustments for Fair Value Losses (Gains)		(10.000.210)	(24.088.895)
Adjustments Related to Tax (Income) Expense		50.139.040	(13.628.239)
Adjustments Related to Losses (Gains) on Disposal of Non-Current Assets		(5.944)	(4.285.241)
Monetary (Gain) / Loss		116.000.815	307.614.358
<b>Changes in working capital</b>		<b>73.704.346</b>	<b>179.644.155</b>
Adjustments for Decrease (Increase) in Financial Investments		67.988.802	156.226.783
Adjustments for Decrease (Increase) in Trade Receivables		3.253.544	13.462.710
Adjustments for Decrease (Increase) in Other Receivables Related to Operations		14.989.038	(10.841.044)
Adjustments for Decrease (Increase) in Inventories		(34.550.913)	98.860.861
Decrease (Increase) in Prepaid Expenses		(7.963.966)	(6.006.529)
Adjustments related to increase (decrease) in trade payables		30.777.567	(337.899)
Increase (Decrease) in Employee Benefit Payables		(2.943.546)	(5.249.198)
Adjustments Related to Increase (Decrease) in Other Payables Related to Operations		(2.715.074)	(3.044.388)
Change in other current and fixed assets		(2.067.120)	8.318.129
Increase (Decrease) in Deferred Income		2.032.662	(8.313.320)
<b>Total Adjustments</b>		<b>142.505.340</b>	<b>422.720.260</b>
<b>Cash Flows from Operating Activities</b>			
Payments made within the scope of provisions for employee benefits	18	(1.094.040)	(1.553.747)
Tax Refunds (Payments)		--	3.193.754
<b>Total</b>		<b>141.411.300</b>	<b>424.360.267</b>
<b>B. Cash flows used in investing activities</b>			
Cash inflows from sale of property, plant and equipment and intangible assets		19.659.074	16.116.808
Cash outflows from the acquisition of property, plant and equipment and intangible assets	12,13,14	(246.491.926)	(167.048.027)
<b>Total</b>		<b>(226.832.852)</b>	<b>(150.931.219)</b>
<b>C. Cash flows from financing activities</b>			
Cash inflows and (outflows) related to debt payments, net		(9.589.256)	(7.931.823)
Cash outflows related to debt payments arising from finance lease agreements		(1.788.137)	(2.091.442)
Dividends Paid		--	(266.132.802)
Interests paid		(3.258.847)	(3.905.828)
Interest received		3.350.182	43.806.549
<b>Total</b>		<b>(11.286.058)</b>	<b>(236.255.346)</b>
<b>Net (decrease) / increase in cash and cash equivalents (A+B+C)</b>		<b>(96.707.608)</b>	<b>37.173.702</b>
<b>D. Inflation Effect on Cash</b>			
		<b>(133.905.450)</b>	<b>(363.227.355)</b>
<b>Net increase (decrease) in cash and cash equivalents (A+B+C+D)</b>		<b>(230.613.058)</b>	<b>(326.053.653)</b>
<b>E. Cash and Cash Equivalents at the Beginning of the Period</b>			
	4	<b>435.637.009</b>	<b>704.269.894</b>
<b>Cash and cash equivalents at the end of the period (A+B+C+D)</b>	4	<b>205.023.951</b>	<b>378.216.241</b>

The accompanying notes form an integral part of these consolidated financial statements.

**Anatolia Tanı ve Biyoteknoloji Ürünleri Ar-Ge Sanayi Ticaret A.Ş. and Group Companies**  
Consolidated Statements of Cash Flows For The Periods Ended at 1 January – 31 December 2024 and 31 December 2023  
(Amounts expressed in thousands of Turkish Lira (“TRL”) in terms of the purchasing power of the TRL at December 31, 2024 unless otherwise indicated)

**1. GROUP'S ORGANIZATION AND NATURE OF OPERATIONS**

The main field of Anatolia Tanı ve Biyoteknoloji Ürünleri Araştırma Sanayi ve Ticaret A.Ş (“Company” or “Anatolia”) and its subsidiaries (collectively “The Group”), is producing kits, installation of robots, developing software and designing of devices for research of real-time PCR and such as DNA sequencing and DNA/RNA Isolation techniques.

Exporting its developed products to more than 50 countries in Europe, Asia, Africa and America, the Group is the first and only Turkish manufacturer company invited by the World Health Organization to determine new global test reference standards on four different viruses (“WHO Collaborative Study”).

As of the 31 December 2024 the total number of employees of the Group is 223.

The company is registered with the Capital Markets Board (“CMB”) and its shares are traded on Borsa Istanbul A.Ş. (“BIST”) as of 2021. As of 31 December 2024, the Company has 32,45% of shares registered in BIST (Note 21). The final control of the Group belongs to Elif Akyüz and Alper Akyüz.

The company is registered in Turkey, its registered address and R&D Departments are as follows:

Hasanpaşa Mh. Beydağı Sk. No:1-9H, Sultanbeyli, İstanbul, Turkey.

The Group has a free zone branch at Aydınlı SB Mahallesi, Matraş Caddesi, No:18/Z02, Tuzla / İstanbul.

The Group carries out production in its head office and free zone branches.

**Subsidiaries**

As of 31 December 2024, the subsidiaries subject to the consolidated financial statements, the countries in which they operate, and their fields of activity are as follows:

Subsidiaries	Country	Main Activity
Alpha IVD SRL (“Alpha”)	Italy	Trading of test kits, devices and software in the field of molecular biology
Euronano Diagnostics (Private) Limited (“Euronano”)	Pakistan	Trading of test kits, devices and software in the field of molecular biology
RhineGene B.V. (“RhineGene”) (*) (**)	Holland	Establishing or acquiring companies and businesses in the field of molecular biology
RhineGene Philippines (“RhineGene PH”) (**)	Philippines	Trading of test kits, devices and software in the field of molecular biology
RhineGene Bulgaria (“RhineGene BG”) (***)	Bulgaria	Trading of test kits, devices and software in the field of molecular biology
RhineGene Poland (“RhineGene PL”) (****)	Poland	Trading of test kits, devices and software in the field of molecular biology
RhineGene Germany (“RhineGene GE”) (*****)	Germany	Trading of test kits, devices and software in the field of molecular biology

Alpha and Euronano were founded by Anatolia, Elif Akyüz and Alper Akyüz in 2017 and 2018, respectively.

(\*) Within the scope of its growth strategy in international markets, the company established and registered its RhineGene B.V subsidiary, located in the Netherlands, with a capital of 2,000,000 Euros, in which it fully participates, on 09.02.2022.

(\*\*) 200,000 of which RhineGene B.V, which is a 100% subsidiary of the Company, has fully participated in on 10.05.2022. -USD capital, RhineGene Philippines Inc. was established.

(\*\*) RhineGene B, which is a 100% subsidiary of the Company, has been decided to increase its capital to EUR 8,000,000 on 03.01.2024.

(\*\*\*) RhineGene Bulgaria was established on 26.07.2022, in which RhineGene B.V, a 100% subsidiary of the Company, fully participated.

(\*\*\*\*) It was decided to increase the capital of RhineGene Bulgaria, a 100% subsidiary of the Company, to 5,868,000 Leva on 03.09.2024.

(\*\*\*\*\*) RhineGene Poland was established on 27.09.2022, in which RhineGene B.V, a 100% subsidiary of the Company, fully participated.

(\*\*\*\*\*) RhineGene Germany was established on 03.11.2023, in which RhineGene B.V, a 100% subsidiary of the Company, fully participated.

**2. BASIS OF PRESENTATION OF CONSOLIDATED FINANCIAL STATEMENTS**

**2.1. Basis of presentation**

**Accounting policies**

The accompanying consolidated financial statements are prepared in accordance with the announcement of the Capital Markets Board ("CMB") "Communiqué on Principles Regarding Financial Reporting in the Capital Markets" ("Communiqué") No. II-14.1 published in the Official Gazette dated 13.06.2013 and numbered 28676 and Turkish Financial Reporting Standards (“TFRS”) published by Public Oversight Accounting and Auditing Standards Board ("POA").

TASs; Turkish Accounting Standards, includes Turkish Financial Reporting Standards (“TFRS”) and related annexes and comments.

Consolidated financial statements are presented in accordance with the “TFRS Taxonomy” published by POA dated on 4 October 2023 and Financial Statement Examples and User Guide published by CMB.

**Approval of consolidated financial statements**

Consolidated financial statements as of 1 January – 31 December 2024 have been approved by the Board of Directors and authorized for publication on 8 November 2024 The General Assembly of the Company and the relevant regulatory authorities have the right to request the amendment of the consolidated financial statements after the publication of the consolidated financial statements.

**Financial reporting in hyperinflationary economy**

With the announcements made by the Public Oversight Accounting and Auditing Standards Authority (POA) on November 23, 2023, entities applying TFRSs have started to apply inflation accounting in accordance with TAS 29 Financial Reporting in Hyperinflation Economies as of financial statements for the annual reporting period ending on or after December 31, 2024. TAS 29 is applied to the financial statements, including the consolidated financial statements, of any entity whose functional currency is the currency of a hyperinflationary economy.

According to the standard, financial statements prepared in the currency of a hyperinflationary economy are presented in terms of the purchasing power of that currency at the balance sheet date. Prior period financial statements are also presented in the current measurement unit at the end of the reporting period for comparative purposes. The Group has therefore presented its consolidated financial statements as of December 31, 2023, on the purchasing power basis as of December 31, 2024. Pursuant to the decision of the Capital Markets Board (SPK) dated December 28, 2023 and numbered 81/1820, it has been decided that issuers and capital market institutions subject to financial reporting regulations that apply Turkish Accounting/Financial Reporting Standards will apply inflation accounting by applying the provisions of IAS 29 starting from their annual financial reports for the periods ending on September, 2024.

The adjustments made in accordance with IAS 29 were made using the adjustment coefficient obtained from the Consumer Price Index (CPI) of Turkey published by the Turkish Statistical Institute (TÜİK). As of December 31, 2024, the indices and adjustment coefficients used in the adjustment of the consolidated financial statements are as follows:

Year End	Indeks	Conversion Factor	Three Year Inflation Rate
31 December 2024	2.684,55	1,0000	%291
31 December 2023	1.859,38	1,3586	%268
31 December 2022	1.128,45	2,0553	%156

The main elements of the Group's adjustment process for financial reporting in hyperinflationary economies are as follows:

- Current period consolidated financial statements prepared in TRY are expressed in terms of the purchasing power at the balance sheet date, and amounts from previous reporting periods are also adjusted and expressed in terms of the purchasing power at the end of the reporting period.

**2. BASIS OF PRESENTATION OF CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

**2.1. Basis of presentation (Continued)**

**Financial reporting in hyperinflationary economy (Continued)**

- Monetary assets and liabilities are not adjusted as they are already expressed in terms of the current purchasing power at the balance sheet date. In cases where the inflation-adjusted values of non-monetary items exceed their recoverable amount or net realizable value, the provisions of IAS 36 “Impairment of Assets” and IAS 2 “Inventories” are applied, respectively.

- Non-monetary assets and liabilities and equity items that are not expressed in terms of the current purchasing power at the balance sheet date have been adjusted using the relevant adjustment coefficients.

- All items in the comprehensive income statement, except for those that have an impact on the comprehensive income statement of non-monetary items on the balance sheet, have been indexed using the coefficients calculated for the periods when the income and expense accounts were first reflected in the financial statements.

- The impact of inflation on the Group's net monetary asset position in the current period is recorded in the net monetary gain/(loss) account in the consolidated income statement.

**Comparative Information and Correction of Prior Financial Statements**

The current period consolidated financial statements of the Group are prepared comparatively with the previous period in order to enable the determination of the financial position and performance trends. Comparative information is reclassified when deemed necessary in order to comply with the presentation of the current period consolidated financial statements.

**Functional and presentation currency**

The Group prepares and maintains its legal books and prepares its statutory financial statements in accordance with the Turkish Commercial Code ("TCC"), accounting principles set forth by tax legislation and the Uniform Chart of Accounts issued by the Ministry of Finance. The valid currency of the Group is Turkish Lira ("TL"). These consolidated financial statements are presented in TL, which is the valid currency of the Group.

**Financial statements of subsidiaries operating in countries other than Turkey**

Subsidiaries in foreign country assets and liabilities are translated into TRY from the foreign exchange rate at the reporting date and income and expenses are translated into TRY at the average foreign exchange rate. The retranslation of net assets at the beginning of the period and the exchange differences which resulting from the using of average exchange rates are followed on differences of foreign currency translation account within shareholders' equity.

**Netting/Offsetting**

Financial assets and liabilities are shown in net, if the required legal right already exists, there is an intention to pay the assets and liabilities on a net basis, or if there is an intention to realize the assets and the fulfilment of the liabilities simultaneously.

**2.2. Changes in Accounting Policies**

Significant changes in accounting policies are applied retrospectively and prior period consolidated financial statements are restated.

2. **BASIS OF PRESENTATION OF CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

2.3. **Basis of presentation (Continued)**

2.3. **Restatement and Errors in the Accounting Policies and Estimates**

If changes in accounting estimates are related to only one period, they are recognised in the period when changes are applied; if changes in estimates are related to future periods, they are recognized both in the period where the change is applied and future periods prospectively.

There was no significant change in accounting estimates of the Group in the current year. The detected significant accounting errors are applied retrospectively, and prior period consolidated financial statements are restated.

2.4. **Going concern**

The consolidated financial statements prepared on a going concern basis, with the assumption that the Group will benefit from its assets and fulfil its obligations in the next year and in the natural course of its activities.

2.5. **New and Amended Turkish Financial Reporting Standards**

As at 31 December 2024, the accounting policies adopted in preparation of the condensed consolidated interim financial statements for the year ended 31 December 2024 are consistent with those of the previous financial year, except for the adoption of new and amended TFRS and TFRIC interpretations effective as of 1 January 2024.

The effects of these standards and interpretations on the financial position and performance of the Group are disclosed in the related paragraphs.

**a) Amendments and interpretations effective from 2024**

TAS 1 (Amendments) Classification of Liabilities as Current or Non-Current  
IFRS 16 (Amendments) Lease Liability in a Sale and Leaseback Transaction  
TAS 1 (Amendments) Long-term liabilities with loan contract terms  
TAS 7 and TFRS 7 (Amendments) Supplier Financing Arrangements  
TSRS 1 General requirements for disclosure of sustainability-related financial information  
TSRS 2 Climate Related Disclosures

**TAS 1 (Amendments) Classification of Liabilities as Current or Non-Current**

The purpose of these amendments is to ensure consistent application of the requirements of the standard by assisting entities in making decisions about whether debt and other liabilities in the statement of financial position that have no fixed maturity should be classified as current (expected to be settled within one year) or non-current.

These amendments to IAS 1 will be effective for annual periods beginning on or after 1 January 2024, with earlier application permitted.

The Group is in the process of assessing the potential impact of the standard, amendments and improvements on the consolidated financial position and performance of the Group / the Company.

**IFRS 16 (Amendments) Lease Liability in a Sale and Leaseback Transaction**

These amendments to TFRS 16 clarify how a seller-lessee subsequently measures sale and leaseback transactions that meet the requirements in TFRS 15 to be recognised as sales.  
These amendments to TFRS 16 are effective for annual periods beginning on or after 1 January 2024, with earlier application permitted.

The Group is in the process of assessing the potential impact of these standards, amendments and improvements on the consolidated financial position and performance of the Group

2. **BASIS OF PRESENTATION OF CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

**New and Amended Turkish Financial Reporting Standards (Continued)**

**IAS 1 (Amendments) Long-term Liabilities with Credit Agreement Terms**

The amendments to TAS 1 clarify how conditions that an entity must meet within twelve months of the reporting period affect the classification of a liability.

The amendments to TAS 1 are effective for annual periods beginning on or after 1 January 2024, with earlier application permitted.

The Group is in the process of assessing the potential impact of these standards, amendments and improvements on the consolidated financial position and performance of the Group

**TAS 7 and TFRS 7 (Amendments) Supplier Financing Arrangements**

The amendments to TAS 7 and TFRS 7 add guidance that requires entities to provide qualitative and quantitative information about supplier financing arrangements and disclosure requirements to existing disclosure requirements. The amendments are effective for annual periods beginning on or after 1 January 2024.

The Group is in the process of assessing the impact of the amendments on financial position or performance of the Group

**TSRS 1 General requirements for disclosure of sustainability-related financial information**

TSRS 1 sets out general requirements for sustainability-related financial disclosures, requiring an entity to disclose information about sustainability-related risks and opportunities that is useful for primary users of general purpose financial reports to make decisions about funding the entity. The application of this standard is mandatory for annual reporting periods beginning on or after 1 January 2024 for entities that meet the relevant criteria in the POA's announcement dated 5 January 2024 and numbered 2024-5 and for banks regardless of the criteria. Other entities may voluntarily report in accordance with TSRS.

The Group is in the process of assessing the impact of the amendment on the financial position and performance of the Group

**TSRS 2 Climate Related Disclosures**

TSRS 2 sets out the requirements for identifying, measuring and disclosing climate-related risks and opportunities that are useful to primary users of general purpose financial reports in making decisions about funding the entity. The application of this standard is mandatory for annual reporting periods beginning on or after 1 January 2024 for entities that meet the relevant criteria in the POA's announcement dated 5 January 2024 and numbered 2024-5 and for banks regardless of the criteria. Other entities may report in accordance with TSRS on a voluntary basis.

**b) Standards, amendments and interpretations to existing standards that are not yet effective**

The Group has not yet adopted the following standards, amendments and interpretations to existing standards that are not yet effective

TFRS 17 Insurance Contracts  
TFRS 17 (Amendments) Insurance Contracts and First-time Adoption of TFRS 17 and TFRS 9 - Comparative Information  
TAS 21 (Amendments) Lack of Exchangeability

**2. BASIS OF PRESENTATION OF CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

**New and Amended Turkish Financial Reporting Standards (Continued)**

***IFRS 17 - Insurance Contracts***

IFRS 17 requires insurance liabilities to be measured at a current settlement value and provides a more uniform measurement and presentation approach for all insurance contracts. These requirements are designed to achieve consistent, principle-based accounting for insurance contracts. IFRS 17 has been deferred for insurance, reinsurance and pension companies for a further year and will replace IFRS 4 Insurance Contracts as at 1 January 2025.

The Group is in the process of assessing the potential impact of the standards, amendments and improvements on the consolidated financial position and performance of the Group

***IFRS 17 (Amendments) Insurance Contracts and First-time Adoption of IFRS 17 and IFRS 9 - Comparative Information***

Amendments have been made to IFRS 17 to reduce implementation costs and facilitate disclosure of results and transition.

In addition, the amendment on comparative information permits entities that are first-time adopters of IFRS 7 and IFRS 9 to present comparative information about a financial asset as if the classification and measurement requirements of IFRS 9 had previously been applied to that financial asset.

The Group is in the process of assessing the potential impact of the standards, amendments and improvements on the consolidated financial position and performance of the Group

***TAS 21 (Amendments) Lack of Exchangeability***

These amendments provide guidance on when a currency is exchangeable and how exchange rates should be determined when it is not. The amendments are effective for annual reporting periods beginning on or after January 1, 2025.

The Group is in the process of assessing the potential impact of the standards, amendments and improvements on the consolidated financial position and performance of the Group

**2.6. Summary of significant accounting policies**

Significant accounting policies applied in the preparation of these consolidated financial statements are summarized below:

**Consolidation Principles**

Full Consolidation:  
Consolidated financial statements include the financial statements of the subsidiary managed by the Group in Note 1.

As of 31 December 2024 and 31 December 2023, the subsidiaries consolidated within the Parent Company have been consolidated using the "full consolidation method" since the control power belongs to the Group.

The applied principles of consolidation as below:

- (i) The balance sheets and income statements of the subsidiaries are consolidated one by one for each item and the carried net book value of the investment, which is owned by the Parent Company, is eliminated with the related equity items. The intra-group transactions, the remaining profit margins balances in the balance sheets which between the Parent Company and its subsidiaries, are eliminated.

**2. BASIS OF PRESENTATION OF CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

**2.6. Summary of significant accounting policies (Continued)**

- (ii) Operating results of subsidiaries are included in the consolidation effective from the date on which the said company controls are transferred to the Parent Company.
- (iii) Non-controlling interests in net assets and operating results of subsidiaries are presented separately as non-controlling interests in the consolidated balance sheet and consolidated income statement.

The following table shows the subsidiaries, total shares of owned and effective partnership ratios as of 31 December 2024 and 31 December 2023:

<b>Subsidiaries</b>	<b>31 December 2024</b>	<b>31 December 2023</b>
Alpha IVD SRL (“Alpha”) (*)	100,00%	100,00%
Euronano Diagnostics (Private) Limited (“Euronano”)	99,99%	99,99%
RhineGene B.V. (“RhineGene”)	100%	100%
RhineGene Philippines (“RhineGene PH”)	100%	100%
RhineGene Bulgaria (“RhineGene BG”)	100%	100%
RhineGene Poland (“RhineGene PL”)	100%	100%
RhineGene Germany (“RhineGene GE”)	100%	100%

(\*) Although the ownership rate of the company is 50% or less, control power can be obtained with the remaining votes belonging to Elif Akyüz and Alper Akyüz, who are also the controlling shareholders of Anatolia. Elif Akyüz and Alper Akyüz declared that they will use their voting rights in line with Anatolia.

The company take over 100% of the company by paying 66,501,299 TL for the remaining 76.67% of Alpha shares. The transfer and delivery procedures were completed on May 25, 2023. This take over is considered as a “business combination under common control” and the difference between Alpha's net equity at the acquisition date and the purchase price is classified under “Share Premiums” under equity. (\*\*) (Footnote 1)

**Related Parties**

To the accompanying consolidated financial statements, key personnel in management and board of directors, their family and controlled or dependent companies, participations and subsidiaries of the Group is referred to as related parties.

**Cash and Cash Equivalents**

Cash and cash equivalents include cash in hand, deposits held at call with banks, other short-term highly liquid investments with original maturities of three months or less (Note 5). To consolidated statements of cash flows, cash and cash equivalents includes cash and cash equivalents with original maturities less than three months, excluding the interest accruals. If any provision provided to the cash and cash equivalents because of a specific event, Group measures expected credit loss from these cash and cash equivalents by the life-time expected credit loss. The calculation of expected credit loss is performed based on the experience of the Group and its expectations for the future indications.

**Trade Receivables and Allowance for Doubtful Receivables**

Trade receivables that are created by the Group by way of providing goods or services in the ordinary course of business directly to a debtor are recognized initially at fair value and subsequently measured at amortized cost, using the effective interest rate method, less provision for impairment. Short-term trade receivables with no specific interest rates are measured at original invoice amount if the effect of interest accrual is insignificant.

**2. BASIS OF PRESENTATION OF CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

**2.6. Summary of significant accounting policies (Continued)**

*Impairment*

IAS 39, “Financial Instruments” valid before 1 January 2018: Instead of “realised credit losses model” in Accounting and Measurement Standard, “expected credit loss model” was defined in IFRS 9 “Financial Instruments” Standard. Expected credit loss is estimated by weighting credit losses, expected to occur throughout the expected life of financial instruments, based on previous statistics. When calculating the expected credit losses, credit losses in the previous years and forecasts of the Group are considered.

**Trade Payables**

Trade payables are stated at their nominal value, discounted to present value as appropriate.

**Inventories**

Inventories are stated at the lower of cost and net realizable value. Cost is calculated using the weighted average method. Costs comprise direct materials, direct labour costs and those overheads that have been incurred in bringing the inventories to their present location and condition. Net realizable value represents the estimated selling price less all estimated costs to completion and costs to be incurred in marketing, selling and distributed.

**Property, plant and equipment and related depreciation**

Property, plant, and equipment are carried at acquisition cost, less any accumulated depreciation and any impairment loss Land is not depreciated as it is deemed to have an indefinite useful life.

Depreciation is provided on the restated amounts of property, plant and equipment on a pro-rata basis. Profit and loss arising out of the sale of property, plant and equipment are included in the other income and expense accounts. Repair and maintenance expenditure related to property, plant and equipment is expensed as incurred.

Cost amounts of property, plant and equipment, other than the lands and construction in progress are subject to depreciation by using systematic pro-rata basis using the straight-line method in accordance with their expected useful life.

The depreciation and amortization periods for property, plant and equipment, which approximate the economic useful lives of such assets, are as follows:

	<u>Year</u>
Buildings	50
Machinery and Equipment	4-14
Motor vehicles	5-10
Furniture and Fixtures	4-10
Leasehold improvements	10-20

**Intangible assets and related amortization**

An intangible asset is recognized if it meets the identifiability criterion of intangibles, control exists over the asset; it is probable that the expected future economic benefits that are attributable to the asset will flow to the entity and the costs can be measured reliably. Intangible assets are carried at cost less accumulated amortization and impairment. Amortization of intangible assets is allocated on a systematic pro-rata basis using the straight-line method Intangible assets including acquired rights, information systems and computer software are amortized using the straight-line.

**2. BASIS OF PRESENTATION OF CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

**2.6. Summary of significant accounting policies (Continued)**

Costs incurred on development projects relating to the design and testing of new or improved products are recognized as intangible assets when it is probable that the project will be a success considering its commercial and technological feasibility, and only if the cost can be measured reliably. Other research and development expenditures are recognized as an expense as incurred. Development expenditures previously recognized as an expense cannot be recognized as an asset in a subsequent period.

The useful lives of intangible assets are as follows:

	<u>Year</u>
Rights	3-5
Research and development costs	5
Other intangible asset	5-10

**Impairment of assets**

The carrying values of all tangible or intangible fixed assets, other than goodwill which is reviewed for impairment at least annually, are reviewed for impairment when events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Whenever the carrying amount of an asset exceeds its recoverable amount, an impairment loss is recognized in the income statement for items carried at cost and treated as a revaluation decrease for items carried at revalued amount to the extent that impairment loss does not exceed the amount held in the revaluation surplus. The recoverable amount of property, plant and equipment is the greater of net selling price and value in use.

**Financial assets**

The Group performs the classification process regarding its financial assets during the acquisition of the related assets and reviews them regularly.

**Classification**

The Group classifies its financial assets in three categories of financial assets measured at amortized cost, financial assets measured at fair value through other comprehensive income and financial assets measured at fair value through profit of loss. The classification of financial assets is determined considering the entity’s business model for managing the financial assets and the contractual cash flow characteristics of the financial assets. The appropriate classification of financial assets is determined at the time of the purchase.

Financial assets are not reclassified after initial recognition except when the Group’s business model for managing financial assets changes; in the case of a business model change, after the amendment, the financial assets are reclassified on the first day of the following reporting period.

**Recognition and Measurement**

**a) Financial assets measured at amortized cost**

Financial assets measured at amortized cost, are non-derivative assets that are held within a business model whose objective is to hold assets to collect contractual cash flows and the contractual terms of the financial assets give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding. The Group’s financial assets measured at amortized cost comprise “cash and cash equivalents”, “trade receivables”, “other receivables” and “financial investments”. Financial assets carried at amortized cost are measured at their fair value at initial recognition and by effective interest rate method at subsequent measurements. Gains and losses on valuation of non-derivative financial assets measured at amortized cost are accounted for under the statement of income.

2. BASIS OF PRESENTATION OF CONSOLIDATED FINANCIAL STATEMENTS (Continued)

2.6. Summary of significant accounting policies (Continued)

Financial assets measured at fair value

*i. Financial assets measured at fair value through other comprehensive income*

Financial assets measured at fair value through other comprehensive income, are non-derivative assets that are held within a business model whose objective is achieved by both collecting contractual cash flows and selling financial assets and the contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding. Gains or losses on a financial asset measured at fair value through other comprehensive income is recognized in other comprehensive income, except for impairment gains or losses and foreign exchange gains and losses until the financial asset is derecognized or reclassified. When the financial asset is derecognized the cumulative gain or loss previously recognized in other comprehensive income is reclassified to retained earnings.

In case of sale of assets, valuation differences classified to other comprehensive income are reclassified to retained earnings.

Group make a choice for the equity instruments during the initial recognition and elect profit or loss or other comprehensive income for the presentation of fair value gain and loss. If the said preference is made, dividends from related investments are recognized in the income statement.

*ii. Financial assets measured at fair value through profit or loss*

Financial assets measured at fair value through profit or loss, are assets that are not measured at amortized cost or at fair value through other comprehensive income. Gains and losses on valuation of these financial assets are accounted for under the statement of income.

*Derecognition*

The Group derecognizes a financial asset when the contractual rights to the cash flows from the asset expires, or it transfers the rights to receive the contractual cash flows in a transaction in which substantially all the risks and rewards of ownership of the financial asset were transferred. Any interest in such transferred financial assets that was created or retained by the Company is recognized as a separate asset or liability.

*Impairment*

Impairment of the financial and contractual assets is measured by using “Expected credit loss model” (ECL). The impairment model applies for amortized financial and contractual assets.

Provisions for losses are measured as below.

- Impairment of the financial and contractual assets is measured by using “Expected credit loss model” (ECL). The impairment model applies for amortized financial and contractual assets.

Provisions for losses are measured as below.

- 12- Month ECL: results from default events that are possible within 12 months after reporting date.

- Lifetime ECL: results from all possible default events over the expected life of financial instrument.

Lifetime ECL measurement applies if the credit risk of a financial asset at the reporting date has increased significantly since 12-month ECL measurement if it has not.

The Group may determine that the credit risk of a financial asset has not increased significantly if the asset has low credit risk at the reporting date. However, lifetime ECL measurement (simplified approach) always apply for trade receivables and contract assets without a significant financing.

2. BASIS OF PRESENTATION OF CONSOLIDATED FINANCIAL STATEMENTS (Continued)

2.6. Summary of significant accounting policies (Continued)

Financial liabilities

Financial liabilities and equity instruments issued by the Group are classified according to the substance of the contractual arrangements entered and the definitions of a financial liability and an equity instrument. An equity instrument is any contract that evidences a residual interest in the assets of the Group after deducting all its liabilities. The accounting policies adopted for specific financial liabilities and equity instruments are set out below.

Financial liabilities are classified as either financial liabilities at fair value through profit and loss or other financial liabilities.

**a) Financial liabilities at fair value through profit and loss**

Financial liabilities are classified as at FVTPL where the financial liability is either held for trading or it is designated as at FVTPL. Financial liabilities at FVTPL are stated at fair value, with any resultant gain or loss recognized in profit or loss. The net gain or loss recognized in profit or loss incorporates any interest paid on the financial liability.

**b) Other financial liabilities**

Other financial liabilities, including borrowings, are initially measured at fair value, net of transaction costs.

Other financial liabilities are subsequently measured at amortized cost using the effective interest method, with interest expense recognized on an effective yield basis.

The effective interest method is a method of calculating the amortized cost of a financial liability and of allocating interest expense over the relevant period. The effective interest rate is the rate that exactly discounts estimated future cash payments through the expected life of the financial liability, or, where appropriate, a shorter period.

**Borrowing Costs**

Borrowing costs directly attributable to the acquisition, construction or production of qualifying assets, which are assets that necessarily take a considerable time to get ready for their intended use or sale, are added to the cost of those assets, until such time as the assets is substantially ready for their intended use or sale. Investment income earned by the temporary investment of the part of the borrowing not yet used is deducted from the borrowing costs eligible for capitalization. All other borrowing costs are recognized in profit or loss in the period in which they are incurred.

**Taxation and Deferred Income Taxes**

Income tax expense represents the sum of the tax currently payable and deferred tax.

**Current tax:** The tax currently payable is based on taxable profit for the year.

**Deferred tax:** Deferred tax is provided, using the liability method, on all temporary differences at the balance sheet date between the tax bases of assets and liabilities and their carrying amounts for financial reporting purposes.

**Employee Benefits / Retirement Pay Provision**

Under the Turkish law and union agreements, severance payments are made to employees retiring or involuntarily leaving the Group. Such payments are considered as being part of defined retirement benefit plan as per International Accounting Standard No: 19 “Employee Benefits” (“IAS 19”). The retirement benefit obligation recognized in the balance sheet represents the present value of the defined benefit obligation as adjusted for unrecognized actuarial gains and losses.

**2. BASIS OF PRESENTATION OF CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

**2.6. Summary of significant accounting policies (Continued)**

**Operating Expenses**

Operating expenses are recognized in profit or loss upon utilization of the service or at the date of their origin. Expenditure for warranties is recognized and charged against the associated provision when the related revenue is recognized.

**Revenue Recognition**

Group recognizes revenue when the goods or services is transferred to the customer and when performance obligation is fulfilled. Goods are counted to be transferred when the control belongs to the customer.

Group recognizes revenue based on the following main principles:

- Identification of customer contracts
- Identification of performance obligations,
- Determination of transaction price in the contract,
- Allocation of price to performance obligations,
- Recognition of revenue when the performance obligations are fulfilled.

Group recognizes revenue from its customers only when all the following criteria are met:

- The parties to the contract have approved the contract (in writing, orally or in accordance with other customary business practices) and are committed to perform their respective obligations,
- Group can identify each party’s rights regarding the goods or services to be transferred,
- Group can identify the payment terms for the goods or services to be transferred.
- The contract has commercial substance,

It is probable that Group will collect the consideration to which it will be entitled in exchange for the goods or services that will be transferred to the customer. In evaluating whether collectability of an amount of consideration is probable, an entity shall consider only the customer’s ability and intention to pay that amount of consideration when it is due.

**Equipment rental revenue**

Rent income from operational rental transactions is accounted if it is measured reliably based on straight-line method during relevant rental agreement and if it is possible that an economic benefit related to transaction is achieved by the Group.

**Provisions**

Provisions are recognized when, and only when the Group has a present obligation because of a past event and it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation, and a reliable estimate can be made of the amount of the obligation. Provisions are recognized by the amortized amount as of balance sheet date in case that the monetary loss is material. Provisions are reviewed at each balance sheet date and adjusted to reflect the current best estimate.

**Commitments and Contingencies**

Transactions that may give rise to contingencies and commitments are those where the outcome and the performance of which will be ultimately confirmed only on the occurrence or non-occurrence of certain future events unless the expected performance is remote. Accordingly, contingent losses are recognized in the financial statements if a reasonable estimate of the amount of the resulting loss can be made. Contingent gains are reflected only if it is probable that the gain will be realized.

**Transactions in foreign currency**

Transactions in foreign currencies during the periods have been translated at the exchange rates prevailing at the dates of these transactions. Balance sheet items denominated in foreign currencies have been translated at the exchange rates prevailing at the balance sheet dates. The foreign exchange gains and losses are recognized in the income statement.

**2. BASIS OF PRESENTATION OF CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

**2.6. Summary of significant accounting policies (Continued)**

The periods-end rates used for USD, EURO and PKR are shown below:

	<b>31 December 2024</b>	<b>31 December 2023</b>
US Dollars	35,2233 TRY	29,4382 TRY
Euro	36,7429 TRY	32,5739 TRY
PKR	0,12578 TRY	0,1050 TRY
PLN (Zloti)	0,1169 TRY	7,5187 TRY
LEVA	18,6817 TRY	16,5611 TRY
PHP	1,6461 TRY	0,5312 TRY

**Earnings per share**

Earnings per share presented in the consolidated statements of profit or loss are determined by dividing consolidated net income attributable to that class of shares by the weighted average number of such shares outstanding during the year concerned. In Turkey, companies can increase their share capital by making a pro-rata distribution of shares (“bonus shares”) to existing shareholders from retained earnings or inflation adjustments. To earnings per share computations, the weighted average number of shares outstanding during the year has been adjusted in respect of bonus shares issued without a corresponding change in resources by giving them retroactive effect for the year in which they were issued and for each earlier period.

**Government incentives and grants**

Grants from the government are recognized at their fair value where there is a reasonable assurance that the grant will be received and the group will comply with all the attached conditions. Government grants relating to costs are deferred and recognized in the income statement over the period necessary to match them with the costs that they are intended to compensate. Government grants relating to property, plant and equipment are included in non-current liabilities as deferred government grants and are credited to the income statement on a straight-line basis over the expected lives of the related assets.

**Cash Flow statement**

Cash and cash equivalents comprise of cash in hand, bank deposits and short-term investments, which can easily be converted into cash for a known amount, has high liquidity with maturities of 3 months or less.

**EBITDA**

EBITDA is defined as earnings before interest expense, income tax expense (benefit), depreciation and amortization. This information should be read with the statements of cash flows contained in the accompanying financial statements (note 3).

*Provisions for doubtful trade receivables:* The provision for doubtful receivables reflects the amounts that the management believes will cover the future losses of the receivables that exist as of the reporting date but have the risk of being uncollectible within the current economic conditions. While evaluating whether the receivables are impaired or not, the past performance of the debtors, their credibility in the market, their performance from the date of the consolidated financial statements until the approval date of the consolidated financial statements and the renegotiated conditions are also taken into. In addition, the “simplified approach” defined in TFRS 9 has been preferred within the scope of the impairment calculations of trade receivables that are accounted at amortized cost in the consolidated financial statements and that do not contain a significant financing component (with a maturity of less than one year). With this approach, the Group measures the provision for impairment on trade receivables at an amount equal to “lifetime expected credit losses”, unless the trade receivables are impaired for certain reasons (excluding realized impairment losses).

2. BASIS OF PRESENTATION OF CONSOLIDATED FINANCIAL STATEMENTS (Continued)

2.7. Significant Accounting Assessments, Estimates and Assumptions

*Provision for employee benefit:* Employment termination benefits pay liability is determined by actuarial calculations based on some assumptions including discount rates, future salary increases and employee turnover rates. Since these plans are long term, these assumptions contain significant uncertainties.

*Lawsuit provisions:* The probability of loss of ongoing lawsuits and the consequences that will be endured if they are lost are evaluated in line with the opinions of the Group's legal advisors. The Group management makes its best estimates using the data in hand and estimates the provision it deems necessary.

*Deferred tax:* The Group recognizes deferred tax assets and liabilities based upon temporary differences arising between their statement of financial position accounts prepared in accordance with TAS/TFRS promulgated by POA Financial Reporting Standards and their statutory financial statements. These temporary differences usually result from the recognition of revenue and expenses in different reporting periods for TAS/TFRS and Tax Laws.

*Impairment of Inventory:* When calculating, data on the list prices of inventories after discounting are used. In cases where the projected net realizable value is below the cost value, an inventory impairment provision is made.

3. SHARES IN OTHER BUSINESS

The details of the Group's shares in other businesses for the periods are as follows:

	31 December 2024	31 December 2023
	Alpha IVD S.p.A (Italy) Solo	Alpha IVD S.p.A (Italy) Solo
Current assets	69.940.155	172.725.243
Non-current assets	7.116.706	53.601.288
<b>Total assets</b>	<b>77.056.861</b>	<b>226.326.531</b>
Current liabilities	8.488.876	10.080.624
Non-current liabilities	1.975.972	2.389.216
<b>Total debts</b>	<b>10.464.848</b>	<b>12.469.840</b>
<b>Net assets</b>	<b>66.592.013</b>	<b>213.856.691</b>
<b>Profit Loss for the period:</b>		
Revenue	42.560.438	35.625.193
Profit / (Loss) for the period	(43.577.713)	(34.029.399)
<b>Profit Loss for the period:</b>	<b>(43.577.713)</b>	<b>(34.029.399)</b>

3. SHARES IN OTHER BUSINESS (continued)

	Euronano (Pakistan) Solo	Euronano (Pakistan) Solo
Current assets	40.185.259	48.002.056
Non-current assets	7.116.706	7.890.072
<b>Total assets</b>	<b>47.301.965</b>	<b>55.892.128</b>
Current liabilities	104.827.657	116.792.618
<b>Total debts</b>	<b>104.827.657</b>	<b>116.792.618</b>
<b>Net assets</b>	<b>(57.525.692)</b>	<b>(60.900.490)</b>
<b>Profit Loss for the period:</b>		
Revenue	10.862.879	7.062.123
Profit / (Loss) for the period	(1.175.528)	(29.008.622)
<b>Profit Loss for the period:</b>	<b>(1.175.528)</b>	<b>(29.008.622)</b>

	31 December 2024 RhineGene B.V. (Hollanda) Solo	31 December 2023 RhineGene B.V. (Hollanda) Solo
Current assets	71.198.423	45.331.834
Non-current assets	111.495.485	22.352.727
<b>Total assets</b>	<b>182.693.908</b>	<b>67.684.562</b>
Current liabilities	251.830	970.676
<b>Total debts</b>	<b>251.830</b>	<b>970.676</b>
<b>Net assets</b>	<b>182.442.078</b>	<b>66.713.886</b>
<b>Profit Loss for the period:</b>		
Revenue	--	--
Profit / (Loss) for the period	(2.030.111)	(7.171.532)
<b>Profit Loss for the period:</b>	<b>(2.030.111)</b>	<b>(7.171.532)</b>

Anatolia Tanı ve Biyoteknoloji Ürünleri Ar-Ge Sanayi Ticaret A.Ş. and Group Companies  
Consolidated Statements of Cash Flows For The Periods Ended at 1 January – 31 December 2024 and 31 December 2023  
(Amounts expressed in thousands of Turkish Lira (“TRL”) in terms of the purchasing power of the TRL at December 31, 2024 unless otherwise indicated)

3. SHARES IN OTHER BUSINESS (continued)

	31 December 2024	31 December 2023
	<b>RhineGene Philippines Solo</b>	<b>RhineGene Philippines Solo</b>
Current assets	1.384.164	2.606.744
Non-current assets	4.177.983	2.097.037
<b>Total assets</b>	<b>5.562.147</b>	<b>4.703.781</b>
Current liabilities	15.966.691	14.321.225
<b>Total debts</b>	<b>15.966.691</b>	<b>14.321.225</b>
<b>Net assets</b>	<b>(10.404.544)</b>	<b>(9.617.444)</b>
<b>Profit Loss for the period:</b>		
Revenue	--	--
Profit / (Loss) for the period	(2.582.216)	(6.808.377)
<b>Profit Loss for the period:</b>	<b>(2.582.216)</b>	<b>(6.808.377)</b>
	<b>31 December 2024</b>	<b>31 December 2023</b>
	<b>RhineGene Bulgaria Solo</b>	<b>RhineGene Bulgaria Solo</b>
Current assets	100.778.600	8.338.463
Non-current assets	1.214.200	694.872
<b>Total assets</b>	<b>101.992.800</b>	<b>9.033.335</b>
Current liabilities	4.997.520	10.826.512
<b>Total debts</b>	<b>4.997.520</b>	<b>10.826.512</b>
<b>Net assets</b>	<b>96.995.280</b>	<b>(1.793.177)</b>
<b>Profit Loss for the period:</b>		
Revenue	5.755.806	2.544.185
Profit / (Loss) for the period	(4.546.907)	(5.804.513)
<b>Profit Loss for the period:</b>	<b>(4.546.907)</b>	<b>(5.804.513)</b>
	<b>31 December 2024</b>	<b>31 December 2023</b>
	<b>RhineGene Poland Solo</b>	<b>RhineGene Poland Solo</b>
Current assets	31.445.194	32.206.798
Non-current assets	--	1.933.212
<b>Total assets</b>	<b>31.445.194</b>	<b>34.140.009</b>
Current liabilities	34.339.620	28.438.425
<b>Total debts</b>	<b>34.339.620</b>	<b>28.438.425</b>
<b>Net assets</b>	<b>(2.894.426)</b>	<b>5.701.584</b>
<b>Profit Loss for the period:</b>		
Revenue	19.567.756	14.044.002
Profit / (Loss) for the period	(5.619.427)	(6.728.784)
<b>Profit Loss for the period:</b>	<b>(5.619.427)</b>	<b>(6.728.784)</b>

Anatolia Tanı ve Biyoteknoloji Ürünleri Ar-Ge Sanayi Ticaret A.Ş. and Group Companies  
Consolidated Statements of Cash Flows For The Periods Ended at 1 January – 31 December 2024 and 31 December 2023  
(Amounts expressed in thousands of Turkish Lira (“TRL”) in terms of the purchasing power of the TRL at December 31, 2024 unless otherwise indicated)

3. SHARES IN OTHER BUSINESS (continued)

	31 December 2024	31 December 2023
	<b>RhineGene Germany Solo</b>	<b>RhineGene Germany Solo</b>
Current assets	3.121.530	3.001.812
Non-current assets	1.886.527	2.936.956
<b>Total assets</b>	<b>5.008.057</b>	<b>5.938.768</b>
Current liabilities	9.274.163	10.210.003
Non-current liabilities	14.723.640	--
<b>Total debts</b>	<b>23.997.803</b>	<b>10.210.003</b>
<b>Net assets</b>	<b>(18.989.746)</b>	<b>(4.271.235)</b>
<b>Profit Loss for the period:</b>		
Revenue	6.692.857	--
Profit / (Loss) for the period	(8.233.666)	(4.266.598)
<b>Profit Loss for the period:</b>	<b>(8.233.666)</b>	<b>(4.266.598)</b>

4. CASH AND CASH EQUIVALENTS

The details of the Group's cash and cash equivalents for the periods are as follows:

	31 December 2024	31 December 2023
Cash in hand	--	2.548
Cash at banks	205.023.951	435.517.897
- Demand deposit	156.909.784	234.116.543
- Time deposit less than 3 months	48.114.167	201.401.354
Other cash and cash equivalents	--	116.564
	<b>205.023.951</b>	<b>435.637.009</b>

Currency	Interest rate	Maturity	31 December 2024
TRY	%4,75-%40	January 2025	4.032.455
USD	%3,5	January 2025	37.614.962
EUR	%2	January 2025	6.466.750
			<b>48.114.167</b>

Currency	Interest rate	Maturity	31 December 2023
TRY	%29,98-%38,97	January 2024	20.835.888
USD	5%	January 2024	67.906.786
EUR	2%	January 2024	112.658.681
			<b>201.401.354</b>

5. FINANCIAL INVESTMENTS

The details of the Group's financial investments for the periods are as follows:

	31 December 2024	31 December 2023
Fair value through	16.286.162	84.274.962
	<b>16.286.162</b>	<b>84.274.962</b>

6. TRADE RECEIVABLES AND PAYABLES

The details of the Group's trade receivables for the periods are as follows:

	31 December 2024	31 December 2023
<b>Short-term trade receivables</b>		
Trade receivables	101.488.674	107.684.535
- Trade receivables from third parties	101.488.674	107.684.535
Notes receivable	5.886.747	4.821.557
Income accruals	1.877.126	--
Doubtful trade receivables (*)	1.302.575	1.314.665
Provision for doubtful trade receivables (-)	(1.302.575)	(1.314.665)
	<b>109.252.547</b>	<b>112.506.091</b>

As of 31 December 2024, the average maturity of the Group's trade receivables is 90 days. (31 December 2023: 90 days).

Explanations on the nature and level of risks in trade receivables are given in Note 31.

(\*) The movement of the allowance for doubtful receivables is as follows:

	1 January- 31 December 2024	1 January- 31 December 2023
<b>Balance at beginning of the period</b>	1.314.665	1.122.684
Current year additions (Note 29)	356.238	142.272
Currency translation differences	123.249	319.002
Inflation adjustments	(491.577)	(269.293)
<b>End of the period</b>	<b>1.302.575</b>	<b>1.314.665</b>

The details of the trade payables are as follows:

	31 December 2024	31 December 2023
<b>Short-term trade payables</b>		
Trade payables	35.382.026	8.657.905
Expense Accruals	4.784.060	3.612.647
Other trade payables	6.270.490	3.388.457
	<b>46.436.576</b>	<b>15.659.009</b>

As of 31 December 2024, the average maturity of the Group's trade receivables is 90 days. (31 December 2023: 90 day).

Explanations on the nature and level of risks in trade payables are given in Note 30.

7. RELATED PARTIES TRANSACTION

As of 31 December 2024, there are no trade receivables from organizations (31 December 2023: None).

**Key management compensation:**

The total amount of wages and similar benefits provided to the Group's President and Vice President of the Board of Directors and other key executives as of 31 December 2024 is TRY 28.222.026 (31 December 2023: TRY 9.567.727)

8. OTHER RECEIVABLES AND PAYABLES

The details of the Group's other receivables and payables for the periods are as follows:

	31 December 2024	31 December 2023
<b>Short term other receivables</b>		
Deposits and guarantees given	2.747.238	1.121.458
Other receivables(*)	8.093.655	24.356.884
	<b>10.840.893</b>	<b>25.478.341</b>

(\*) Other receivables consist of VAT receivables.

	31 December 2024	31 December 2023
<b>Long term other receivables</b>		
Deposits and guarantees given	973.552	1.325.142
	<b>973.552</b>	<b>1.325.142</b>

	31 December 2024	31 December 2023
<b>Short term other payables</b>		
Free zone overdue deferred tax liabilities	4.006.000	2.305.289
Other payables	--	4.415.786
	<b>4.006.000</b>	<b>6.721.074</b>

9. INVENTORIES

The details of the Group's inventories for the periods are as follows:

	31 December 2024	31 December 2023
Raw materials	164.417.364	133.485.445
Work in Process	138.070.203	161.154.642
Trade goods	46.179.238	29.820.095
Other Inventories	19.658.081	11.860.623
Provision for impairment in inventory	(7.339.930)	(9.886.762)
	<b>360.984.956</b>	<b>326.434.043</b>

	31 December 2024	31 December 2023
<b>Balance at beginning of the period</b>	9.886.761	6.625.332
Current year additions	(2.246.623)	(768.779)
Currency translation differences	(300.208)	4.030.208

	31 December 2024	31 December 2023
<b>End of the period</b>	<b>7.339.930</b>	<b>9.886.761</b>

**Anatolia Tanı ve Biyoteknoloji Ürünleri Ar-Ge Sanayi Ticaret A.Ş. and Group Companies**  
Consolidated Statements of Cash Flows For The Periods Ended at 1 January – 31 December 2024 and 31 December 2023  
(Amounts expressed in thousands of Turkish Lira (“TRL”) in terms of the purchasing power of the TRL at December 31, 2024 unless otherwise indicated)

**10. PREPAID EXPENSES AND DEFERRED INCOME**

The details of short and long-term prepaid expense for the periods are as follows:

<u>Short-term prepaid expenses</u>	<u>31 December 2024</u>	<u>31 December 2023</u>
Advances given to suppliers (*)	13.955.253	8.964.238
Prepaid expenses (**)	847.456	4.503.961
	<b>14.802.709</b>	<b>13.468.199</b>

(\*) Consists of personnel expenses in the Center and Free Zone.

(\*\*) Order advances given consist of advances given for building modernization and investment to move the Group's headquarters and R&D center.

<u>Long-term prepaid expenses</u>	<u>31 December 2024</u>	<u>31 December 2023</u>
Prepaid expenses for the following years	7.413.887	257.287
Advances given	--	527.144
	<b>7.413.887</b>	<b>784.431</b>

<u>Deferred income-short term</u>	<u>31 December 2024</u>	<u>31 December 2023</u>
Advances received	9.851.904	6.528.277
	<b>9.851.904</b>	<b>6.528.277</b>

(\*) Advances received consist of advances received by the Group from customers regarding sales.

Advances received consist of advances received by the Group from customers regarding sales.

**11. OTHER ASSETS AND LIABILITIES**

The details of other assets and liabilities for the periods are as follows:

<u>Other current assets</u>	<u>31 December 2024</u>	<u>31 December 2023</u>
Deferred VAT	38.161.095	34.333.735
Other current assets	2.085.288	2.248.211
	<b>40.246.383</b>	<b>36.581.947</b>

<u>Other short-term liabilities</u>	<u>31 December 2024</u>	<u>31 December 2023</u>
Prepaid taxes and dues	9.908.423	8.316.440
Other	24.038	18.707
	<b>9.932.461</b>	<b>8.335.147</b>

**Anatolia Tanı ve Biyoteknoloji Ürünleri Ar-Ge Sanayi Ticaret A.Ş. and Group Companies**  
Consolidated Statements of Cash Flows For The Periods Ended at 1 January – 31 December 2024 and 31 December 2023  
(Amounts expressed in thousands of Turkish Lira (“TRL”) in terms of the purchasing power of the TRL at December 31, 2024 unless otherwise indicated)

**12. PROPERTY, PLANT AND EQUIPMENTS**

Movement of property, plant, and equipment for the period 01.01.-31.12.2024 is as follows:

<u>Cost</u>	<u>1 January 2024</u>	<u>Additions</u>	<u>Disposals (-)</u>	<u>Foreign currency translation differences</u>	<u>31 December 2024</u>
	Land and land improvements	105.846.519	4.501.713	--	576.156
Buildings	288.080.958	--	(12.677.053)	1.758.282	277.162.187
Machinery and equipment	333.933.880	37.307.470	(12.676.280)	6.790.336	365.355.406
Vehicles	48.619.716	3.070.055	(2.235.539)	130.193	49.584.425
Furniture and fixtures	83.462.897	27.474.557	--	38.406	110.975.860
Other tangible assets	1.742.496	170.815	--	--	1.913.311
Leasehold improvements	27.279.575	28.664	(49.331)	14.062	27.272.970
Construction in progress	201.592	--	(201.592)	--	--
	<b>889.167.633</b>	<b>72.553.274</b>	<b>(27.839.795)</b>	<b>9.307.435</b>	<b>943.188.547</b>
				<u>Foreign currency translation differences</u>	<u>31 December 2024</u>
	<u>1 January 2024</u>	<u>Current year charge</u>	<u>Disposals (-)</u>		
<u>Accumulated depreciation</u>					
Buildings	(16.402.362)	(6.458.147)	253.541	(979.495)	(23.586.463)
Machinery and equipment	(160.314.563)	(43.276.614)	2.535.256	(1.963.181)	(203.019.102)
Vehicles	(19.131.458)	(9.836.022)	894.216	(54.663)	(28.127.927)
Furniture and fixtures	(31.118.343)	(16.037.596)	--	(1.491.267)	(48.647.206)
Other tangible assets	(289.508)	(45.712)	--	(37.794)	(373.014)
Leasehold improvements	(19.560.303)	(3.328.877)	14.799	(20.701)	(22.895.082)
	<b>(246.816.537)</b>	<b>(78.982.968)</b>	<b>3.697.812</b>	<b>(4.547.101)</b>	<b>(326.648.794)</b>
<b>Net book value</b>	<b>642.351.096</b>				<b>616.539.753</b>

As of 31 December 2024, property, plant, and equipment are insured for TRY 363.250.000 and there is no mortgage on it (31.12.2023: 273.075.000 TRY ).

**Anatolia Tanı ve Biyoteknoloji Ürünleri Ar-Ge Sanayi Ticaret A.Ş. and Group Companies**  
Consolidated Statements of Cash Flows For The Periods Ended at 1 January – 31 December 2024 and 31 December 2023  
(Amounts expressed in thousands of Turkish Lira (“TRL”) in terms of the purchasing power of the TRL at December 31, 2024 unless otherwise indicated)

**12. PROPERTY, PLANT AND EQUIPMENTS (continued)**

Movement of property, plant and equipment for the period 01.01.-31.12.2023 is as follows:

	1 January 2023	Additions	Disposals (-)	Foreign currency conversion differences	31 December 2023
<b>Cost</b>					
Land and land improvements	105.846.519	--	--	--	105.846.519
Buildings	274.924.601	4.670.429	--	8.485.928	288.080.958
Machinery and equipment	273.797.260	50.131.660	(18.241.428)	28.246.388	333.933.880
Vehicles	37.359.107	11.805.475	(2.841.393)	2.296.527	48.619.716
Furniture and fixtures	74.201.458	9.577.663	(856.951)	540.727	83.462.897
Other tangible assets	1.059.140	91.783	--	591.573	1.742.496
Leasehold improvements	26.564.914	652.529	--	62.132	27.279.575
Construction in progress	686.450	--	(484.858)	--	201.592
	<b>794.439.449</b>	<b>76.929.539</b>	<b>(22.424.630)</b>	<b>40.223.275</b>	<b>889.167.633</b>
	1 January 2023	Current year charge	Disposals (-)	Foreign currency conversion differences	31 December 2023
<b>Accumulated depreciation</b>					
Buildings	(9.829.974)	(5.842.186)	--	(730.202)	(16.402.362)
Machinery and equipment	(116.690.300)	(43.336.104)	9.278.014	(9.566.173)	(160.314.563)
Vehicles	(13.331.762)	(6.631.890)	1.683.891	(851.697)	(19.131.458)
Furniture and fixtures	(19.547.471)	(10.337.155)	151.613	(1.385.330)	(31.118.343)
Other tangible assets	(165.882)	(110.737)	--	(12.889)	(289.508)
Leasehold improvements	(15.005.800)	(3.683.715)	--	(870.788)	(19.560.303)
	<b>(174.571.189)</b>	<b>(69.941.787)</b>	<b>11.113.518</b>	<b>(13.417.079)</b>	<b>(246.816.537)</b>
<b>Net book value</b>	<b>619.868.260</b>				<b>642.351.096</b>

**Anatolia Tanı ve Biyoteknoloji Ürünleri Ar-Ge Sanayi Ticaret A.Ş. and Group Companies**  
Consolidated Statements of Cash Flows For The Periods Ended at 1 January – 31 December 2024 and 31 December 2023  
(Amounts expressed in thousands of Turkish Lira (“TRL”) in terms of the purchasing power of the TRL at December 31, 2024 unless otherwise indicated)

**13. INTANGIBLE ASSETS**

Movement of intangible fixed asset for the period 01.01.-31.12.2024 is as follows:

	1 January 2024	Additions	Disposals (-)	Transfers	Foreign currency conversion differences	31 December 2024
<b>Cost</b>						
Rights (*)	85.572.376	115.479	--	(19.621.636)	958	66.067.177
Research and development costs (**)	213.868.837	179.344.822	--	19.621.636	--	412.835.295
Other intangible fixed assets	1.083.451	566.236	(148.732)	--	--	1.500.955
	<b>300.524.664</b>	<b>180.026.537</b>	<b>(148.732)</b>	<b>--</b>	<b>958</b>	<b>480.403.427</b>
	1 January 2024	Current year charge	Disposals (-)	Transfers	Foreign currency conversion differences	31 December 2024
<b>Accumulated depreciation</b>						
Rights	(7.499.338)	(17.204.717)	--	--	(34.052)	(24.738.107)
Research and development costs (**)	(61.475.104)	(12.134.619)	--	--	--	(73.609.723)
Other intangible fixed assets	(1.638.079)	(50.413)	44.620	--	--	(1.643.872)
	<b>(70.612.521)</b>	<b>(29.389.749)</b>	<b>44.620</b>	<b>--</b>	<b>(34.052)</b>	<b>(99.991.702)</b>
<b>Net book value</b>	<b>229.912.143</b>					<b>380.411.725</b>

(\*) Rights mostly consist of R&D projects of the Group that are activated by reaching the final product.

(\*\*) Research and development costs consist of ongoing R&D projects of the Group.

The Group invested a total of TRY 129.473.773 R&D projects in the accounting period ending on 31 December 2024 (12-month period) (31 December 2023: TRY 101.237.216 TRY (12-month period))

**Anatolia Tanı ve Biyoteknoloji Ürünleri Ar-Ge Sanayi Ticaret A.Ş. and Group Companies**  
Consolidated Statements of Cash Flows For The Periods Ended at 1 January – 31 December 2024 and 31 December 2023  
(Amounts expressed in thousands of Turkish Lira (“TRL”) in terms of the purchasing power of the TRL at December 31, 2024 unless otherwise indicated)

**13. INTANGIBLE ASSETS (continued)**

Movement of intangible fixed assets for the period 01.01.-31.12.2023 is as follows:

	<b>1 January 2023</b>	<b>Additions</b>	<b>Disposals</b>	<b>Transfers</b>	<b>Foreign currency conversion differences</b>	<b>31 December 2023</b>
<b>Cost</b>						
Rights (*)	91.212.929	9.830.185	--	(15.472.644)	1.906	85.572.376
Research and development costs (**)	118.393.831	80.002.362	--	15.472.644	--	213.868.837
Other intangible fixed assets	1.186.539	285.942	(473.141)	--	84.111	1.083.451
	<b>210.793.299</b>	<b>90.118.489</b>	<b>(473.141)</b>	<b>--</b>	<b>86.017</b>	<b>300.524.664</b>
		<b>Current year charge</b>	<b>Disposals</b>	<b>Transfers</b>	<b>Foreign currency conversion differences</b>	<b>31 December 2023</b>
<b>Accumulated depreciation</b>						
Rights	(1.741.435)	(5.755.901)	--	--	(2.002)	(7.499.338)
Research and development costs (**)	(51.933.166)	(9.541.938)	--	--	--	(61.475.104)
Other intangible assets	(1.182.799)	(289.684)	(47.314)	--	(118.282)	(1.638.079)
	<b>(54.857.400)</b>	<b>(15.587.523)</b>	<b>(47.314)</b>	<b>--</b>	<b>(120.284)</b>	<b>(70.612.521)</b>
<b>Net book value</b>	<b>155.935.899</b>					<b>229.912.143</b>

(\*) Rights mostly consist of R&D projects of the Group that are activated by reaching the final product.

(\*\*) Research and development costs consist of ongoing R&D projects of the Group.

**14. RIGHTS OF USE ASSETS**

Movement of rights of use assets for the period 01.01.-30.2024 is as follows:

	<b>Buildings</b>	<b>Total</b>
<b>1 January 2024</b>	<b>28.948.606</b>	<b>28.948.606</b>
Additions/(Disposals)	(3.541.645)	(3.541.645)
<b>31 December 2024</b>	<b>25.406.961</b>	<b>25.406.961</b>
	<b>Buildings</b>	<b>Total</b>
<b>Accumulated depreciation</b>		
<b>1 January 2024</b>	<b>(4.481.225)</b>	<b>(4.481.225)</b>
Period depreciation	(1.136.705)	(1.136.705)
<b>31 December 2024</b>	<b>(5.617.930)</b>	<b>(5.617.930)</b>
<b>Net book value</b>		
<b>31 December 2024</b>	<b>19.789.031</b>	<b>19.789.031</b>

**Anatolia Tanı ve Biyoteknoloji Ürünleri Ar-Ge Sanayi Ticaret A.Ş. and Group Companies**  
Consolidated Statements of Cash Flows For The Periods Ended at 1 January – 31 December 2024 and 31 December 2023  
(Amounts expressed in thousands of Turkish Lira (“TRL”) in terms of the purchasing power of the TRL at December 31, 2024 unless otherwise indicated)

**14. RIGHTS OF USE ASSETS (continued)**

	<b>Buildings</b>	<b>Total</b>
<b>Cost</b>		
<b>1 January 2023</b>	<b>30.304.785</b>	<b>30.304.785</b>
Additions/ (Disposals)	(1.356.179)	(1.356.179)
<b>31 December 2023</b>	<b>28.948.606</b>	<b>28.948.606</b>
	<b>Buildings</b>	<b>Total</b>
<b>Accumulated depreciation</b>		
<b>1 January 2023</b>	<b>(3.565.266)</b>	<b>(3.565.266)</b>
Period depreciation	(915.959)	(915.959)
<b>31 December 2023</b>	<b>(4.481.225)</b>	<b>(4.481.225)</b>
<b>Net book value</b>		
<b>31 December 2023</b>	<b>24.467.381</b>	<b>24.467.381</b>

**15. LEASE LIABILITIES**

The details of lease of liabilities for the periods are as follows:

	<b>31 December 2024</b>	<b>31 December 2023</b>
Short-term lease liabilities	2.527.649	2.714.617
Long-term lease liabilities	15.423.004	21.625.321
	<b>17.950.653</b>	<b>24.339.938</b>
	<b>1 January- 31 December 2024</b>	<b>1 January- 31 December 2023</b>
<b>Operating lease as of January 1</b>	24.339.938	28.003.195
Current operating lease liability payment	(1.788.137)	(2.091.442)
Current interest expense	(802.125)	(966.327)
Current foreign currency effects	(6.326.672)	(605.488)
<b>Operating lease at the end of the periods</b>	<b>15.423.004</b>	<b>24.339.938</b>

## 16. FINANCIAL BORROWINGS

The details of financial borrowings for the periods are as follows:

	31 December 2024	31 December 2023
Short-term borrowings	--	9.457.560
Other financial borrowings (*)	1.335.737	1.062.070
<b>Short-term borrowings</b>	<b>1.335.737</b>	<b>10.519.630</b>
Short term portion of long term borrowings	--	405.363
<b>Short-term portion of long-term borrowings</b>	<b>--</b>	<b>405.363</b>
Long-term borrowings	--	405.363
<b>Long-term borrowings</b>	<b>--</b>	<b>--</b>
<b>Total financial borrowings</b>	<b>1.335.737</b>	<b>10.924.993</b>

(\*) Other financial borrowings consist of credit card borrowings.

The details of currency-based financial liabilities are as follows:

	Interest rate	31 December 2024
TRY bank borrowings	--	--
		--
	Interest rate	31 December 2023
TRY bank borrowings	%7,50 - %16,80	405.363
		<b>405.363</b>

## 17. EMPLOYEE BENEFITS

### Severance pay provision

Under the Turkish Legislations, the Company and its subsidiaries which located in Turkey, is required to pay termination benefits to each employee, who has completed one year of service and whose employment is terminated without due cause, is called up for military service, dies, who retires after completing 25 years for man and 20 years for women of service and reaches the retirement age (58 for women and 60 for men). Due to the amendment of the legislation as of 8 September 1999, there are certain transitional obligations regarding the length of service due to retirement.

These payments are calculated based on the rate on the day of retirement or termination per year worked, with a maximum of TL 41.828,42 over the 30-day salary as of 31 December 2024 (31 December 2023: TL 35.058,58). The provision for severance pay is calculated on a current basis and is reflected in the Consolidated financial statements. The provision is calculated according to the severance pay ceiling announced by the Government.

Provision for termination benefits is made by calculating the present value of the possible liability to be paid in case of retirement of employees. To calculate the liabilities of the Group in accordance with TAS 19 (Employee Benefits), a calculation made with actuarial assumptions is required. Accordingly, the actuarial assumptions used in the calculation of total liabilities are given below. The basic assumption is that the maximum liability for each year of service will increase in line with inflation. Hence the discount rate applied represents the expected real interest rate after adjusting for the effects of future inflation. As a result, the liabilities in the accompanying Consolidated financial statements as of 31 December 2024 and 31 December 2023 are calculated by estimating the present value of the future probable obligation arising from the retirement of the employees.

	31 December 2024	31 December 2023
Discount rate	27,05%	27,05%
Estimated rate of salary increasing /inflation rate	23,72%	22,01%
The turnover ratio used to calculate the probability of retirement	95 %	100%

It is planned that the severance pay rights will be paid at the end of the concession agreement. Accordingly, the terms of the concession agreements are considered in calculating the present value of the liabilities to be paid in the future.

The details of long-term severance pay provisions for the periods are as follows:

<u>Long-term provisions</u>	31 December 2024	31 December 2023
Provision for employment termination benefits	7.552.762	4.090.229
	<b>7.552.762</b>	<b>4.090.229</b>

Movement of severance pay provisions for the periods are as follows:

	31 December 2024	31 December 2023
Balance at January 1	4.090.229	19.328.308
Provisions	5.250.407	(987.548)
Interest cost	1.022.557	1.134.221
Actuarial (gain)/ losses	(426.978)	(8.681.433)
Payments during the year	(1.094.040)	(1.553.747)
Inflation effect	(1.289.413)	(5.149.572)
<b>Balance at September 31</b>	<b>7.552.762</b>	<b>4.090.229</b>

**17. EMPLOYEE BENEFITS (continued)**

The details of short-term employee benefits provisions for the periods are as follows:

<u>Short-term provisions</u>	<u>31 December 2024</u>	<u>31 December 2023</u>
Provision for vacation pay liability	7.107.361	7.139.428
	<b>7.107.361</b>	<b>7.139.428</b>

Movement of vacation pay provisions as follows:

<u>Short-term provisions</u>	<u>31 December 2024</u>	<u>31 December 2023</u>
Balance at January 1	7.139.428	3.984.646
Current year provision expense (*)	(832.808)	2.369.810
Inflation effect	800.741	784.971
<b>Balance at the end of the periods</b>	<b>7.107.361</b>	<b>7.139.428</b>

(\*) Leave provision expenses for the relevant periods are included in personnel expenses.

**18. COMMITMENTS, CONTINGENT ASSETS AND LIABILITIES**

**a) Guarantees received**

As of 31 December 2024, the Group has no guarantees received (31 December 2023: None).

**b) Guarantees given**

Collaterals/ pledges/ mortgages/bill of guarantees (“CPMB”) position of the Group as of 31 December 2024 and 31 December 2023 are as follows:

<u>CPMB’s given by the Group</u>	<u>31 December 2024</u>	<u>31 December 2023</u>
A. CPMB’s given for Group’s own legal personality	16.365.885	16.365.885
B. CPMB’s given on behalf of fully consolidated companies	--	--
C. CPMB’s given on behalf of third parties for ordinary course of business	--	--
D. Total amount of other CPMB’s	--	--
i) Total amount of CPMB’s given on behalf of the majority shareholder	--	--
ii) Total amount of CPMB’s given on behalf of other Group companies which are not in scope of B and C	--	--
iii) Total amount of CPMB’s given on behalf of third parties which are not in scope of C	--	--
	<b>16.365.885</b>	<b>16.365.885</b>

As of 31 December 2023, the ratio of other CPMs given by the Group to the Group's equity is 0% (31 December 2023: 0%).

**19. PAYABLES WITHIN BENEFIT TO EMPLOYEES**

The details of employee benefits obligations for the periods are as follows:

	<u>31 December 2024</u>	<u>31 December 2023</u>
Due to personnel	265.187	885.156
Social security premiums payable	5.882.270	8.205.847
	<b>6.147.457</b>	<b>9.091.003</b>

**20. INCOME TAX**

The details of current period tax assets for the periods are as follows:

	<u>31 December 2024</u>	<u>31 December 2023</u>
Deferred tax assets/liabilities	(125.932)	(1.963.528)
Deferred tax income/(expense)	(50.013.108)	15.591.767
	<b>(50.139.040)</b>	<b>13.628.239</b>

**Corporation tax**

As of 31 December 2023, the corporate tax rate is 25% in Turkey (31 December: 25%). Corporation tax rate is applied to net income of the companies after adjusting for certain disallowable expenses, exempt income and allowances. With the provision added to Article 35 of the Law No. 7256 and Article 32 If more than 20 percent of its shares are offered to the public for the first time in the Borsa Istanbul market, the Group pays corporate tax with a discount of 2 points for 5 years. As of April 22, 2021, the company's corporate tax rate has been calculated 18%. Accordingly, in the Group's consolidated financial statements as of December 31, 2023, when calculating deferred tax assets and liabilities for its subsidiaries residing in Turkey, the tax rate is 23% for the parts of the temporary differences that will occur. Corporate tax losses can be carried forward for a maximum period of 5 years following the year in which the losses were incurred. The tax authorities can inspect tax returns and the related accounting records for a retrospective maximum period of five years.

10% withholding applies to dividends distributed by resident real persons, those who are not liable to income and corporation tax, non-resident real persons, non-resident corporations (excluding those that acquire dividend through a permanent establishment or permanent representative in Turkey) and non-resident corporations exempted from income and corporation tax.

Dividend distribution by resident corporations to resident corporations is not subject to a withholding tax. Furthermore, in the event the profit is not distributed or included in capital, no withholding tax shall be applicable.

To benefit from the exemption, the said income must be kept in a passive fund account and not withdrawn from the business for a period of 5 years. The sales price must be collected until the end of the second calendar year following the year of sale.

There is no practice in Turkey to reach an agreement with the tax administration regarding the taxes to be paid. Corporate tax returns are submitted within four months following the end of the period. The tax inspection authorities may examine the tax returns and the accounting records underlying them for five years following the accounting period and make a reassessment because of their findings.

20. INCOME TAX (continued)

**Income tax withholding**

There is a withholding tax liability on dividend distributions, and this withholding liability is accrued in the period when the dividend payment is made. Dividend payments are subject to 15% withholding tax, excluding those made to non-resident companies that generate income through a workplace or their permanent representative in Turkey, and to companies residing in Turkey. In the application of withholding tax rates for profit distributions to non-resident companies and natural persons, the withholding tax rates in the relevant Double Taxation Agreements are also considered. The addition of retained earnings to the capital is not considered as profit distribution, so it is not subject to withholding tax.

**Transfer pricing regulations**

In Turkey, transfer pricing regulations are specified in Article 13 of the Corporate Tax Law, titled "Hidden income distribution through transfer pricing". The notified dated 18 November 2007 on hidden income distribution via transfer pricing regulates the details of the implementation.

If the taxpayer buys or sells goods or services with related parties at the price or price, they have determined in peer assessment, the profit is deemed to have been distributed through transfer pricing, in whole or in part. Hidden income distribution through is considered as a non-deductible expense for corporate tax.

**Deferred tax assets and liabilities:**

Deferred tax liability or assets are determined by calculating the tax effects of temporary differences between the values of assets and liabilities shown in the Consolidated financial statements and the amounts considered in the legal tax base calculation. Deferred tax liability or assets are reflected in the accompanying Consolidated financial statements by considering the tax rates that are expected to be valid in the future periods when the temporary differences will disappear.

In reflecting the deferred tax asset to the consolidated financial statements, the developments in the sector in which it operates, taxable profit estimates in the future, it considers factors such as the general economic and political situation in Turkey and/or the international general economic and political situation that may affect the Group.

The Group considers factors such as developments in the sector in which it operates, taxable profit estimates in the future, general economic and political situation in Turkey and/or international general economic and political situation that may affect the Group while reflecting the deferred tax asset to the consolidated financial statements. The Group estimates that it will generate sufficient taxable profits in the future.

20. INCOME TAX (continued)

**Recognized deferred tax assets and liabilities**

The details of deferred tax assets and liabilities for the periods are as follows:

	31 December 2024		31 December 2023	
	Cumulative temporary differences	Deferred tax	Cumulative temporary differences	Deferred tax
<b>Deferred tax assets</b>				
Provision for employment termination benefits	11.586.451	2.896.613	8.693.243	1.999.445
Other	2.924.935	731.234	(154.511)	(536.029)
Financial lease liabilities	(1.691.308)	(422.827)	(126.841)	(29.173)
Trade receivables provisions	261.177	65.294	407.935	93.825
Financial investments	(49.820.533)	(12.455.133)	(86.262.937)	(19.840.476)
Trade payables provisions	--	--	(23.604)	(5.429)
Inventories	(60.883.924)	(15.220.981)	(39.303.148)	(9.039.724)
Property, plant and equipment and intangible assets	(394.083.695)	(98.520.924)	(341.586.449)	(78.564.883)
<b>Deferred tax assets</b>	<b>(491.706.897)</b>	<b>(122.926.724)</b>	<b>(458.356.311)</b>	<b>(105.922.444)</b>
<b>Net deferred tax</b>		<b>(122.926.724)</b>		<b>(105.922.444)</b>

The reconciliation of tax expense for the period to profit for the period is as follows:

	31 December 2024	31 December 2023
Beginning of period	(105.922.444)	(130.273.874)
Associated with comprehensive income (actuarial)	(98.205)	(1.996.730)
Inflation effect	(16.906.075)	26.348.159
	<b>(122.926.724)</b>	<b>(105.922.444)</b>

21. SHARE CAPITAL AND NON-CONTROLLING INTERESTS

**Share Capital**

The paid capital structure of the Group for the periods are as follows:

	31 December 2024		31 December 2023	
	Share TRY	Share %	Share TRY	Share %
<b>Shareholders</b>				
Alper Akyüz	93.562.286	42,53	93.562.286	42,53
Elif Akyüz	45.603.000	20,73	45.603.000	20,73
Actual Shares Outstanding (*)	75.301.617	29,43	64.898.588	29,43
Other	5.533.097	7,31	15.936.126	7,31
<b>Total paid-in capital</b>	<b>220.000.000</b>	<b>100</b>	<b>220.000.000</b>	<b>100</b>

(\*) The company is registered with the Capital Markets Board (“CMB”) and its shares are traded on Borsa İstanbul A.Ş. (“BIST”) as of 21.10.2021. As of 31 December 2024, the Company has 32,45% of shares registered in BIST.

As of 31 December 2024, the capital of the Group consists of 220.000.000 shares. (31 December 2023: TL 220.000.000). The nominal value of the shares is TL 1 per share. (31 December 2023: per share TL 1). Company shares are represented by two separate share groups as A and B group, and A group shares provide voting rights to the shareholder. The Company's shares consist of 40.000.000 Group A shares and 180.000.000 Group B shares.

21. SHARE CAPITAL AND NON-CONTROLLING INTERESTS (continued)

**Anatolia Tam ve Biyoteknoloji Ürünleri Ar-Ge Sanayi Ticaret A.Ş. and Group Companies**  
Consolidated Statements of Cash Flows For The Periods Ended at 1 January – 31 December 2024 and 31 December 2023  
(Amounts expressed in thousands of Turkish Lira (“TRL”) in terms of the purchasing power of the TRL at December 31, 2024 unless otherwise indicated)

***Other comprehensive income not to be reclassified under profit and loss***

	31 December 2024	31 December 2023
<b>Balance at January 1</b>	1.680.573	(5.004.131)
Additions	426.978	6.684.704
Deferred tax	(98.205)	(1.996.730)
	<b>2.009.346</b>	<b>(316.156)</b>

***Restricted Reserves***

	31 December 2024	31 December 2023
<b>Balance at January 1</b>	227.322.639	227.322.639
Additions	--	--
	<b>227.322.639</b>	<b>227.322.639</b>

***Non-controlling interests***

As of 31 December 2024, there is no non-controlling interests (31 December 2023: there is no non-controlling interests).

**22. EARNINGS PER SHARE**

Earnings per share for the periods are as follows:

	31 December 2024	31 December 2023
Net profit for the period of the equity holders of the parent	(218.876.146)	(197.323.031)
Weighted average number of ordinary shares with nominal value (kuruş1 per value)	220.000.000	220.000.000
<b>Earnings per share (TRY)</b>	<b>(0,9949)</b>	<b>(0,8969)</b>

**23. REVENUE AND COST OF SALES**

Revenue for the periods are as follows:

	1 January- 31 December 2024	1 January- 31 December 2023
Domestic Sales	187.592.233	166.235.519
Export Sales	339.020.419	177.144.841
Other Revenue	4.489.870	6.370.960
<b>Gross Sales</b>	<b>531.102.522</b>	<b>349.751.319</b>
Sales Returns (-)	(1.110.928)	(628.231)
Sales Discount (-)	(159.887)	(5.204.705)
<b>Net Sales</b>	<b>529.831.707</b>	<b>343.918.384</b>
Cost of goods sold (-)	(124.126.366)	(64.432.981)
Cost of merchandise sold (-)	(67.516.965)	(3.261.548)
Cost of services sold (-)	(3.619.792)	(1.710.204)
<b>Gross Profit</b>	<b>334.568.584</b>	<b>274.513.650</b>

	1 January - 31 December 2024	1 January - 31 December 2023
Direct raw material and supplies expense	(96.863.190)	(30.301.560)
Depreciation and amortization expenses	(40.970.205)	(12.816.645)
Direct labor expense	(44.994.439)	(20.861.737)
Indirect labor expenses	(2.540.309)	(794.681)
Food expenses	(3.209.076)	(1.003.890)
Other	(6.685.904)	(3.626.221)
	<b>(195.263.123)</b>	<b>(69.404.734)</b>

**Anatolia Tam ve Biyoteknoloji Ürünleri Ar-Ge Sanayi Ticaret A.Ş. and Group Companies**  
Consolidated Statements of Cash Flows For The Periods Ended at 1 January – 31 December 2024 and 31 December 2023  
(Amounts expressed in thousands of Turkish Lira (“TRL”) in terms of the purchasing power of the TRL at December 31, 2024 unless otherwise indicated)

**24. MARKETING, SELLING AND DISTRIBUTION EXPENSES**

The details of selling and marketing expenses for the periods are as follows:

	1 January- 31 December 2024	1 January- 31 December 2023
Personnel expenses	(93.858.673)	(73.498.090)
Depreciation and amortization expenses	(19.994.873)	(19.140.293)
Transportation expenses	(13.784.840)	(15.371.374)
Travel expenses	(8.571.898)	(5.619.612)
Export expenses	(7.024.641)	(1.557.211)
Tax, duty and fee expenses	(6.906.376)	(2.253.900)
Material usage expenses	(5.042.374)	(6.302.537)
Benefits and services provided from outside	(4.613.432)	(3.696.909)
Transportation expenses	(3.807.392)	(4.357.550)
Commission expenses	(3.236.750)	(5.292.435)
Representation and hospitality expenses	(1.696.375)	(887.188)
Other	(3.297.158)	(4.289.518)
	<b>(171.834.782)</b>	<b>(142.266.617)</b>

**25. GENERAL ADMINISTRATIVE EXPENSES**

The details of general administrative expenses for the periods are as follows:

	1 January- 31 December 2024	1 January- 31 December 2023
Personnel expenses	(68.912.530)	(67.446.234)
Depreciation and amortization expenses	(41.380.176)	(31.563.065)
Outsourced benefits and services	(21.656.035)	(25.607.536)
Insurance expenses	(5.664.322)	(2.059.536)
Tax, fee and duty expenses	(438.061)	(5.788.408)
Other	(1.700.892)	(2.006.069)
	<b>(139.752.016)</b>	<b>(134.470.846)</b>

**26. RESEARCH AND DEVELOPMENT EXPENSES**

The details of research and development expenses for the periods are as follows:

	1 January- 31 December 2024	1 January- 31 December 2023
Depreciation and amortization expenses	(3.139.933)	(12.993.064)
	<b>(3.139.933)</b>	<b>(12.993.064)</b>

The Group invested a total of TRY 129.473.773 R&D projects in the accounting period ending on 31 December 2024 (12-month period) (31 December 2023: TRY 101.237.216 TRY (12-month period))

**27. OTHER OPERATING INCOME AND EXPENSES**

The details of other operating income and expenses for the periods are as follows:

**Anatolia Tam ve Biyoteknoloji Ürünleri Ar-Ge Sanayi Ticaret A.Ş. and Group Companies**  
Consolidated Statements of Cash Flows For The Periods Ended at 1 January – 31 December 2024 and 31 December 2023  
(Amounts expressed in thousands of Turkish Lira (“TRL”) in terms of the purchasing power of the TRL at December 31, 2024 unless otherwise indicated)

	1 January- 31 December 2024	1 January- 31 December 2023
<b>Other operating income</b>		
Exchange rate difference income on trade receivables and payables	50.454.417	200.193.081
Financial investment income	89.908	49.370
Other	8.503.203	13.606.804
	<b>59.047.528</b>	<b>213.849.255</b>
<b>Other operating income loss</b>		
Foreign exchange loss on trade receivables and payables	(4.939.301)	(33.567.370)
Provisions for doubtful receivables (Note 7)	(356.238)	(142.272)
Other (*)	(10.622.394)	(62.239.014)
	<b>(15.917.933)</b>	<b>(95.948.657)</b>

(\*) Other expenses include 2022 Additional Earthquake Tax payment of 41,106,581 TL in the period of 31 December 2023.

## 28. INCOME AND EXPENSES FROM INVESTMENT ACTIVITIES

	1 January- 31 December 2024	1 January- 31 December 2023
<b>Other operating income</b>		
Income from financial investments	13.555.300	19.754.283
Foreign currency hedged deposit income	--	49.370
Gain on sale of tangible assets	5.944	4.285.241
	<b>13.561.244</b>	<b>24.088.895</b>
<b>Other operating expenses</b>		
Expenses from financial investments	(3.519.421)	(11.241.819)
Foreign exchange losses on financial assets	(41.613)	(2.617.239)
	<b>(3.561.034)</b>	<b>(13.859.058)</b>

## 29. FINANCIAL INCOME AND EXPENSES

The details of finance income and expenses for the periods are as follows:

	1 January- 31 December 2024	1 January- 31 December 2023
<b>Finance income</b>		
Foreign exchange gains	25.495.896	132.199.925
Interest income	3.350.182	43.806.549
	<b>28.846.078</b>	<b>176.006.475</b>

**Anatolia Tam ve Biyoteknoloji Ürünleri Ar-Ge Sanayi Ticaret A.Ş. and Group Companies**  
Consolidated Statements of Cash Flows For The Periods Ended at 1 January – 31 December 2024 and 31 December 2023  
(Amounts expressed in thousands of Turkish Lira (“TRL”) in terms of the purchasing power of the TRL at December 31, 2024 unless otherwise indicated)

## 29. FINANCIAL INCOME AND EXPENSES (continued)

	1 January- 31 December 2024	1 January- 31 December 2023
<b>Finance expenses</b>		
Foreign exchange losses	(679.987)	(26.552.659)
Interest expense	(2.456.722)	(3.905.828)
Loan interest expenses	(802.125)	(966.327)
	<b>(3.938.834)</b>	<b>(31.424.815)</b>

## 30. FINANCIAL INSTRUMENTS

### Capital Risk Management

While trying to ensure the continuity of its activities in capital management, the Group also aims to increase its profits by using the debt and equity balance in the most efficient way. The Group's capital structure consists of equity items including issued capital, reserves and retained earnings.

The gearing ratios for the periods are as follows:

	1 January- 31 December 2024	1 January- 31 December 2023
Total financial liabilities	19.286.390	35.264.931
Less: Cash and cash equivalents	(205.023.951)	(435.637.009)
<b>Net debt</b>	<b>(185.737.561)</b>	<b>(400.372.078)</b>
Total equity	1.551.365.517	1.751.677.031
<b>Debt/equity ratio</b>	<b>(0,1197)</b>	<b>(0,2286)</b>

### Risk Management System

When calculating the Group's capital risk management, debts and equity items including cash and cash equivalents, paid-in capital, defined benefit plans remeasurement gains / losses, restricted reserves from profit and retained earnings / (losses) are considered, respectively.

The risks associated with each capital class, together with the group capital cost, are evaluated by the senior management. Based on senior management assessments, it is aimed to keep the capital structure in balance through the acquisition of new debt or repayment of existing debt, as well as through dividend payments.

31. NATURE AND LEVEL OF RISKS ARISING FROM DERIVATIVE FINANCIAL INSTRUMENTS

**Risk management disclosures**

The Group’s activities expose it to a variety of financial risks, including the effects of changes in debt and equity market prices, foreign currency exchange rates and interest rates. The Group’s overall risk management program focuses on the unpredictability of financial markets and seeks to minimize potential adverse effects on the financial performance of the Group.

**Credit risk**

Credit risk is the risk that a customer or a counterparty will not fulfil its contractual obligations and arises mainly from customer receivables.

	Receivables				Bank deposits	Financial Investments
	Trade receivables		Other receivables			
	Related Party	Third Party	Related Party	Third Party		
<b>31 December 2024</b>						
<b>Maximum credit risk exposed as of balance sheet date, (A+B+C+D)</b>	--	109.252.547	--	11.814.445	205.023.951	16.286.162
- Secured portion of the maximum credit risk by guarantees	--	--	--	--	--	--
<b>A. Net book value of financial assets that are neither past due nor impaired</b>	--	109.252.547	--	11.814.445	205.023.951	16.286.162
<b>B. Net book value of the impaired assets</b>	--	--	--	--	--	--
- Past due (gross carrying amount)	--	1.302.575	--	--	--	--
- Impairment (-)	--	(1.302.575)	--	--	--	--
- Secured portion of the net value by guarantees, etc.	--	--	--	--	--	--

	Receivables				Bank deposits	Financial Investments
	Trade receivables		Other receivables			
	Related Party	Third Party	Related Party	Third Party		
<b>31 December 2023</b>						
<b>Maximum credit risk exposed as of balance sheet date, (A+B+C+D)</b>	--	112.506.091	--	26.803.483	435.517.897	84.274.962
- Secured portion of the maximum credit risk by guarantees	--	--	--	--	--	--
<b>A. Net book value of financial assets that are neither past due nor impaired</b>	--	112.506.091	--	26.803.483	435.517.897	84.274.962
<b>B. Net book value of the impaired assets</b>	--	--	--	--	--	--
- Past due (gross carrying amount)	--	1.314.665	--	--	--	--
- Impairment (-)	--	(1.314.665)	--	--	--	--
- Secured portion of the net value by guarantees, etc.	--	--	--	--	--	--

The Group monitors the collectability of its trade receivables periodically and allocates provision for doubtful receivables for possible losses that may arise from doubtful receivables based on the collection rates of previous years. Following the provision for doubtful receivables, if all or part of the doubtful receivable amount is collected, the collected amount is deducted from the doubtful receivable provision and associated with profit or loss

31. NATURE AND LEVEL OF RISKS ARISING FROM DERIVATIVE FINANCIAL INSTRUMENTS  
(continued)

**Liquidity risk**

The Group manages liquidity risk by maintaining adequate funds and available borrowing by regularly monitoring forecast and actual cash flows and matching the maturities of financial assets and liabilities. Prudent liquidity risk management expresses the ability to keep sufficient cash, the availability of sufficient credit transactions, the availability of fund resources and the ability to close market positions.

The funding risk of current and prospective debt requirements is managed by maintaining the availability of sufficient number of high-quality lenders.

The table below shows the maturity distribution of the Group's non-derivative financial liabilities:

Contractual maturity	31 December 2024					
	Carrying Value	Contractual cash flows	Up to 3 months	3 - 12 month	1 - 5years	More than 5 years
<b>Non derivative financial liabilities</b>	<b>69.728.966</b>	<b>69.728.966</b>	<b>52.410.225</b>	<b>1.895.737</b>	<b>12.638.245</b>	<b>2.784.759</b>
Loans and borrowings	1.335.737	1.335.737	1.335.737	--	--	--
Lease liabilities	17.950.653	21.806.404	631.912	1.895.737	19.278.755	21.806.404
Trade payables	46.436.576	46.436.576	46.436.576	--	--	--
Other payables	4.006.000	4.006.000	4.006.000	--	--	--

Contractual maturity	31 December 2023					
	Carrying Value	Contractual cash flows	Up to 3 months	3 - 12 month	1 - 5years	More than 5 years
<b>Non derivative financial liabilities</b>	<b>57.645.013</b>	<b>58.683.000</b>	<b>33.679.708</b>	<b>2.339.984</b>	<b>14.539.412</b>	<b>8.052.237</b>
Loans and borrowings	10.924.993	10.996.652	10.620.972	304.021	--	--
Trade payables	24.339.938	25.306.265	678.654	2.035.963	14.539.412	8.052.237
Other payables	15.659.008	15.659.008	15.659.008	--	--	--
Other debts	6.721.074	6.721.074	6.721.074	--	--	--

**31. NATURE AND LEVEL OF RISKS ARISING FROM DERIVATIVE FINANCIAL INSTRUMENTS (continued)**

For the periods, the Group's foreign currency position consists of foreign currency denominated assets and liabilities stated in the table below:

	31 December 2024			31 December 2023		
	TRY Equivalent	USD	EUR	TRY Equivalent	USD	EUR
1 Trade payables	10.467.585	198.852	93.968	44.391.781	178.080	1.201.865
2a. Monetary financial assets	83.516.542	199.044	2.082.257	390.296.699	5.021.761	7.443.540
2b. Non-Monetary financial assets	--	--	--	--	--	--
3 Other	--	--	--	2.469.439	11.178	65.708
<b>4 Current assets (1+2+3)</b>	<b>93.984.127</b>	<b>397.896</b>	<b>2.176.225</b>	<b>437.157.919</b>	<b>5.211.018</b>	<b>8.711.113</b>
5 Trade receivables	--	--	--	--	--	--
6a. Monetary financial assets	--	--	--	--	--	--
6b. Non-Monetary financial assets	--	--	--	--	--	--
7 Other	--	--	--	--	--	--
<b>8 Non- Current assets (5+6+7)</b>	<b>--</b>	<b>--</b>	<b>--</b>	<b>--</b>	<b>--</b>	<b>--</b>
<b>9 Total assets (4+8)</b>	<b>93.984.127</b>	<b>397.896</b>	<b>2.176.225</b>	<b>437.157.919</b>	<b>5.211.018</b>	<b>8.711.113</b>
10 Trade payables	(10.090.795)	189.891	(457.048)	437.157.919	5.211.018	8.711.113
11 Financial borrowings	21.803	618	--	9.400.613	169.608	135.313
12a. Other Monetary financial liabilities	--	--	--	--	--	--
12b. Other Non-Monetary financial liabilities	--	--	--	--	--	--
<b>13 Current liabilities (10+11+12)</b>	<b>(10.068.992)</b>	<b>190.509</b>	<b>(457.048)</b>	<b>9.400.613</b>	<b>169.608</b>	<b>135.313</b>
14 Trade payables	--	--	--	9.400.613	169.608	135.313
15 Financial borrowings	--	--	--	--	--	--
16a. Other Monetary financial liabilities	--	--	--	--	--	--
16b. Other Non-Monetary financial liabilities	--	--	--	--	--	--
<b>17 Non-Current liabilities (14+15+16)</b>	<b>--</b>	<b>--</b>	<b>--</b>	<b>--</b>	<b>--</b>	<b>--</b>
<b>18 Total liabilities (13+17)</b>	<b>(10.068.992)</b>	<b>190.509</b>	<b>(457.048)</b>	<b>9.400.613</b>	<b>169.608</b>	<b>135.313</b>
<b>19 Net asset / liability position of off-balance sheet derivatives (19a-19b)</b>	<b>--</b>	<b>--</b>	<b>--</b>	<b>--</b>	<b>--</b>	<b>--</b>
19a. Total amount of assets hedged	--	--	--	--	--	--
19b. Total amount of liabilities hedged	--	--	--	--	--	--
<b>20 Net foreign currency asset / (liability) position (9-18+19)</b>	<b>104.053.119</b>	<b>207.387</b>	<b>2.633.273</b>	<b>427.757.306</b>	<b>5.041.411</b>	<b>8.575.800</b>
<b>21 Net foreign currency asset / (liability) position of monetary items (1+2a+5+6a-10-11-12a-14-15-16a)</b>	<b>104.053.119</b>	<b>207.387</b>	<b>2.633.273</b>	<b>427.757.306</b>	<b>5.041.411</b>	<b>8.575.800</b>

**31. NATURE AND LEVEL OF RISKS ARISING FROM DERIVATIVE FINANCIAL INSTRUMENTS (continued)**

**Foreign currency risk(continued)**

*Sensibility analysis*

The Group's currency risk consists of the value changes of TL against Euro and USD. The basis of the sensitivity analysis to measure the currency risk is to make the total currency statement made throughout the organization. Total foreign currency position includes all foreign currency based short-term and long-term purchase agreements and all assets and liabilities.

The exchange rate sensitivity analysis for the periods are as follows:

	2024		2023	
	Profit / (Loss)		Profit / (Loss)	
	Appreciation of foreign currency	Depreciation of foreign currency	Appreciation of foreign currency	Depreciation of foreign currency
<b>In case of %10 appreciation of USD against TRY</b>				
1- USD net asset/liability	2.075.910	(2.075.910)	14.841.027	(14.841.027)
2- Amount hedged for USD risk (-)	--	--	--	--
<b>3- USD net effect (1+2)</b>	<b>2.075.910</b>	<b>(2.075.910)</b>	<b>14.841.027</b>	<b>(14.841.027)</b>
4- EUR net asset/liability	9.673.644	(9.673.644)	27.934.712	(27.934.712)
5- Amount hedged for EUR risk (-)	--	--	--	--
<b>6- EUR net effect (4+5)</b>	<b>9.673.644</b>	<b>(9.673.644)</b>	<b>27.934.712</b>	<b>(27.934.712)</b>
<b>Total net effect (3+6+9)</b>	<b>11.749.554</b>	<b>(11.749.554)</b>	<b>42.775.740</b>	<b>(42.775.740)</b>

**32. FINANCIAL INSTRUMENTS (FAIR VALUE EXPLANATION)**

For the periods, the book values and fair values of assets and liabilities are shown in the table below:

	Note	31 December 2024		31 December 2023	
		Book value	Fair value	Book value	Fair value
<b>Financial assets</b>					
Cash and cash equivalents	4	205.023.951	205.023.951	435.637.009	435.637.009
Financial investments	5	16.286.162	16.286.162	84.274.964	84.274.964
Trade receivables	6	109.252.547	109.252.547	112.506.091	112.506.091
Other receivables	8	11.814.445	11.814.445	26.803.483	26.803.483
<b>Total financial assets</b>		<b>342.377.105</b>	<b>342.377.105</b>	<b>659.221.547</b>	<b>659.221.547</b>
<b>Financial liabilities</b>					
Financial borrowings		1.335.737	1.335.737	10.897.781	10.924.993
Trade payables	6	46.436.576	46.436.576	15.659.008	15.659.008
Other payables	8	23.987.584	23.987.584	21.584.497	21.584.497
Payables related to employment benefits		6.147.457	6.147.457	9.091.003	9.091.003
<b>Total financial liabilities</b>		<b>77.907.354</b>	<b>77.907.354</b>	<b>57.232.289</b>	<b>57.259.501</b>
<b>Net</b>		<b>264.469.751</b>	<b>264.469.751</b>	<b>601.989.258</b>	<b>601.962.046</b>

**33. OTHER MATTERS THAT SIGNIFICANTLY AFFECT THE FINANCIAL STATEMENTS OR SHOULD BE DISCLOSED IN ORDER TO MAKE THE FINANCIAL STATEMENTS CLEAR, INTERPRETABLE AND UNDERSTANDABLE.**

The effects of the adjustments made by the Group within the scope of IAS 29 on an account group basis are as follows:

Monetary Loss/Gain

	1 January- 31 December 2024	1 January- 31 December 2023
<b>Operating Profit Before Finance Expenses</b>	<b>72.971.658</b>	<b>112.913.558</b>
Finance Expenses (-)	(3.938.834)	(31.424.815)
Finance Income (+)	28.846.078	176.006.475
Monetary Loss	(266.616.008)	(468.446.488)
<i>Stocks</i>	<i>78.887.557</i>	<i>(70.390.208)</i>
<i>Financial Investments</i>	<i>117.195.137</i>	<i>83.196.945</i>
<i>Fixed Assets</i>	<i>295.086.251</i>	<i>175.314.401</i>
<i>Equity</i>	<i>(585.310.187)</i>	<i>(674.284.777)</i>
<i>Index effect on statement of profit and loss</i>	<i>(81.397.687)</i>	<i>(86.824.369)</i>
<i>Current period adjustment factor indexation effect</i>	<i>(91.077.079)</i>	<i>104.541.521</i>
<b>Profit Before Tax</b>	<b>(168.737.106)</b>	<b>(210.951.270)</b>
Tax	(50.139.040)	13.628.239
<b>Profit/(Loss) for the Period</b>	<b>(218.876.146)</b>	<b>(197.323.031)</b>

**34. FEES RELATED TO THE SERVICES RECEIVED FROM THE INDEPENDENT AUDIT ORGANIZATION**

The Group's explanation regarding the fees for the services provided by the independent auditors, which is prepared in accordance with the Board Decision of the POA published in the Official Gazette dated 30 March 2021 and based on the POA letter dated 19 August 2021, is explained below:

	31 Aralık 2024	31 Aralık 2023
Independent Audit Fee for the Reporting Period	966.883	613.610
<b>Toplam</b>	<b>966.883</b>	<b>613.610</b>

**35. SUBSEQUENT EVENTS**

There is none.

# ANATOLIA

## ANNUAL

## REPORT

# 2024

**Anatolia Tanı ve Biyoteknoloji  
Ürünleri Ar-Ge San. ve Tic. A.Ş.**

Hasanpaşa Mah. Beydağı Sok.  
No: 1-9 H, 34920,  
Sultanbeyli/İstanbul

Tel: +90 216 330 04 55  
Fax: +90 216 330 00 42  
info@anatoliagenetworks.com  
www.anatoliagenetworks.com

**Anatolia**  
genetworks